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7GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Background
Pregnancy results in a lot of changes in the female body. Therefore 
pregnancy can infl uence the disease status of the woman as well as the 
pharmacodynamics and –kinetics of drugs [1-2]. As pregnant women are 
generally excluded from clinical trials for ethical reasons, hardly any drug 
information is available on effi  cacy and safety prior to market approval [3-4]. 
This lack of experience makes pregnant women (and their unborn child) a 
very vulnerable group of patients.
Due to lack of effi  cacy and safety evidence, and the fear for teratogenicity, 
doctors often rely on their own experience and it is therefore likely that they 
prescribe to pregnant women older rather than newer drugs [5-6]. These older 
drugs, like for example methyldopa for hypertension, are no longer prescribed 
as a fi rst or second choice drug for non-pregnant women, as newer treatment 
options are more eff ective or are associated with less adverse eff ects [7].
A teratogen is an agent causing malformations during the prenatal 
development. The human embryo is most susceptible for teratogenicity from 
3 to 12 weeks after conception [2]. In a broader sense teratogenicity can be 
defi ned as developmental toxicity and includes: altered growth (including 
growth retardation), functional defi cits or impairments, malformations and 
death [2]. This thesis will focus on physical major congenital malformations. 
In particular, this means that the chapters do not consider the risk of 
behavioural development, such as mental retardation.
To keep track on the teratogenicity and other adverse eff ects of drugs used by 
pregnant women, observation and recording of daily practice drug use is very 
important. Collecting evidence in daily practice is a time-consuming task and 
it requires long follow-up to confi rm or rule out potential teratogenicity [8]. 
This is nicely described in a paper of Lo and Friedman stating that no adequate 
information is available for pregnant women and their health care professionals 
for most drugs that were approved to the market the last 20 years [4].
However, to obtain more information on eff ectiveness and safety of 
maternal drug use, proper registration is highly important [9]. Both the 
prospective registration of exposure to these drugs and later on their pregnancy 
outcome, in specifi c ‘Disease & Drug Registries’ (e.g. epilepsy and antiepileptic 
drug registries) and registration of negative outcomes in ‘Registries of 
Malformations’ (e.g. EUROCAT network of congenital malformations or 
Slone Epidemiology Center) are valuable. Especially because the restrictive 
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factor in studies looking at specifi c malformations associated with specifi c 
drugs, is the number of (exposed) pregnancy outcomes included [10-12]. This 
power problem is nicely put into words by Michale Papagiannis: ‘The absence 
of evidence is not the evidence of absence’.
It is important to investigate the risk for general malformations to get an 
idea of the overall teratogenicity of a drug. However, as most drugs, with an 
increased risk for teratogenicity, are associated with a specifi c malformation 
or a small range of malformations, this specifi c increase is often not seen in a 
signifi cant increased rate for overall malformation [8]. For example a drug is 
associated with a four times increased risk for orofacial clefts (prevalence 1 
per 1000). The total prevalence of any malformation will increase from 3% to 
3.3%, which is (still 3% and) within the normal variation.
In the trajectory of gathering information about the safety of drug use in 
pregnancy, several study designs are important [13]. Descriptive studies – like 
case reports and case series – are informative in the period direct after market 
approval when hardly any information is available. Later on, small cohort 
studies can provide information on the risk for malformations in general 
and moreover these cohort studies can provide indications for possible 
associations with specifi c malformations. These indications can best be tested 
in a population-based case-control designed study. This specifi c design allows 
for calculation of a more powered estimate of the risk for associations found. 
Unfortunately, most population-based datasets that are appropriate for case-
control studies do not include a random sample of non-malformed controls. 
Therefore, either external groups or malformed control groups are used. 
External control groups are used as a proxy for drug exposure in the general 
pregnant population. For malformed controls, the results are presented 
relative to other malformed outcomes and not compared to the general 
pregnant population. In case of malformed controls, it is assumed that no 
relation exists between the malformations included in the control group and 
the exposure under study or the malformations investigated. By using a wide 
range of malformations assumed to be unrelated to the exposure, the eff ect 
of one potential relation is small. Among such a control group, consisting of 
pregnancy outcomes not associated with the drug under study, the exposure 
to the drug under study is assumed to be representative for the use of this 
drug in the general pregnant population.
Major disadvantages of the use of observational data compared to data from 
randomized clinical trials are the occurrence of bias and confounding [8, 
13-14]. In clinical trials drugs are randomly assigned to the patient which 
means that there is implicitly controlled for all possible infl uencing factors 
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(if possible, depending on sample size). However, in daily practice there are 
often diff erences between patients with the same disease who are receiving 
diff erent drugs or diagnostic tests (selection bias). And records reporting 
maternal drug exposure of patients might be more complete for pregnancies 
with a malformed pregnancy outcome compared to those with a non-
malformed outcome (information bias). In case of chronic diseases and 
increased risks for teratogenicity there always is an additional problem: is the 
disease or the drug associated with the teratogenic event? In case of epilepsy 
and antiepileptic drugs this confounding by indication issue is also relevant. 
The disease might increases the risk for the foetus, although the risk induced 
by the drug is higher in a woman with good disease control [15-16].
This thesis will focus on the use of antiepileptic drugs around pregnancy. The 
use of antiepileptic drugs is defi ned as the use of any drug having an ATC-
code starting with ‘N03A’, irrespective of prescribed indication [17]. The name 
‘antiepileptic drug’ assumes use for the indication of epilepsy. However, the 
approved indications of some drugs classifi ed as antiepileptic drug are much 
wider: anxiety disorders, central or peripheral neuropathic pain, depressive 
or manic episodes in bipolar disorders, essential tremor, infantile spasms and 
migraine [18].
Compared to the indication of epilepsy, treatment decisions involving 
switching or stopping the antiepileptic drug might be easier for some of these 
other indications in case of a child wish, such as for migraine [19]. Still, if the 
drug use is continued during the fi rst trimester of pregnancy the teratogenic 
risk will be the same irrespective of the indication, at least if the dosage used 
is comparable.
To individually assess the treatment options for women requiring antiepileptic 
drugs, it is important that they visit their health care professional to discuss 
possible suitable alternatives and to make treatment decisions early, before 
pregnancy. In case of antiepileptic drugs, most women will need to continue 
using them if they get a child wish. Therefore, it is highly important to 
investigate and compare the risks of the treatment options for these women. 
Within the fi eld of teratology these investigations and comparisons 
are mainly pure epidemiological. However, also economic evaluations are 
considered to be of increasing importance for drug assessments. In particular, 
the drug that is chosen to be used/continued during pregnancy could be 
interpreted as a safety intervention for the off spring. Which may result in 
high cost-eff ectiveness ratio’s being accepted [20].
Additional to treatment decisions being discussed before getting 
pregnant, it is important for all women with a child wish to start using folic 
acid [21]. Although direct evidence is lacking folic acid use is thought to be 
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more important for women using antiepileptic drugs (compared to the general 
pregnant population). In particular, in the summary of product characteristics of 
valproic acid 5 mg folic acid is recommended for women using valproic acid [22].
The goal of this thesis is to investigate the use of antiepileptic drugs around 
pregnancy, to provide a risk assessment related to teratogenicity of the most 
frequently used antiepileptic drugs, to show the impact of these teratogenic 
risks in daily practice and to provide a health economic view on teratogenicity. 
The risk assessment studies included in this thesis are the fi rst combining 
international EUROCAT data to assess the risk of a specifi c drug on specifi c 
malformations.
For the studies presented in this thesis two datasets were used: the international 
EUROCAT network of congenital malformations and the IADB.nl including 
pharmacy prescription data [23-27]. These datasets have some important 
characteristics in common. Both databases are population-based continuing 
surveillance systems in which data is entered locally and kept centrally. More 
information about the IADB.nl and the EUROCAT network can be found in 
box I and II.
Box I
The IADB.nl is a longitudinal, population-based pharmacy prescription database 
in the Netherlands established in 1999. Data is collected form 55 pharmacies 
covering about half a million people. Case data starts in 1994. The IADB.
nl includes all prescriptions of community pharmacies. Prescriptions during 
hospitalization and information about OTC drugs are not available. Within the 
IADB.nl, a pregnancy database is set up by linkage of the address code of a child 
with a woman aged 15-50 at birth of the child with the same address code. 
Approximately 65% of all children can be linked to one potential mother and are 
available in the pregnancy database. As only the date of birth is known and not 
the actual gestational length, the length of each pregnancy is estimated 273 day 
(divided into three trimesters of 91 days). The use of the pregnancy database is 
especially suitable for drugs used for chronic indications like antiepileptic drugs 
in which the exact timing in less important as the exposure is constant. Studies 




EUROCAT (European Surveillance of Congenital Anomalies) is a population-
based network of local congenital malformation registries established in 1979. 
The network grew in time and currently the network consists of 42 registries 
covering over 1.7 million births per year (>30% of all births in the European 
Union). Information is recorded of all livebirths, stillbirths (gestational age ≥20 
weeks) and terminations of pregnancy following prenatal diagnosis, aff ected 
with major structural malformations, chromosomal anomalies, syndromes or 
other hereditary conditions associated with structural malformations. Isolated 
minor malformations are not collected centrally (EUROCAT guide 3.2). Up to 
eight malformations and one syndrome per case are coded locally using ICD9 or 
in more recent years ICD10 codes with extension codes from the British Pediatric 
Association. Additionally to variables concerning the diagnosis of malformations 
variables providing information about ‘baby and mother’, exposure, family 
history and socio-demographic are available, but not all obligatory. Local 
registries have their own policy and methods to collect the data and multiple 
sources are used. Once or twice a year data are transmi ed to the Central registry.
Antiepileptic Study Database and EUROmediCAT
Within EUROCAT several Working Groups exist. One of them, the Medication 
during pregnancy working group, aims to develop and implement post marketing 
surveillance of teratogenic risks of medications (used for maternal chronic 
diseases). To achieve this, a reproductive pharmacovigilance case-control 
monitoring system will be developed: EUROmediCAT. One of the milestones 
was the creation of the EUROCAT Antiepileptic Study Database in 2007. All local 
registries with good maternal drug exposure data were invited to participate in 
this dataset. The exact criteria were: 1) maternal antiepileptic drug use or epilepsy 
reported for at least 3 per 1000 registrations, and 2) specifi c drug name or complete 
ATC code available for at least 80% of the antiepileptic drug exposed pregnancies. 
At the start of the project 19 local registries met these inclusion criteria and were 
willing to participate. The studies performed with this database are presented in 
chapter 3, 4 and 5 of this thesis.
The development of the pharmacovigilance case-control monitoring system 
continues with the start of an EU Framework 7 funding March 2011. Some of the 
goals of this project are to enhance the maternal exposure data by linkage with 
existing datasets containing drug prescription data, and to provide risk assessment 
of drug exposure in the fi rst trimester of pregnancy associated with teratogenicity.
Outline thesis
In this thesis, epidemiological and health economic aspects of antiepileptic 
drug use around pregnancy are described and evaluated. The thesis consists 
of three parts.
General introduction and outline of the thesis
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In part I of this thesis entitled ‘Drug utilization patterns in the general pregnant 
population’, two drug utilization studies are presented to determine the use 
of drugs around pregnancy in the general pregnant population. Chapter 
1 describes the use of drugs from two years before pregnancy until three 
months after delivery in the Netherlands, based on the IADB.nl a community 
pharmacy prescription database. In chapter 2 the use of antiepileptic drugs 
around pregnancy is described for three European countries: France, Italy 
and the Netherlands. 
Part II entitled ‘Risk assessment of antiepileptic drugs in the fi rst trimester 
of pregnancy’ three international, multi-centre, population-based case-
control studies are performed. In chapter 3 the indication of the association 
between lamotrigine exposure in the fi rst trimester of pregnancy and 
the risk for orofacial clefts is tested. Next in chapter 4 and chapter 5 two 
systematic literature reviews are performed to fi nd indications of specifi c 
major congenital malformations associated with respectively valproic acid 
and carbamazepine. The indications identifi ed in the literature are tested in a 
case-control study using malformed controls.
The last part of the thesis, part III entitled ‘Considerations for treatment 
practice’ consists of another case-control study and an economic evaluation. 
Chapter 6 describes a case-control study estimating the protective eff ect of 
folic acid on the risk for spina bifi da in women using valproic acid. Whether 
or not folic acid helps to protect against the type of spina bifi da caused by 
valproic acid is uncertain. Finally, the economic consequences of the choice 
for a specifi c antiepileptic drug in young women with childbearing potential 
are described in chapter 7, applying the societal perspective.
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Part I
Drug utilization pa erns in the 
general pregnant population
Chapter 1:  Drug prescription patterns before, during and after pregnancy 
for chronic, occasional and pregnancy-related drugs in the 
Netherlands




DRUG PRESCRIPTION PATTERNS BEFORE, DURING 
AND AFTER PREGNANCY FOR CHRONIC, OCCASIONAL 
AND PREGNANCY-RELATED DRUGS IN THE 
NETHERLANDS
MK Bakker, J Jentink, F Vroom, PB Van Den Berg, HEK De Walle, 
LTW De Jong-Van Den Berg
BJOG 2006;113:559-568
Objective: To compare the prescription of drugs in women over a period from 
2 years before until 3 months after pregnancy, regarding the type of drugs 
used and the fetal risk.
Design and Setting: A cohort study based on pharmacy records of women 
giving birth to a child between 1994 and 2003. The study was performed with 
data from the InterAction database, containing prescription-drug-dispensing 
data from community pharmacies.
Population: The study population included 5412 women for whom complete 
pharmacy records were available.
Methods and outcome measures: Drugs were classified into three categories: 
(1) drugs for chronic conditions, (2) drugs for occasional use and (3) drugs for 
pregnancy-related symptoms and also classified according to the Australian 
classification system. The prescription rate was calculated as the number of 
women per 100 women who received one or more prescriptions for a given 
drug within a specified time period.
Results: About 79.1% of the women received at least one prescription during 
pregnancy. The prescription rate for most drugs for chronic diseases and 
for occasional use decreased during pregnancy, whereas, as expected, the 
prescription rate for pregnancy-related drugs increased. During the first 
trimester of pregnancy, 1.7% of all drugs prescribed for chronic conditions 
and 2.3% of the occasional drugs were classified as harmful.
Conclusions: The increase in prescription rate during pregnancy is caused by 
an increase in prescription rate of drugs for pregnancy-related symptoms. 
The prescription of harmful drugs is more commonly associated with drugs for 
occasional use rather than with drugs for chronic conditions. Therefore, a more 
cautious prescribing of drugs to healthy women in the fertile age is necessary.
1
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Introduction
Since the teratogenic risk of most drugs is still undetermined, it is important 
to monitor drug use regularly among pregnant women. Drug-utilization 
studies reveal that most women use drugs during pregnancy, with estimations 
varying from 44 to 99%[1-2]. However, comparison is diffi  cult because of 
diff erences in study design. Interviews or prescription databases may be used 
for collecting drug-use data, and the type of drugs studied may or may not 
include over-the-counter (OTC) drugs such as vitamins, iron and analgesics. 
Most studies found an increasing trend in drug use during pregnancy [2-7].
Drug use cannot be always avoided during pregnancy. For women with 
certain chronic medical conditions such as epilepsy, diabetes, inflammatory 
bowel disease and asthma, the use of drugs is essential, and benefits for 
mother and child may well outweigh the teratogenic risk of the drug [8-9]. 
Other non-chronic diseases related or unrelated to the pregnancy may 
require medical treatment. Most studies do not distinguish between the 
diff erent reasons for which the drugs are prescribed. Therefore, it is not clear 
to what extent changes in drug use among pregnant women can be explained 
by chronic, occasional or pregnancy-related drug use.
The aim of this study was to compare the prescription of drugs in pregnant 
women, with respect to the type of drugs and the fetal risk before, during and 
after pregnancy.
Methods
This study was performed with the InterAction database (IADB), which 
contains data on prescriptions dispensed from community pharmacies in 
the Netherlands. The IADB includes all prescription drugs from an estimated 
population of 220,000 from 1994 to 1999 and was expanded to approximately 
450,000 since 1999 [10-11]. Registration is irrespective of health insurance 
and is considered representative for the general population. Each prescription 
record contains information about the drug, date of dispensing, quantity 
dispensed, dose regimen and the prescribing physician. The indication for the 
prescription is not known. All the drugs are coded according to Anatomical 
Therapeutic Chemical (ATC) classification [12]. Each patient has a unique 
(anonymous) identifier; date of birth and gender of patients are known. Due to 
a high patient–pharmacy commitment in the Netherlands and sophisticated 
pharmacy software, the medication records for each patient are virtually 




To identify mothers, all children born between 1 January 1994 and 1 January 
2004 were selected from the database. For each child within the IADB, the 
female person 15–50 years older than the child with the same address code was 
considered to be the mother, providing there were no other female persons 15–50 
years older with the same address code. Using this method, 65% of the mothers 
could be identifi ed. Validation of this method is described in detail by Schirm et 
al [14]. Because only the child’s birth date is known, the theoretical conception 
date was determined as the date of birth minus 273 days (i.e. 9 months). Between 
1 January 1994 and 1 January 2004, 10,261 women were identified, with a total 
of 13,894 pregnancies. To rule out the influence of previous pregnancies, we 
included only the first pregnancy, as registered in the database, for which 
complete pharmacy records were available in the IADB from 2 years before the 
theoretical conception date until 3 months after delivery. According to these 
criteria, 5,501 women were included. To avoid misclassification of medication 
use, we subsequently excluded women who gave birth to twins (n = 87) or triplets 
(n =2) because the gestation period in twin and triplet pregnancies is more 
likely to be shorter than in singleton pregnancies. Thus, for the final analysis, 
pharmacy data for 5,412 women were used. To allow direct comparisons of 
prescription rates over time, the whole study period of 3 years was divided into 
12 periods of 13 weeks (trimesters). The 12 trimesters were numbered as can be 





































-8 -7 -6 -5 -4 -3 -2 -1 1 2 3 4
prescription rate per 100 women for all drugs excluding contraceptives
mean number of individual drugs among women who recieved at least prescription drug
Figure 1:  Prescription rate for all prescriptions and the mean number of drugs dispensed 
among women with at least one prescription. Trimester –8 to –5 represents the 
second year before pregnancy, trimester –4 to –1 represents the first year before 
pregnancy. The period between the do ed lines (trimester 1–3) is the pregnancy 
period, and trimester 4 is the period a er pregnancy.
We ordered drugs that were commonly prescribed into three mutually 
exclusive categories: (1) drugs for chronic conditions, (2) drugs for occasional 
and short-time use and (3) drugs for pregnancy-related symptoms. Drugs 
and drug groups belonging to these three categories are listed in Table 1. 
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Table 1:  Categorization of drugs and drug groups included in this study, according to their 
ATC code
Categories ATC code
Category I: Drugs for chronic conditions
Drugs used in diabetes
Corticosteroids, dermatological preparations
Corticosteroids for systemic use
Thyroid therapy

















Category II: Drugs for occasional 
and short-time use




Antifungals for dermatological use
Emollients and protectives
Antibiotics and chemotherapeutics for 
dermatological use
Antiacne preparations




Antiparasitic products, insecticides and 
repellents
Antihistamines for systemic use












R06, excl. R06AD & R06AE
S02, S03, S01, R01, R02A, R05





Folic acid and derivatives
Gynaecological anti-infectives and 
antiseptics 
Gonadotrophins and other ovulation 
stimulants 
A02A






The drug categories are mutually exclusive.
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Drugs for chronic conditions are not necessarily taken on a chronic basis 
but can also be taken during episodes when the disease surfaces. The drugs 
were also classified based on the Australian risk classification for pregnancy 
(Table 2) [15]. Categories D and X were combined because for both categories, 
the use of drugs during pregnancy is clearly contraindicated and only one 
drug was classified as X (isotretinoine, D10BA01). The three B categories were 
combined for statistical purposes. Drugs that were not classified according to 
the Australian classification system were categorized as B because their fetal 
risk was obviously unknown.
Per trimester, we counted the number of specific drugs prescribed to individual 
women, excluding contraceptives. If a specific drug was prescribed twice during a 
trimester, it was counted only once. In addition, prescriptions covering more than 
one trimester were counted only in the trimester in which they were dispensed. 
The prescription rate was calculated as the number of women per 100 women 
who received one or more prescriptions for a given drug or drug class within 
one trimester or otherwise specified time period. Prescription rates were tested 
in SPSS 12.0.2 for Windows (Chicago, USA) over the 3-year study period and the 
pregnancy period, using the chi-square test for trend.
Table 2:  Risk classification based on the Australian risk classification and as used in this study [15]
A Drugs that have been taken by a large number of pregnant 
women and women of childbearing age, without any proven 
increase in the frequency of malformations or other direct or 
indirect harmful eff ects on the fetus having been observed.
Safe
B Drugs that have been taken by only a limited number of 
pregnant women and women of childbearing age, without 
an increase in the frequency of malformation or other direct 
or indirect harmful eff ects on the human fetus having been 
observed. Studies in animals have not shown evidence of an 
increased occurrence of fetal damage or have shown evidence 
of an increased occurrence of fetal damage, of which the 
signifi cance is considered uncertain in humans.
Undetermined
C Drugs that, owing to their pharmacological eff ects, have 
caused or may be suspected of causing harmful eff ects on 
the human fetus or neonate, without causing malformations. 
These eff ects may be reversible.
Potentially harmful
D/X Drugs that have caused or suspected to have caused or may 
be expected to cause an increased incidence of human fetal 
malformations or irreversible damage. These drugs may also 
have adverse pharmacological eff ects.
Harmful
Results
The mean age at birth of the 5,412 mothers included was 29.6 years (range 
15–49 years). During the 3-year study period, they received a total of 78,944 
drugs, excluding contraceptives, of which 12,407 drugs were dispensed during 
pregnancy. Overall, 5,236 women (96.7%) received at least one prescription 
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drug during the 3-year study period and 4,280 (79.1%) received at least one 
prescription drug during their pregnancy. Figure 1 presents the prescription 
rates per trimester for all drugs, excluding contraceptives. In the 2 years 
before pregnancy, the prescription rate was constant, approximately 43 per 
100 women. The average number of drugs per trimester among women who 
were prescribed drugs was two (range 1–17). The prescription rate increased 
from 43.6 per 100 women in the fi rst trimester to 49.3 and 60.8 per 100 
women in the second and third trimester of pregnancy. During pregnancy, the 
mean number of prescription drugs per trimester among women who were 
prescribed drugs was approximately the same as before pregnancy (1.9).
During the 3-year study period, 865 diff erent drugs (based on ATC code) 
were prescribed to our study population, while during the pregnancy period, 
470 diff erent drugs were prescribed. The drugs categorized in Table 1 accounted 
for 57.3% of all the diff erent drugs prescribed and for 81.9% of all prescriptions 
during the 3-year study period. For the pregnancy period, these were 65.7 and 
89.1%, respectively. The prescription rates per trimester for the drugs listed in 
Table 1 are reported in Appendix 1. A graphical reproduction of the prescription 
patterns for certain drug groups of the three categories is shown in Figures 2–4.
A clear decrease in prescription rate in pregnancy was seen for antidepressants 
and antipsychotics (N06A/N05A), antimigraine drugs (N02C; Figure 2), anti-
inflammatory and antirheumatic drugs (M01). The prescription rates for 
antiepileptics (N03A; Figure 2), antiasthmatics (R03) were nearly constant 
during pregnancy. There seems to be an increase in prescription rate for 
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drugs used in diabetes anti-epileptics antimigraine medication
Figure 2:  Prescription pa erns for certain drugs for chronic conditions in the period from 2 years 
before pregnancy until 3 months a er delivery. The dots represent the prescription 
rate per trimester for the specific drug class. The period between do ed lines is the 
pregnancy period. Categorization of drug groups according to Table 1: drugs used in 
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antibiotics (systemic) ear, eye, nose and throat prepanalgesics and antipyrectics
Figure 3:  Prescription pa erns for certain drugs for occasional and short-time use in the period 
from 2 years before pregnancy until 3 months a er delivery. The dots represent the 
prescription rate per trimester for the specific drug class. The period between do ed 
lines is the pregnancy period. Categorization of drug groups according to Table 1: 
antibacterials for systemic use (J01), analgesics and antipyretics (N02B) and ear, eye, 
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anti-emetics
Figure 4:  Prescription pa erns for certain drugs for pregnancy-related symptoms in the period 
from2 years before pregnancy until 3months a er delivery. The dots represent the 
prescription rate per trimester for the specific drug class. The period between do ed 
lines is the pregnancy period. Categorization of drug groups according to Table 1: 
antacids (A02A), gynaecological anti-infectives and antiseptics (G01) and antiemetics 
(A03FA01, A04A, N05AB04, R06AD and R06AE).
The prescription rates of drugs for occasional use generally showed a decrease 
during pregnancy, followed by an increase after delivery. For antibiotics (J01; 
Figure 3), there was a decrease in prescription rate in the first trimester in 
pregnancy but an increasing pattern in the second and third trimester. For 
antispasmodic and anticholinergic agents (A03) and for antihistamines 
for systemic use (R06), there was a decrease in prescription rate during 
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pregnancy. For analgesics (N02B, Figure 3), hypnotics and anxiolytics (N05C/
N05B) and for ear, eye, nose and throat preparations (S02, S03, S01, R01, 
R02A, R05; Figure 3), there was a decreasing trend during the 3-year period 
but constant rates during pregnancy. As expected, the prescription patterns of 
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Figure 5:  Total number of prescription drugs for chronic conditions (only the prescribed drugs 
that were categorized as drugs for occasional and short-time use as presented in 
Table 1 were counted) per trimester and the distribution of these drugs according to 
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Figure 6:  Total number of prescription drugs for occasional and short-time use (only the 
prescribed drugs that were categorized as drugs for occasional and short-time use as 
presented in Table 1 were counted) per trimester and the distribution of these drugs 
according to the pregnancy risk classification.
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For folic acid and derivatives (B03B) and for antiemetics (A03FA01, A04A, 
R06AD, R06AE; Figure 4), the highest rates can be seen in the first trimester. 
Iron preparations (B03A), antacids (A02A; Figure 4) and gynecological anti-
infectives (G01; Figure 4) were most prescribed in the second and third 
trimester in pregnancy. The prescription of laxatives (A06) was highest 
after pregnancy. Ovulation stimulants (G03G) were most prescribed before 
pregnancy, with a prescription rate of 4.2 per 100 women.
Figures 5–7 show the distribution of the fetal risk classifi cation of the 
prescribed drugs. In these fi gures, we included only the drugs that were ordered 
in the three categories according to Table 1. The corresponding numbers can 
be found in Appendix 2. As previously described, there was a clear decrease 
in the total number of prescribed drugs for chronic conditions (Figure 5) and 
for occasional and short-time use (Figure 6) during pregnancy. This decrease 
was in contrast with the number of prescribed drugs for pregnancy-related 
symptoms, which showed a large increase during pregnancy, as shown in 
Figure 7. When taking all categories together, 81.7% of all drugs prescribed 
during pregnancy were classified as A, 10.9% as B, 6.3% as C and 1.1% as D 
or X. For the drugs prescribed during the first trimester, these percentages 
were 70.9, 16.5, 10.2 and 2.4, respectively. However, when we investigated 
the distribution of the prescribed drugs per category (chronic, occasional or 
pregnancy related), large diff erences are observed.
In the first trimester, only 50.4% of the prescribed drugs for chronic 
diseases were considered safe (A), 30.8% were potentially harmful (C) and 
1.7% were classified as harmful (D or X). During pregnancy, the proportion 
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Figure 7:  Total number of prescription drugs for pregnancy-related symptoms (only the 
prescribed drugs that were categorized as drugs for occasional and short-time use as 
presented in Table 1 were counted) per trimester and the distribution of these drugs 
according to the pregnancy risk classification.
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of drugs classified as C decreased to less than 15%. The proportion of 
harmful drugs was constant (1.9% in the third trimester). After pregnancy, 
the proportion of potentially harmful and harmful drugs increased to 45%.
When we investigated the prescribed drugs for occasional and short-time 
use, 60.8% of the drugs in the first trimester were classified as safe, 7.8% as 
potentially harmful and 2.3% as harmful. During pregnancy, the proportion of 
drugs classified as A increased to over 70% in the second and third trimester. 
The proportion of harmful drugs decreased to 0.4% in the third trimester. 
The majority of the drugs prescribed for pregnancy-related symptoms in the 
first trimester were classified as safe, 2.1% as potentially harmful and 2.9% as 
harmful. In the second and third trimester of pregnancy, 97.6% of the drugs 
prescribed for pregnancy-related symptoms were classified as A, 1% as C and 
0.2% as D or X.
Discussion
A clear change in drug prescription patterns is visible among pregnant women 
in the Netherlands. Drugs for chronic conditions and for occasional and 
short-time use were prescribed less during pregnancy, while at the same time, 
an increased prescribing of drugs for pregnancy-related symptoms was seen. 
For all three categories, the proportion of drugs classified as safe increased 
during pregnancy compared with the period before and after pregnancy.
The prescription rate covering the 3-year study period was very high, 
with 97 per 100 women receiving at least one prescription drug. The high 
prescription rate may reflect the origin of our study population. To be 
included in the prescription database, a person had to purchase at least one 
prescription drug at a participating pharmacy since 1994. In our population, 
the prescription rate during pregnancy, including vitamins and iron, was 79%. 
This percentage is somewhat higher than found in a Dutch cohort of women 
with a low-risk pregnancy (76.5% of the women attending a gynecologist and 
57.4% of the women attending a midwife used medications during pregnancy), 
but in the latter study, iron supplements were excluded [16]. The prescription 
rate in this study was high compared with register-based studies in Denmark 
(44.2%, excluding iron and vitamins), Finland (46.2%) and USA (64%, 
excluding vitamins and minerals) [1,17-18]. Higher prescription rates during 
pregnancy were found in the South West of France (99%, including iron and 
vitamins) and in Germany (96.4 and 85.2%, including and excluding vitamins, 
respectively) [2,4]. Several explanations can be given for the diff erences in 
prescription rates. The Danish study used a database that did not include 
prescribed drugs that were not refunded, such as benzodiazepines, many 
analgesics and antacids, explaining the lower prescription rates. Cultural 
prescribing diff erences might also play a role in these variations.
Except for drugs used in diabetes, most drugs for chronic conditions 
were prescribed less during pregnancy. In the trimester after pregnancy, 
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the prescription rate increased but not to the pre-pregnancy level. Low 
prescription rates shortly after pregnancy are most likely a result of 
breastfeeding. For some drugs, such as antidepressants and antipsychotics 
and antiepileptics, the decrease in prescription rate started before pregnancy. 
This decrease may indicate precautionary measures by women planning 
pregnancy, as the safety of these drugs is not established. Several studies 
have associated the use of antidepressants with adverse pregnancy outcomes 
such as spontaneous abortions, low birth weight and gestational age [19-20]. 
From our data, it is not possible to infer whether the decreases are physician 
driven or woman driven. As the indication for prescription is not known, 
the possible adverse eff ects of stopping some of these medications are not 
known. The prescription rate of antimigraine medication decreased in the 
second and third trimester of pregnancy, which might be a consequence of 
less migraine attacks during pregnancy or the use of other analgesics such 
as paracetamol. Anti-inflammatory and antirheumatic drugs were also 
rarely prescribed in pregnancy: the use of these drugs is contraindicated 
in pregnancy and moreover, rheumatic disease activity improves in most 
women during pregnancy [21].
The prescription of most drugs for occasional and short-time use 
decreased during pregnancy. The increase in the prescriptions for antibiotics 
in the second and third trimester can be explained by urinary tract infections, 
a complication in pregnancy for which treatment is recommended. The 
high prescription rate of antibiotics after pregnancy is most likely caused by 
infections of the breast and uterus. Because antibiotics are also frequently 
prescribed outside pregnancy, we decided to categorize antibiotics as drugs 
for occasional and short-time use.
The proportion of class A drugs prescribed during pregnancy is somewhat 
lower than the proportion found in an other study conducted with the IADB 
(81.7 versus 86%) [6]. This diff erence can be explained because we restricted 
our analysis to the drugs that were ordered into the three categories (65.7% 
of all drugs). In the previous study of the IADB, all drugs were included. 
The proportion of category A drugs in our study is much higher than found 
in a Danish study, where 40.9% of all prescriptions during pregnancy were 
classified as safe (A) [22]. We found that 2.4% of all drugs prescribed in the 
first trimester were harmful drugs. The harmful drugs prescribed in the 
first trimester for pregnancy-related symptoms were ovulation-stimulating 
drugs, and for chronic conditions, antiepileptics. Doxycycline, a tetracycline 
antibiotic, was responsible for the high percentage of harmful drugs for 
occasional use in the first trimester. Doxycycline may aff ect the bone and 
tooth development of the developing fetus and is therefore contraindicated 
in pregnancy.
The strength of our study was that for all women included in this study, 
complete data were available on drugs prescribed in the period from 2  years 
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before pregnancy until 3 months after delivery. Because we applied a 
cohort design comparing the prescription rates during pregnancy with the 
prescription rates before pregnancy in the same population, selection bias is 
minimized. Some drug-utilization studies compare drug use among pregnant 
women with drug use among non-pregnant women of comparable age. This 
might introduce bias, since factors related to pregnancy and drug use might 
be disproportionately present in the two groups. A Finnish study showed that 
more non-pregnant women had a chronic disease such as epilepsy, rheumatoid 
diseases, diabetes, hypertension, ulcerative colitis and psychotic and mental 
disorders when compared with pregnant women of comparable age [17].
By distinguishing drugs based on their indication, we could demonstrate 
that the increase in prescription rate during pregnancy is caused by an 
enhanced prescribing of drugs for pregnancy-related symptoms. Most other 
drug-utilization studies that investigated drug-use patterns among pregnant 
women make no distinction between the indications for drug use.
Although our study was conducted with data from a population-based 
prescription database, only women with a liveborn child are included. 
Women with a spontaneous or induced abortion and women whose 
pregnancy resulted in a stillbirth or whose child did not survive until the first 
prescription were not included.
Since we have no information on the actual length of the gestation period, 
the time of conception was estimated at 273 days (39 weeks) before birth. The 
use of a standard gestational period, mostly 270 days, is common in studies 
using administrative data [4,17-18]. A recent study, comparing administrative 
data with data from a birth registry, showed that gestational age assumptions 
can result in a small proportion of misclassification. The extent of potential 
drug-exposure misclassification was larger for category X drugs in the first 
trimester of pregnancy [23]. We believe that administrative datasets with 
estimated gestational age can be useful in research on prescription of drugs 
during pregnancy. However, in studies evaluating the risk of drugs on birth 
outcome, precise timing of drug exposure is essential and then administrative 
datasets alone are insuffi  cient.
In our study, ovulation-stimulating drugs were prescribed in the first 
trimester of pregnancy, an indication that misclassification has occurred. 
Prescription of other harmful drugs in the first trimester can also be explained 
by unawareness of the pregnancy. Although almost 80% of the pregnancies 
in the Netherlands are planned, a woman mostly does not recognize her 
pregnancy until the third week after conception.
The prescription rate as defined in this study reflects the prescribing 
behavior of physicians and cannot be translated directly into exposure rates. 
Drugs prescribed for a longer period of time can lead to an underestimation 
of exposure in the subsequent trimesters. Also, particularly in pregnancy, 
prescribed drugs are not always taken, leading to overestimation of drug 
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exposure. In a Danish study, only 43% of all drugs dispensed to pregnant 
women were reported to be taken. Compliance was high for drugs used in 
chronic diseases but low for drugs used for local or short-time treatment [24]. 
Furthermore, the prescription database does not include drugs administered 
in hospitals and OTC drugs. For some drugs, underestimation of exposure 
may be considerable. The prescription rate of analgesics and antipyretics, for 
instance, is very low, with approximately 1.5 per 100 women during pregnancy. 
The number of women who used analgesics during pregnancy is probably 
much higher because analgesics are freely available in the Netherlands. In 
a recent study in the USA, where data on maternal drug use were evaluated 
from two case–control studies of birth defects, at least 65% of the women 
took paracetamol at some point during pregnancy [25]. Other pregnancy-
related drugs such as antacids, laxatives, folic acid and some antiemetics are 
also available as OTC drugs in the Netherlands.
Although not all drugs prescribed to the study population were ordered 
into the three categories, we believe that this study is representative for drugs 
prescribed to pregnant women. The drugs included in the three categories 
accounted for almost 90% of all prescriptions in the pregnancy period. Drugs 
not included in the analyses were rarely prescribed.
The use of population-based prescription databases is an important tool 
to monitor the use of drugs among pregnant women to identify problems. 
In addition, this individual-level exposure data can serve as a reference for 
future risk-assessment studies and provide relevant information for education 
programmes of health professionals as well as for prevention. Although 
drug use during pregnancy is mostly studied in relation to the occurrence of 
congenital anomalies at birth, other adverse long-term eff ects in the off spring, 
such as developmental delay, may also be associated with maternal drug use in 
the second and third trimester. In a cohort study in the South West of England, 
frequent paracetamol use in late pregnancy was associated with an increased 
risk of wheezing in the off spring at 30–42 months [26]. If maternal drug use can 
be linked to the prescription of drugs to their children, prescription databases 
may also be used to screen for certain long-term drug eff ects.
In conclusion, this register-based study shows that the majority of the 
Dutch women use drugs during pregnancy. The increase in prescription 
rate during pregnancy is caused by an increase in prescription rate for drugs 
used for pregnancy-related symptoms, whereas the prescription rate for 
drugs for chronic diseases and for occasional and short-time use declines 
during pregnancy. Also, the prescription of harmful drugs decreases during 
pregnancy. However, 2.3% of all drugs prescribed for occasional and short-
time use in the first trimester were classified as harmful. Therefore, the 
results of this study argue in favor for a cautious prescribing of drugs to 
healthy women in the fertile age, in which the prescription of harmful drugs 
should be avoided as much as possible.
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DIFFERENCES IN ANTIEPILEPTIC DRUG USE DURING 
PREGNANCY IN THREE EUROPEAN COUNTRIES
J.Jentink , C. Damase-Michel, AJ Neville, C Hurault-Delarue, HJ. Bos, A Puccini, 
E Calzolari, L.T.W. de Jong-van den Berg.
Background: Among malformed pregnancy outcomes the distribution of the 
type of antiepileptic drug exposure varies between countries in the EUROCAT 
Antiepileptic Study Database. However data of antiepileptic drug exposure in 
the general pregnant population is scarce.
Objective: To identify antiepileptic drug utilization patterns in pregnancy in 
European countries using prescription databases.
Methods: Data of population-based prescription databases is used. Included 
were the region of Midi-Pyrenees in France (June 2003-June 2008) based on 
the ‘French Health Insurance Service’, the region of Emilia Romagna (2003-
2007) based on a linkage between the Regional Health authority database 
and the birth database and the northern part of the Netherlands (2003-2008) 
using the IADB.nl based on data of community pharmacies.
Antiepileptic drug exposure was defi ned as at least 1 prescription for any 
Antiepileptic drug (atc N03A) irrespective of indication.
Results: In total 83,005 French, 185,133 Italian and 13,036 Dutch pregnancies 
were included. The exposure to antiepileptic drugs before pregnancy is 
higher in France (7/1000) compared with Italy and the Netherlands (4/1000). 
However in pregnancy all regions have exposures around 2 to 3/1000. In the 
Netherlands about 60% of all antiepileptic drug exposed pregnancies used 
valproic acid or carbamazepine, this is around twice as much as in France. 
The use of clonazepam and lamotrigine is more common in France and the 
use of phenobarbital and gabapentine in Italy.
Conclusions: Teratogenicity is expected to be comparable within Europe, but 
the use of Antiepileptic drugs in the general pregnant population in France, 
Italy and the Netherlands is not similar.
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Introduction
Although, the majority of antiepileptic drugs are known teratogens, most 
women need to continue their drug use during pregnancy.
In earlier studies with the EUROCAT congenital anomalies registries 
we found that the type of antiepileptic drugs used in pregnancies (with a 
malformed outcome) varied between countries (unpublished data). We 
wondered if this dissimilarity was a coincidence due to small numbers, or if 
it was due to diff erent treatment practices and therefore, diff erent use among 
the general fertile population in European countries.
In literature several reports can be found about antiepileptic drug treatment 
in the general non-pregnant population [1-3]. The estimates of the prevalence of 
antiepileptic drug use vary widely between 0.8 and 5.2% in adults. Epilepsy is 
the most common indication, although antiepileptic drugs are more frequently 
prescribed for other indications, such as pain or mood disorders [2-3]. Especially, 
in the countries with higher prevalences the use for other indications is more 
prevalent. The therapy of some of these other indications can be discontinued 
if a women wishes to become pregnant. Additionally, the use of antiepileptic 
drugs increases with age; among women in the fertile age 25-44 the prevalence 
of antiepileptic drug use is estimated at 7.2 per 1000 in Denmark [1].
In the Netherlands and Norway population based drug utilization studies 
are available for exposure around pregnancy. The use of antiepileptic drugs 
in these studies during pregnancy was 3 per 1000, but no information was 
available from these studies on the use of specifi c antiepileptic drugs [4-5].
From pregnancy registries we know that carbamazepine, lamotrigine and 
valproic acid are in various orders the most commonly used antiepileptic drugs in 
pregnancy. Noteworthy, is the increasing trend of the prevalence of lamotrigine 
and the decreasing trend of carbamazepine and valproic acid in recent years [6-7].
European population-based data including information about specifi c 
antiepileptic drug exposure around pregnancy is scarce and therefore our 
objective is to describe and compare the maternal exposure to specifi c anti-
epileptic drugs (before and) during pregnancy in France, Italy and the Netherlands.
Methods
Databases
For this study we included three regions in three countries. In the three datasets 
drug information is available, although no information is available on the 
indication of prescribing the antiepileptic drugs.
The French data is based on the ‘French Health Insurance Database’ for the 
region Midi Pyrénées (2.8 million inhabitants) including babies born from June 
2003 to May 2004 and 2007. For July 2004-2006 and January 2008 to June 2008 
only data of Haute Garonne (1.1 million inhabitants) are included which is part 
of the region of Midi Pyrénées. About 80% of all inhabitants are insured by 
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this health insurance company, mainly farmers and civil servants are insured 
by another organization and therefore not included. In France, women have to 
declare their pregnancy to the Health Insurance System before the end of the 
third month of pregnancy in order to receive full reimbursement of care and all 
reimbursed drugs from the 6th month of pregnancy. Information is available for 
all out-patient prescribed drugs. Both the fi rst day of the last menstrual period 
and the data of delivery are known by the Health organization.
The Italian data from the region of Emilia Romagna (4 million inhabitants) 
is derived from a linkage of the Regional Health authority database (including 
drug prescription data) with the birth database (containing information about 
pregnancies). Linkage was based on personal fi scal code. Data is available for 
2003-2007. Information is available for all out-patient prescribed antiepileptic 
drugs and the fi rst day of the last menstrual period is known.
For the Netherlands we used data of the IADB.nl.: a community pharmacy 
prescription database including pregnancies. This database holds the 
prescription history for 500,000 people in the Northern Netherlands and is 
described and validated earlier [4,8]. Dutch data is included for pregnancies 
ending from 2003 to 2008. Information is available for all out-patient 
prescriptions. The fi rst day of the last menstrual period is unknown, but 
estimated as 273 days before the delivery date.
Analyses & Statistics
All prevalences presented are based on prescription data, not on verifi ed use. 
Prevalences are calculated as the total number of individual women with at 
least 1 prescription per trimester divided by the total number of pregnancies 
included. Trimesters were defi ned as a period of 91 days. If a specifi c 
antiepileptic drug was prescribed twice in a trimester it was counted only 
once and if a prescription covered a longer time period than one trimester it 
was only counted in the trimester in which the prescription was dispensed. 
Polytherapy is defi ned as at least two diff erent antiepileptic drugs (based on 
atc-code) received in one trimester. It is not possible to receive a prescription 
for a period longer than our defi ned trimester in one of the included countries.
Results
In total 83,005 French, 185,133 Italian and 13,036 Dutch pregnancies were 
available for analysis (see table 1). The French women were slightly older than 
the Dutch women (not signifi cant) and the age of the Italian women lies in 
between them. More women in France compared to Italy and the Netherlands 
had at least one prescription for any antiepileptic drug during pregnancy (5.2 
versus 4.0 and 4.2 per 1000, France versus Italy p<0.01). The proportion of 
mono and poly therapy varied between 11% in the Netherlands, 14% in Italy 
and 16% in France. The antiepileptic drug combinations in the poly therapy 
varied both within and between regions.
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Table 1: Characteristics of the study population
region, country Northern Netherlands Midi Pyrenee, France^ Emilia Romagna, Italy
included years 2003-2008 2003-2008 2003-2007
total pregnancies 13,036 83,005 185,133
age of mother at birth 30.9 (21-49) 31.7 (18-44) 31.23 (18-61)
prevalence any AED* 4.1/1000 5.2/1000 4.0/1000
      mono 89% 84% 86%
      poly 2 AEDs# 11% 14% 11%
      poly 3 AEDs# 0% 2% 3%
*  prevalence of antiepileptic drugs calculated as women with at least 1 prescription during 
pregnancy.
#  poly 2/3 AEDs= at least 1 prescription of 2/3 diff erent antiepileptic drugs in 1 trimester.
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Figure 1: Prescription rate for any antiepileptic drug (prevalence per 1000) per region.
In fi gure 1 the prescription rate for any antiepileptic drug is presented per region. 
Data for France were available from one and a half year before pregnancy until 
delivery and the Italian and Dutch data were available from two years before 
pregnancy until three months after delivery. As you can see the prescription 
rate over time is lower and much more stable in Italy and the Netherlands 
compared to France. All three countries show a drop in the prevalence towards 
the beginning of pregnancy however this drop is much bigger in France. Italy 
has the lowest prevalence of the three regions during pregnancy.
Figure 2 shows the trend over years in the use of antiepileptic drugs during 
pregnancy in the diff erent regions. For the fi rst generation antiepileptic 


































































Figure 2:  Time trends in the prevalence of antiepileptic drug use during pregnancy (line) and 
specifi c types of antiepileptic drugs (bars) in France, Italy and the Netherlands
higher in the Netherlands than in France or Italy. The other way around 
clonazepam exposure is much more frequent in France and phenobarbital 
is more frequent used in Italy. Lamotrigine is in France and the Netherlands 
the most used second generation antiepileptic drug. The fi rst lamotrigine 
prescriptions appeared in the Netherlands in 2003 and in France in 2004. 
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However the exposure rate is higher in France. In Italy gabapentine is the 
most frequently used second generation antiepileptic drug during pregnancy. 
The prevalence of gabapentine decreases towards more recent years probably 
due to the increase of pregabaline use (presented in the graph as ‘other new 
monotherapy).
The prevalence of antiepileptic drug exposure remains more or less stable 
over time in France and Italy, but in the Netherlands it seems that exposure 
increases in the more recent years however this is not statistically signifi cant 
(line in Figure 2). This increase in the Dutch prevalence remains if the study 
period is enlarged to 1995-2009 (data not shown).
Discussion
The prescribed antiepileptic drugs around pregnancy are not similar for 
France, Italy and the Netherlands. The prevalence for any antiepileptic 
drug exposure during pregnancy is higher in France than in Italy and the 
Netherlands, respectively 5.2, 4.0 and 4.2 per 1000. Next to this the types 
of drugs prescribed are diff erent too. Remarkable is the large proportion of 
clonazepam use in France, the use of phenobarbital in Italy and carbamazepine 
in the Netherlands.
Policy & Literature
A French population-based study in Béziers estimated an antiepileptic drug 
exposure prevalence of around 8 per 1000 in women 20-40 years [9]. This 
seems to be in line with the prevalence we found for France before pregnancy. 
In France it seems more common to reconsider the need for antiepileptic 
drugs before or in the beginning of the pregnancy and after this reconsidering 
process both regions in France and Netherlands end up with a comparable 
prevalence of antiepileptic drug exposure of 3 per 1000. The Italian prevalence 
is somewhat lower; 2 per 1000 (p<0.01).
In a French survey (2003) epileptologists were asked which antiepileptic drug 
they found most appropriate for newly diagnosed women of childbearing 
age considering pregnancy and those not considering pregnancy [10]. For all 
types of epilepsy included in the survey lamotrigine was considered to be the 
most appropriate drug for women considering pregnancy with valproic acid 
as an overall drug of second choice. In women not considering pregnancy it 
is the other way around: valproic acid is the most appropriate followed by 
lamotrigine. In both groups of women, carbamazepine is only an appropriate 
choice according to the epileptologists in case of symptomatic or cryptogenic 
partial epilepsy. This explains the small proportion of carbamazepine in 
France compared to the proportion in the Netherlands and the decreasing 
trend of valproic acid and the increasing trend of lamotrigine. However, 
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based on this survey the proportion of lamotrigine exposure might be 
expected higher in our study, but this survey was based on newly diagnosed 
patients. As switching between antiepileptic drugs is not usual in case of 
good control the young women receiving lamotrigine are maybe not pregnant 
yet (lamotrigine got market approval in 1995 in France). The proportion of 
lamotrigine exposure in pregnancy is expected to increase further in future. 
Remarkable is the proportion of clonazepam exposure in pregnancy in our 
study (almost 30%). In particular as the epileptologists in the survey reported 
that this drug is ‘sometimes useful in case of failure or contraindication of 
the other antiepileptic drugs’. However in practice it seemed to be considered 
safer than other antiepileptic drugs and it seems to be used in the treatment 
of depression.
Two studies estimating the use of antiepileptic drugs in Italy in the general 
non-pregnant population including men and women of all ages (both 
study periods 2003-2005) show a similar top 3 of antiepileptic drug use: 
phenobarbital, carbamazepine and valproic acid [11-12]. In our study 
carbamazepine is the most used antiepileptic drug during pregnancy followed 
by phenobarbital and clonazepam and valproic acid as a number 4 (see fi gure 
2). The median age of phenobarbital users was relatively high: 58 years in 
at least one of the two studies [11]. This might explains why in a pregnant 
population the proportion of phenobarbital is somewhat lower. However, 
compared to France and the Netherlands the phenobarbital use is still very 
high. Like in France it is remarkable to fi nd a high proportion of clonazepam 
exposure during pregnancy compared to the use found in literature. The 
clonazepam used by Italian women in this study is mainly used for the 
treatment of depression.
Of the second generation antiepileptic drugs gabapentine is both in our 
study and in the two studies performed in the general population the most 
frequently prescribed drug [11-12].
For the Netherlands valproic acid and carbamazepine were the two drugs of 
fi rst choice in case of partial epilepsy. However in 2009 lamotrigine changed 
from a second to a fi rst choice option for this type of epilepsy. For generalized 
epilepsy the only fi rst choice option is valproic acid [13]. This explains why 
over 65% of all monotherapy exposed pregnancies were exposed to valproic 
acid or carbamazepine in our study period. The prevalence of lamotrigine will 
probably increase in future due to this change in guidelines and the fact that 
potential teratogenicity gets more attention. The use of antiepileptic drugs for 
other indications than epilepsy seems to be less frequent in the Netherlands 
(although we do not know the indication in our data). In particular clonazepam 
is not registered for depression in the Netherlands [13].
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Strengths & Limitations
As far as we know this is the fi rst population-based drug utilization study 
presenting the type of antiepileptic drug use around pregnancy for several 
European regions.
This study is based on prescription data and we therefore cannot be sure 
if the drugs are really taken by the women. ‘Only’ 4-5 per 1000 pregnancies 
are exposed to antiepileptic drugs and therefore despite the large number of 
pregnancies included we still have small numbers for the individual drugs. 
Another limitation is that we do not know the fi rst day of the last menstrual 
period for the Dutch data. We estimated each pregnancy to last 273 days. 
However, as antiepileptic drugs mainly are used chronically we do not expect 
a major bias. 
Daily practice
The use of antiepileptic drugs varies between the included regions, however 
the teratogenicity can be expected to be comparable within these western 
European countries (maybe except for infl uence of epigenetic diff erences). 
As local guidelines for treatment around pregnancy should be based on all 
evidence available world-wide we expected to fi nd fewer diff erences in actual 
use between France, Italy and Netherlands. Although, it is of course known 
that keeping daily practice in concordance with constantly updating scientifi c 
knowledge is hard [14-15].
From earlier studies we know that valproic acid seems to be the most teratogenic 
antiepileptic drug [16]. In 2009, the American Academy of Neurology advised 
to avoid valproic acid in pregnancy if possible [17]. Carbamazepine seems to be 
relatively safe [18] and although there is less experience up to now lamotrigine 
also does not seem to be very strongly related to a specifi c malformation 
(except for an indication for an association with club foot) [19-20]. Based 
on this information one would expect to see relatively large proportions 
of carbamazepine and lamotrigine during pregnancy in the near future. 
However, antiepileptic drugs are used for complex diseases for which the 
therapy choice can only be made on individual basis. Additionally, although 
if possible valproic acid should be avoided during pregnancy still the majority 
of children are born without malformations. Although, a less clear fi gure 
exists of the behavior problems, (possibly) related to valproic acid, such as 
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DOES LAMOTRIGINE USE IN PREGNANCY INCREASE 
OROFACIAL CLEFT RISK RELATIVE TO OTHER 
MALFORMATIONS?
H. Dolk, J. Jentink, M. Loane, J. Morris, L.T.W. de Jong–van den Berg On behalf of The 
EUROCAT Antiepileptic Drug Working Group
Neurology 2008;71:714-722
Objective: To investigate whether fi rst trimester exposure to lamotrigine 
monotherapy is specifi cally associated with an increased risk of orofacial 
clefts relative to other malformations, in response to a signal regarding 
increased orofacial cleft risk.
Methods: Population-based case-control study with malformed controls based 
on EUROCAT congenital anomaly registers. The study population covered 3.9 
million births from 19 registries 1995–2005. Registrations included congenital 
anomaly among livebirths, stillbirths, and terminations of pregnancy 
following prenatal diagnosis. Cases were 5,511 nonsyndromic orofacial 
cleft registrations, of whom 4,571 were isolated, 1,969 were cleft palate and 
1,532 were isolated cleft palate. Controls were 80,052 nonchromosomal, 
non-orofacial cleft registrations. We compared fi rst trimester lamotrigine 
and antiepileptic drug (antiepileptic drug) use versus nonepileptic non-
antiepileptic drug use, for mono and polytherapy, adjusting for maternal 
age. An additional exploratory analysis compared the observed and expected 
distribution of malformation types associated with lamotrigine use.
Results: There were 72 lamotrigine exposed (40 mono- and 32 polytherapy) 
registrations. The odds ratios for lamotrigine monotherapy versus no 
antiepileptic drug use were 0.67 (95%CI 0.10–2.34) for orofacial cleft relative 
to other malformations, 0.80 (95%CI 0.11–2.85) for isolated orofacial cleft, 0.79 
(95%CI 0.03–4.35) for cleft palate, and 1.01 (95% CI 0.03–5.57) for isolated cleft 
palate. odds ratios for any antiepileptic drug use versus no antiepileptic drug use 
were 1.43 (95% CI 1.03–1.93) for orofacial cleft, 1.21 (95%CI 0.82–1.72) for isolated 
orofacial cleft, 2.37 (95%CI 1.54–3.43) for cleft palate, and 1.86 (95%CI 1.07–2.94) 
for isolated cleft palate. The distribution of other nonchromosomal malformation 
types with lamotrigine exposure was similar to non-antiepileptic drug exposed.
Conclusion: We fi nd no evidence of a specifi c increased risk of isolated 
orofacial clefts relative to other malformations due to lamotrigine 
3
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monotherapy. Our study is not designed to assess whether there is a 
generalized increased risk of malformations with lamotrigine exposure.
Introduction 
Post marketing surveillance of the second generation antiepileptic drug 
(antiepileptic drug) lamotrigine (lamotrigine) during pregnancy has recently 
generated a signal regarding higher risk of orofacial clefts (orofacial clefts) 
based on data from the North American antiepileptic drug Pregnancy Registry. 
They reported an unexpectedly high prevalence of isolated nonsyndromic, 
orofacial clefts in infants exposed to lamotrigine monotherapy during the 
fi rst trimester of pregnancy: 3 isolated cleft palate (cleft palate) and 2 isolated 
cleft lip with or without palate were identifi ed among 564 exposed pregnancy 
outcomes, a rate of 8.9 per 1,000[1]. These results were followed by a Food and 
Drug Administration (FDA) alert [2]. Three other registries have reported one 
or two cases of orofacial cleft, and one none, but have not provided enough 
evidence to confi rm or refute the orofacial cleft signal [3-7].
Case-control studies are recommended to test signals emanating from 
pregnancy registers [8]. The EUROCAT network of population-based 
congenital anomaly registers covers more than one quarter of births in 
Europe, following standardized methodology and contributing to a central 
database [9-10]. We report a case-control study, with malformed controls, to 
assess whether fi rst trimester exposure to lamotrigine monotherapy versus 
nonepileptic non-antiepileptic drug use is specifi cally associated with an 
increased risk of orofacial cleft relative to other malformations. We also 
report an exploratory analysis of the types of malformations associated 
with lamotrigine exposure, comparing them to what would be expected in a 
nonepileptic non-antiepileptic drug exposed population.
Method 
Study population and database.
The EUROCAT central database holds individual standardized records of 
congenital anomaly registrations since 1980 including livebirths, stillbirths, 
and terminations of pregnancy following prenatal diagnosis. The standard 
data on each registration are described in EUROCAT Guide 1.3 [10]. One 
syndrome and up to eight malformations are coded by ICD9 or ICD10 codes. 
Babies with only anomalies on the EUROCAT list of minor anomalies are 
excluded [10]. Other variables include date of birth, pregnancy outcome 
(live, still, termination), maternal age, maternal disease before and during 
pregnancy (ICD coded + text), and drugs taken in the fi rst trimester of 
pregnancy. Up to 2004 (birth year), registries could give up to three drug codes 
Chapter 3
49
(grouped into 20 categories) as well as text information on the drug [11]. From 
2005, and for some registries before 2005, drugs are coded according to the 
Anatomic Therapeutic Chemical (ATC) classifi cation [12]. Information about 
maternal drug exposure is mainly obtained from obstetric records, and some 
registries also use maternal interviews after birth or linkage with pharmacy 
databases [11].
Table 1:  Participating registries, study years, number of births surveyed, number and 
prevalence of orofacial cle s (orofacial cle ), and number of controls.
Registry years total births Orofacial cle  cases Controls#
number prevalence* number
Antwerp, Belgium 97 - 05 162,545 246 1.51 3,491
Basque Country, Spain 95 - 05 193,037 137 0.71 2,576
Cork & Kerry, Ireland 96 - 03 63,007 73 1.16 1,262
Emilia Romagna, Italy 00 - 04 140,726 108 0.77 2,054
Hainaut, Belgium 97 - 05 110,557 153 1.38 2,354
Mainz, Germany 96 - 04 29,859 61 2.04 1,220
Malta 96 - 04 38,495 58 1.51 1,180
Northern Netherlands 95 - 05 216,940 377 1.74 3,921
Norway 99 - 05 406,805 728 1.79 13,440
Odense, Denmark 95 - 04 55,677 104 1.87 1,063
Paris, France 97 - 05 347,778 381 1.10 9,192
Poland 99 - 04 1,189,902 1,744 1.47 15,739
Saxony Anhalt, Germany 96 - 05 146.511 303 2.07 4,115
Strasbourg, France 97 - 02 80,919 117 1.45 2,053
Tuscany, Italy 02 - 05 112,684 107 0.94 1,891
Vaud, Switzerland 97 - 05 65,339 69 1.06 2,070
Wales, UK 98 - 05 255,077 360 1.41 7,872
Wielkopolska, Poland 99 - 04 206,481 320 1.55 3,780
Zagreb, Croatia 95 - 04 59,253 65 1.10 779
Total 95 - 05 3,881,592 5511 1.42 80,052
* Prevalence of orofacial cle  per 1000 births 
# Controls: all non chromosomal, non orofacial cle , registrations 
Criteria for registries to participate in the study were as follows:
1.  Maternal epilepsy or antiepileptic drug exposure recorded for at least 
3 per 1,000 registrations for the study period. This criterion was set a 
priori based on population information on epilepsy prevalence to exclude 
registries with low ascertainment of epilepsy.
2.  Specifi c drug name or complete seven-digit ATC code available for at least 
80% of antiepileptic drug exposed babies/fetus for the study period.
Nineteen registries met these criteria. The study period for each registry 
(table 1) started in or after the year of lamotrigine licensing in the country. 
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The study population comprised a total of 3,881,592 births. The total number 
of congenital anomaly registrations in the study population was 98,075, of 
which 11,784 were chromosomal and 86,291 nonchromosomal.
Part I: Case-control study
Study design
Population-based case-control study, with malformed controls. Odds of 
lamotrigine exposure among orofacial cleft registrations (cases) was compared 
with the odds of lamotrigine exposure among malformed non-orofacial cleft 
registrations (controls).
Case defi nition
Livebirths, fetal deaths from 20 weeks, and terminations of pregnancy 
following prenatal diagnosis with nonchromosomal orofacial clefts. The 
primary hypothesis concerned isolated orofacial cleft, the subject of the 
FDA alert, and secondary hypotheses concerned isolated cleft palate, which 
carried a higher relative risk than cleft lip in the original signal, and a wider 
defi nition of nonsyndromic orofacial cleft and cleft palate, including multiply 
malformed cases [1-2].
Monogenic syndromes (n=163) were excluded. Also excluded were cases 
where orofacial cleft was secondary to another primary anomaly (n=345) such 
as holoprosencephaly or Pierre Robin sequence. Isolated (I) orofacial clefts 
were designated by a panel of three medical geneticists, blind to exposure 
status, to include only those orofacial clefts without another anomaly, or 
with only a minor or unspecifi ed anomaly, or an anomaly forming part of the 
orofacial cleft malformation [10].
Control defi nition
Livebirths, fetal deaths from 20 weeks gestation, and terminations of 
pregnancy following prenatal diagnosis, with nonchromosomal, non orofacial 
cleft, major defects.
Exposure defi nition
Registrations with coded maternal epilepsy or antiepileptic drug exposure 
(whether for epilepsy or not) were extracted from the database, and verifi ed 
with participating registries. Exposures were classifi ed as monotherapy versus 
polytherapy (use of two or more drugs in the fi rst trimester), and by type of 
antiepileptic drug (lamotrigine, valproic acid, carbamazepine, other). After 
verifi cation with registries, 98.9% of antiepileptic drug exposures were of 
known drug name. To avoid misclassifi cation we excluded epileptic mothers 
without recorded antiepileptic drug exposure from both cases and controls 
(9 cases, 185 controls). An additional 5 case and 21 control mothers were 
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excluded (mothers with childhood epilepsy or epilepsy prior to pregnancy or 
unconfi rmed epilepsy without antiepileptic drug use).
Statistical analysis
Crude odds ratios were calculated ignoring the registry of origin. In order to 
analyze the data taking into account the registry and including all registries (even 
if they had no exposure to lamotrigine in either cases or controls) the WinBUGS 
computer package was used to fi t multinomial responses with a logistic link. 
Maternal age was treated as a categorical variable (<20, 20–24, 25–30, 30–35, 
and 35> years of age). Due to the small numbers of exposures to lamotrigine it 
was not possible to adjust simultaneously for both registry and maternal age. 
Odds ratios are equivalent to a relative risk where the outcome is rare.
Statistical power
We designed the study to answer the concern raised by the FDA alert regarding 
an observed relative risk of isolated orofacial clefts of approximately 17 
relative to a generally raised risk of other malformations1-2. We estimated 
with the EUROCAT population expected to be available for study, and the 
estimated exposure rate, 80%power and p 0.05, that the study could detect an 
odds ratio of 5 for isolated orofacial clefts and 10 for isolated cleft palate, i.e., 
enough power to confi rm or refute an excess of the size of the original signal. 
The fi nal study population was larger than estimated, giving a higher power.
Table 2: Antiepileptic drug (antiepileptic drug) exposure among registrations*
number Per 1,000 registrations
N= 85,563
Any antiepileptic drug 495 5.79
Any antiepileptic drug monotherapy 409 4.78
   Valproic acid monotherapy 181 2.12
   Carbamazepine monotherapy 125 1.46
   Lamotrigine monotherapy 40 0.47
   Other monotherapy* 63 0.74
Any antiepileptic drug polytherapy 86 1.01
   Including valproic acid 57 0.67
   Including carbamazepine 39 0.46
   Including lamotrigine *** 32 0.37
   Other polytherapy**** 4 0.05
*  Registrations include cases of orofacial cle  and controls (other malformations) as defi ned in 
the Methods section.
**  26 phenobarbital, 9 oxcarbazepine, 7 clonazepam, 5 phenytoin, 3 primidon, 3 topiramate, 
2 methylphenobarbital, 1 levetriacetam, 1 ethosuximide, 6 unspecifi ed
***  22 out of 32 of lamotrigine polytherapy included valproic acid and 8 out of 32 included 
carbamazepine
****  polytherapy without valproic acid, carbamazepine or lamotrigine
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Part II: Exploratory hypothesis-generating analysis.
An exploratory hypothesis-generating analysis compared the proportion 
of diff erent malformation subgroups, according to EUROCAT subgroup 
defi nitions, among all nonchromosomal registrations, between lamotrigine 
exposed (all and mono) and antiepileptic drug unexposed registrations. 
Exclusions were the same as for the case-control analysis [10].
A further analysis compared the proportion of chromosomal registrations 
among lamotrigine exposed and antiepileptic drug unexposed registrations, 
controlling for maternal age in 5-year age groups. Assuming no relationship 
between exposure and chromosomal anomaly risk, we would expect a lower 
proportion of chromosomal registrations if the risk of nonchromosomal 
anomalies was raised.
Ethics approval: approved by the University of Ulster Ethics Committee.
Results
Case-control study
A total of 85,563 registrations comprising 5,511 orofacial cleft cases and 
80,052 non-orofacial cleft controls were eligible for the case-control analysis 
(table 1). Of the 5,511 orofacial cleft cases, 4,571 were isolated, and 1,969 had 
cleft palate of whom 1,532 were isolated.
There were 495 antiepileptic drug exposed cases and controls (table 2) or 
5.8 per 1,000 registrations. Seventeen out of 495 had no recorded maternal 
epilepsy, of which 1 was exposed to lamotrigine. Over 80%, 409 out of 495, 
of these antiepileptic drug exposed mothers used monotherapy (table 2). 
There were 72 lamotrigine exposed cases and controls of which 56% (40/72) 
were lamotrigine monotherapy (table 2). The proportion of antiepileptic drug 
exposed registrations declined over time (table 3) while the proportion of 
lamotrigine exposure per 1,000 registrations doubled from 0.5 in 1995–1998 
to 1.1 in the period 2002–2005 (table 3). The proportion of lamotrigine use 
among all antiepileptic drug use grew from 7.3% (6/82) in 1995–1998 to 20.5% 
(45/219) in the period 2002–2005 (table 3).
Antiepileptic drug exposed registrations were similar in maternal age to 
non exposed (28.8 versus 28.9 years), but lamotrigine exposed tended to be 
younger: 26.8 years for monotherapy and 27.8 for polytherapy. orofacial cleft 
cases had a similar mean maternal age to controls, but more detailed analysis 
shows a slightly higher risk of orofacial cleft in young mothers [13].
As expected given the types of anomalies, there were more terminations 
of pregnancy following prenatal diagnosis among controls (5,718/80,052 or 
7.1%) than among orofacial cleft cases (159/5,511 or 2.9%). The proportion 
of fetal deaths was similar between controls (1.3%) and cases (1.4%). The 
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Table 5: Distribution* of malformation subgroups by lamotrigine exposure 


















Nervous system 7,948 9.3 12 16.7 5 12.5
 Neural tube defects 3,582 4.2 6 8.3 2 5.0
   Spina bifi da 1,930 2.3 6 8.3 2 5.0
 Hydrocephaly 1,952 2.3 1 1.4 0 -
 Microcephaly 730 0.9 2 2.8 1 2.5
Eye 1,379 1.6 2 2.8 1 2.5
Ear, face & neck 1,119 1.3 3 4.2 1 2.5
Congenital heart disease 26,347 31.0 23 31.9 12 30.0
 Common arterial truncus 258 0.3 1 1.4 0 -
 Ventricular septal defect 11,872 14.0 8 11.1 2 5.0
 Atrial septal defect 8,402 9.9 10 13.9 5 12.5
 Atrial ventricular septal 
defect
639 0.8 2 2.8 1 2.5
 Tetralogy of fallot 986 1.2 1 1.4 1 2.5
 Pulmonary valve stenosis 1,362 1.6 1 1.4 1 2.5
Respiratory 1,675 2.0 3 4.2 1 2.5
Oro-facial cle s *** 5,467 6.4 5 6.9 2 5.0
 Cle  lip 3,524 4.1 3 4.2 1 2.5
 Cle  palate 1,943 2.3 2 2.8 1 2.5
Digestive system 5,382 6.3 7 9.7 5 12.5
 Oesophageal atresia 899 1.1 2 2.8 1 2.5
 Atresia/stenosis small 
intestine
299 0.3 1 1.4 1 2.5
 Ano-rectal 1,073 1.3 2 2.8 2 5.0
 Diaphragmatic hernia 761 0.9 2 2.8 1 2.5
Urinary 11,093 13.0 11 15.3 4 10.0
 Cystic kidney 2,009 2.4 5 6.9 0 -
 Cong. Hydronephrosis 3,806 4.5 1 1.4 1 2.5
Genital 6,916 8.1 5 6.9 3 7.5
 Hypospadias 5,408 6.4 4 5.6 2 5.0
Limb 16,407 19.3 19 26.4 11 27.5
 Limb reduction 2,202 2.6 1 1.4 0 -
  Upper limb reduction 1,596 1.9 1 1.4 0 -
 Club foot 3,733 4.4 7 9.7 5 12.5
 Hip dislocation 2,941 3.5 1 1.4 0 -
 Polydactyly 3,568 4.2 5 6.9 2 5.0
 Syndactyly 2,181 2.6 1 1.4 0 -
Musculo-skeletal 3,052 3.6 4 5.6 3 7.5
Disorders of skin 1,490 1.8 3 4.2 1 2.5
*  One baby can be counted in more than one subgroup if he/she has multiple malformations, 
but only once in the total.
**  the total number of registrations (85,563) minus those exposed to AEDs (495)
***  secondary cle s excluded (of whom none were exposed to lamotrigine), see Methods.
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among livebirths, 8.6 per 1,000 among fetal deaths, and 8.3 per 1,000 among 
terminations.
Table 4 shows the odds ratios for orofacial cleft (in four categories) 
with antiepileptic drug mono and polytherapy, and lamotrigine mono and 
polytherapy versus no antiepileptic drug exposure. Adjusting for registry did 
not materially aff ect the odds ratios (data not shown); however, adjusting for 
maternal age did reduce the odds ratios for lamotrigine mono and polytherapy 
as younger mothers were more likely to take lamotrigine and they were also 
at a slightly increased risk of orofacial clefts. Therefore for consistency all 
crude odds ratios and maternal age-adjusted odds ratios are presented. There 
was no evidence of an increased risk of isolated orofacial cleft relative to 
other malformations with lamotrigine monotherapy versus no antiepileptic 
drug exposure (table 4, odds ratio=0.80, 95% CI 0.11–2.85). Nor was there an 
increased risk for any of the other three categories of orofacial cleft (table 4).
Signifi cantly increased odds ratios were found with any antiepileptic 
drug exposure versus no antiepileptic drug exposure for orofacial cleft 
(adjOR=1.43, 95%CI 1.03–1.93), cleft palate (adjOR=2.37, 95%CI 1.54–3.43), 
and isolated cleft palate (adjOR=1.86, 95% CI 1.07–2.94) (table 4). Odds ratios 
for any antiepileptic drug therapy were higher for mono than for polytherapy, 
higher for cleft palate than all orofacial clefts, and higher for isolated and 
multiple orofacial clefts combined than isolated orofacial clefts alone 
(table 4). However, due to the small sample sizes, none of these diff erences 
were signifi cant.
Table 5 gives the distribution of nonchromosomal malformation subgroups 
among the 72 lamotrigine exposed and 40 lamotrigine monotherapy exposed 
cases and controls, compared to non-antiepileptic drug exposed. Shown in 
table 5 are all EUROCAT subgroups with at least one lamotrigine exposed 
registration. Cardiac anomalies are the most frequent anomalies, irrespective 
of exposure (31.0% of non-antiepileptic drug exposed registrations and 31.9% 
of exposed registrations). Most subgroups had only one or two registrations 
associated with lamotrigine exposure, so a comparison of proportions with 
non-antiepileptic drug exposed registrations is imprecise. Moreover, with 37 
subgroups, approximately two would be expected by chance alone to show 
a diff erence with a probability of less than 1 in 20. In this context, we found 
one signifi cant observation related to lamotrigine monotherapy: 5 cases 
of clubfoot (without spina bifi da) where 1.7 would be expected (p<0.05). In 
the lamotrigine group including mono and polytherapy three signifi cant 
diff erences were found: spina bifi da was in excess (p<0.01) as well as cystic 
kidney (p<0.05) and clubfoot (p<0.05).
The proportion of chromosomal registrations (n=11,781) among all non-
antiepileptic drug exposed registrations (chromosomal+nonchromosomal) 
was 12.0% compared with 4.0% for all lamotrigine exposed (n=3), and 4.8% 
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for lamotrigine monotherapy (n=2). The relative odds of a nonchromosomal 
case rather than a chromosomal case given lamotrigine monotherapy was 
2.86 (95% CI 1.00–12.5), adjusted for maternal age.
Discussion
We found no evidence of an increased risk of isolated orofacial cleft relative 
to other nonchromosomal malformations for lamotrigine monotherapy 
exposure (adjOR=0.80, 95% CI 0.11–2.85), nor any evidence of an increased 
risk for isolated cleft palate (adjOR=1.01, 95% CI 0.03–5.57). Despite the 
huge size of our study population, lamotrigine exposure and orofacial clefts 
are both so rare that the CIs around our estimates of risk are wide. We can 
at present consider very unlikely a more than threefold risk of isolated 
orofacial clefts relative to other nonchromosomal malformations. Our results 
therefore do not support the results of the North American antiepileptic drug 
Pregnancy Register suggesting a 14-fold increased risk of isolated orofacial 
clefts against a 1.4-fold increase in non-orofacial cleft malformations, 
i.e., a 10-fold increased risk of isolated orofacial clefts relative to other 
malformations [1,2 revised in 6]. We fi nd a twofold higher rate of isolated 
orofacial clefts in Europe (1.2 per 1,000 births), with some variation between 
countries, than in the single hospital comparison population used by the 
North American antiepileptic drug Pregnancy Registry (0.37 per 1,000 revised 
to 0.6 per 1,000), demonstrating the importance of analyzing comparable 
exposed and unexposed populations [1,6,14-15]. Given the concern about very 
high relative risks of orofacial clefts with lamotrigine monotherapy, we report 
here the results to date, but continued surveillance will allow us to address 
the possibility of less than threefold relative risks more precisely.
Our case-control study is not designed to assess whether there is a generalized 
increased risk of malformations with lamotrigine exposure, for which we would 
need to collect information on non-malformed controls as a comparison group, 
an area EUROCAT intends to develop in the future. It is possible therefore 
that some malformations resulting from lamotrigine exposure were in our 
control group, and moreover that orofacial cleft risk, while not raised relative 
to other malformations, is raised to the same degree as malformations in 
general. Our exploratory analyses showed that 1) there is no malformation 
subgroup that stands out as of particular concern in relation to monotherapy, 
suggesting that any excess risk, if present, is very non-specifi c, and 2) 
nonchromosomal anomalies are overrepresented among lamotrigine-exposed 
registrations compared to chromosomal, compatible with a generally raised 
risk of nonchromosomal malformations but based on very small numbers. The 
evidence from other studies about general malformation risk is inconclusive. 
To date, publications have reported 2,665 monotherapy exposed pregnancy 
outcomes, although some of these may come from overlapping pregnancy 
registers [1,4,6,7,16]. The UK register with 647 lamotrigine monotherapy 
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exposed fetuses found a general malformation rate of 3.2% (95% CI 2.1–4.9) 
excluding genetic syndromes. The rate of major malformations among the 
carbamazepine exposed, the main available comparison group, was 2.2% (95% 
CI 1.4–3.4) [4]. The GSK International Lamotrigine pregnancy register with 
1,053 fi rst trimester lamotrigine exposed fetuses found a prevalence of major 
congenital anomalies of 2.6% (95% CI 1.7–3.8%) excluding genetic syndromes, 
without a direct comparison group, and possibly biased by a high 26.6% loss to 
follow-up rate [6]. The North American antiepileptic drug Pregnancy Registry 
has reported 15 infants with major malformations among 564 lamotrigine 
monotherapy exposed fetuses, a rate of 2.7% (95% CI 1.5–4.3), which they 
compare to an unexposed comparison group rate of 1.6%, giving a relative 
risk of 1.7 (95% CI 1.0–2.7), or 1.4 excluding orofacial cleft [1]. The Australian 
Pregnancy register reported 6 malformed babies among 102 lamotrigine 
monotherapies (5.9%), similar to the rate for carbamazepine (10/198 or 5.0%) 
[16]. The Swedish Medical Birth Registry reported 14 malformed children, 
including minor malformations but not including terminations of pregnancy 
for fetal anomaly, among 347 women using lamotrigine monotherapy, a rate of 
4.0% (95% CI 2.3–6.8), compared to a malformation rate of 3.6% in the general 
population [6]. In Denmark, one case of VSD with lamotrigine polytherapy was 
reported among 51 lamotrigine exposed fetuses (proportion monotherapy not 
specifi ed) [7].
We did not have information on lamotrigine dose. We cannot therefore 
exclude the possibility of a specifi c risk of orofacial clefts associated with high 
dosage lamotrigine therapy, although if high dosage therapy were common 
this would have been detectable in the overall result. A higher mean dose 
among malformed compared to non-malformed outcomes has been found in 
the United Kingdom and Australia, although the latter was not signifi cant, 
but the GSK International Lamotrigine Registry could not fi nd evidence of a 
dose-response eff ect [3-4,16]. It is possible that lamotrigine dosages have been 
increasing in response to fi ndings regarding kinetics during pregnancy, and 
further surveillance of this issue is necessary [17].
We found an increased risk of orofacial cleft relative to other 
nonchromosomal malformations for antiepileptic drug exposure in general, 
which is consistent with much of the literature on drugs such as valproic 
acid and carbamazepine commonly used by epileptic mothers in our study 
population [4,18-20]. It is of interest that the increase in risk of cleft palate 
with antiepileptic drug exposure is higher than that of cleft lip (though not 
signifi cantly). In our European population, there was a 2.5-fold increase of 
cleft palate (isolated and multiple combined) relative to other malformations 
with antiepileptic drug monotherapy. The increase in risk for multiple 
malformations including orofacial cleft is higher than the increase in risk 
for isolated orofacial cleft (though again not signifi cantly). We suggest that 
in the future, attention should not be focused only on isolated orofacial 
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clefts, but also on multiply malformed individuals with orofacial clefts. The 
tendency for strong teratogens to produce multiple malformations is well 
established [21]. We also fi nd higher risks of orofacial clefts with monotherapy 
than with polytherapy. This may in part refl ect the increased risk of other 
malformations than orofacial cleft rather than the decreased risk of orofacial 
cleft, with polytherapy.
The main strengths of our study were its huge geographically defi ned study 
population, and the well validated, comparable, and specifi c information 
about congenital anomaly diagnoses in exposed and unexposed pregnancies. 
The overall rate of antiepileptic drug exposure—5.8 per 1,000 registrations—
is higher than estimated in the general pregnant population (for example, 
Dutch fi rst trimester antiepileptic drug exposure is 2.5 per 1,000), consistent 
with a higher risk of malformation with antiepileptic drug exposure, and 
confi rms good ascertainment of antiepileptic drug exposure [22]. The 
validity of our data for the detection of antiepileptic drug-associated risks of 
specifi c malformations is further supported by fi nding the well known strong 
association between valproic acid and spina bifi da in an embedded validation 
study (appendix 2), and the commonly documented association of orofacial 
cleft with other antiepileptic drug.
Post marketing surveillance of the teratogenic eff ects of antiepileptic 
drug exposure is essential to provide women and clinicians with the safety 
information they need to make optimal decisions. Very large population 
sizes are needed for surveillance as both antiepileptic drug exposure and 
congenital anomalies are rare. We have demonstrated here the usefulness of 
a multicentric case-control approach based on congenital anomaly registers 
for addressing signals relating to specifi c malformations emanating from 
pregnancy cohorts.
Our study does not support the very large specifi c risk of orofacial clefts 
reported by one previous study (see Note Added in Proof). Further surveillance 
is recommended to rule out smaller relative risks (less than threefold) of 
orofacial clefts, to investigate whether other malformation groups are at 
excess risk, and to investigate risks associated with high dose exposure.
Note added in proof: The full publication of the North American antiepileptic 
drug Registry study was online April 30, 2008, after acceptance of our paper 
for publication. The fi nal fi gures in this publication diff er from those we 
quoted from previous publications; the rate of isolated orofacial clefts among 
lamotrigine monotherapy-exposed pregnancies was revised to 7.3/1,000, and 
the rate in the comparison group to 0.7/1,000, resulting in an increased risk of 
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(Registre Vaudois des Malformations), Switzerland.
Risk assessment of antiepileptic drug use in pregnancy
60
Appendix 2
A validation study was also conducted to determine whether the well-known 
association between valproic acid and spina bifi da could be detected in the 
EUROCAT data, since this was our fi rst full antiepileptic drug study [24]. The 
same dataset was used, with the same exclusions as described for Part I, but 
the exposure of interest was valproic acid monotherapy versus no antiepileptic 
drug use and cases were nonchromosomal spina bifi da registrations, controls 
were non–spina bifi da, nonchromosomal registrations. There were 1,979 
nonchromosomal spina bifi da registrations, of which 23 were valproic acid 
monotherapy exposed and 1,933 were not exposed to any antiepileptic drug. 
Of 83,801 non–spina bifi da, nonchromosomal registrations, 158 were valproic 
acid monotherapy exposed and 83,643 were not exposed to any antiepileptic 
drug. Comparing VPA exposure to no antiepileptic drug exposure, the crude 
odds ratio was 6.3 (95% CI 4.1–9.8). Adjusting for age made no material 
diff erence.
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VALPROIC ACID MONOTHERAPY IN PREGNANCY AND 
MAJOR CONGENITAL MALFORMATIONS
J Jentink, MA Loane, H Dolk, I Barisic, E Garne, JK Morris, LTW de Jong-van den Berg, 
the EUROCAT Antiepileptic Study Working Group
N Engl J Med 2010;362:2185-2193
Background: The use of valproic acid in the fi rst trimester of pregnancy is 
associated with an increased risk of spina bifi da, but data on the risks of other 
congenital malformations are limited.
Methods: We fi rst combined data from eight published cohort studies (1565 
pregnancies in which the women were exposed to valproic acid, among which 
118 major malformations were observed) and identifi ed 14 malformations 
that were signifi cantly more common among the off spring of women who 
had received valproic acid during the fi rst trimester. We then assessed the 
associations between use of valproic acid during the fi rst trimester and these 
14 malformations by performing a case–control study with the use of the 
European Surveillance of Congenital Anomalies (EUROCAT) antiepileptic-
study database, which is derived from population-based congenital-anomaly 
registries. Registrations (i.e., pregnancy outcomes with malformations 
included in EUROCAT) with any of these 14 malformations were compared 
with two control groups, one consisting of infants with malformations not 
previously linked to valproic acid use (control group 1), and one consisting 
of infants with chromosomal abnormalities (control group 2). The data set 
included 98,075 live births, stillbirths, or terminations with malformations 
among 3.8 million births in 14 European countries from 1995 through 2005.
Results: Exposure to valproic acid monotherapy was recorded for a total of 
180 registrations, with 122 registrations in the case group, 45 in control group 
1, and 13 in control group 2. As compared with no use of an antiepileptic drug 
during the fi rst trimester (control group 1), use of valproic acid monotherapy 
was associated with signifi cantly increased risks for 6 of the 14 malformations 
under consideration; the adjusted odds ratios were as follows: spina bifi da, 
12.7 (95% confi dence interval [CI], 7.7 to 20.7); atrial septal defect, 2.5 (95% 
CI, 1.4 to 4.4); cleft palate, 5.2 (95% CI, 2.8 to 9.9); hypospadias, 4.8 (95% CI, 
2.9 to 8.1); polydactyly, 2.2 (95% CI, 1.0 to 4.5); and craniosynostosis, 6.8 (95% 
CI, 1.8 to 18.8). Results for exposure to valproic acid were similar to results for 
exposure to other antiepileptic drugs.
4
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Conclusions: The use of valproic acid monotherapy in the fi rst trimester 
was associated with signifi cantly increased risks of several congenital 
malformations, as compared with no use of antiepileptic drugs or with use of 
other antiepileptic drugs.
Introduction
Valproic acid, which has been used for the treatment of seizure for more 
than 30 years, has long been recognized as a teratogen. Maternal exposure 
to valproic acid monotherapy during the fi rst trimester was fi rst linked to 
an increased risk of congenital spina bifi da in the 1980s; subsequent studies 
confi rmed this increased risk and also suggested increased risks of other 
major congenital malformations [1-8]. Recently, the American Academy 
of Neurology recommended avoidance of valproic acid during pregnancy 
if possible [9]. However, if treatment with valproic acid has been providing 
good seizure control, it can be diffi  cult to change the drug before or during 
pregnancy [10-11].
Although a number of cohort studies of women exposed to valproic acid 
in pregnancy have shown an association with a range of malformations, these 
studies have had limited power individually to detect excess risks of specifi c 
malformations. For rare outcomes, such as these specifi c malformations, 
large population-based case-control studies are more appropriate [12-18].
We combined the data from cohort studies to identify indications that 
malformations were occurring at greater frequency than expected among 
off spring exposed to valproic acid during the fi rst trimester of pregnancy. 
We then conducted a population-based, case–control study to test our 
hypotheses, using the antiepileptic-study database established by European 
Surveillance of Congenital Anomalies (EUROCAT).
Methods
EUROCAT Database
We used the EUROCAT antiepileptic-study database, which included data 
on aff ected live births, stillbirths, fetal deaths after 20 or more weeks of 
gestation, and terminations of pregnancy after prenatal diagnosis for the 
years 1995 through 2005 from 19 population-based EUROCAT registries 
in 14 countries (for more information, see Section 1 of the Supplementary 
Appendix, available with the full text of this article at NEJM .org) [19]. The 
study sample consisted of 3,881,592 live births and stillbirths, of which 98,075 
involved a major congenital malformation.
The standard data recorded for each registration are described in EUROCAT 
Guide 1.3 [20]. Multiple sources are used to ascertain pregnancy outcomes 
with malformations (registrations) [21]. Data are managed in a standard 
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software program that is used by all registries and includes error checks [20]. 
Infants or fetuses having only malformations categorized as minor according 
to EUROCAT defi nitions were excluded [20]. One syndrome and up to eight 
malformations are coded with International Classifi cation of Diseases, Ninth 
Revision (ICD-9) or International Classifi cation of Diseases, Tenth Revision 
(ICD-10) codes, with British Pediatric Association (BPA) one-digit extensions. 
These codes are regrouped into the standard EUROCAT malformation 
subgroups [20]. Maternal illness before and during pregnancy (ICD-9 or ICD-
10 code plus descriptive information) and drug exposure in the fi rst trimester 
of pregnancy (descriptive information or Anatomical Therapeutic Chemical 
[ATC] code) are recorded [22]. The fi rst trimester is defi ned as the period from 
the fi rst day of the last menstrual period through the 12th week of gestation.
Ascertainment of Exposure
Information on maternal antiepileptic-drug exposure is mainly obtained from 
medical hospital records generated during pregnancy (for all 19 registries). 
Five registries also use other prospectively recorded sources of information 
(records from general practitioners, pharmacy records, and medical records 
held by the patient), and three registries use a structured interview or 
questionnaire after birth to acquire additional information on drug exposure. 
The persons who recorded information in registries were not aware of 
the specifi c hypothesis of the study. Antiepileptic drugs are available by 
prescription only and are typically supplied for long-term use; thus, medical 
records were considered to be a good source of data for ascertainment of 
exposure.
To be included in the EUROCAT antiepileptic study database, a registry 
must have recorded a diagnosis of maternal epilepsy or antiepileptic drug 
exposure for at least 3 registrations per 1000 (to exclude registries with low 
rates of exposure ascertainment) and must have recorded a complete drug 
name or ATC code for at least 80% of all pregnancies exposed to antiepileptic 
drugs throughout the study period (to exclude registries with incomplete data 
on exposure to antiepileptic drugs).
Study Design
We searched PubMed, Web of Science, and Embase for studies addressing 
exposure to valproic acid in pregnancy. Eight cohort studies met the inclusion 
criteria and were included in the review (see Sect ion 2 in the Supplementary 
Appendix for a description of the inclusion criteria) [12-17,23-24]. These eight 
studies included 1565 pregnancy outcomes in which there was exposure to 
valproic acid monotherapy during the fi rst trimester; in 118 of these outcomes 
there was a major congenital malformation as defi ned by EUROCAT. The 
overall rate of major congenital malformations was 7.5% (95% confi dence 
interval [CI], 6.3 to 9.0) (Table 1).
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Table 1: Overview of included studies [12-17, 23, 24]
VPA mono exposed
Study Country Included 
years
number malformed Rate (CI 95%)
Samrén 
1997




Ro erdam & 
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149 16  10.7%  (6.3-16.8)
Meador 
2006











715 44    6.2%  (4.6-8.2)
All studies 1972-2005 1565 135    8.6%  (7.3-10.1)
All studies, according to the 
EUROCAT MCM classifi cation*
1565 118    7.5%  (6.3-9.0)
*  According to the EUROCAT major congenital malformation classifi cation (based on ICD-10) 17 
were only minor and therefore excluded.
Al l 14 malformations with prevalences that were signifi cantly higher in the 
studies of maternal exposure to valproic acid than in the EUROCAT reference 
group (of 3.8 million) (P<0.05) were included in the case-control study. The 
number of cases with each of these 14 malformations is detailed in Section 2 
in the Supplementary Appendix.
To minimize the chances that we missed a group that warranted inclusion 
by looking only at cohort studies in the literature review, we also searched 
case-control studies. The one additional group we found — limb-reduction 
malformations [25-26] — was excluded to avoid a possible underestimation 
in the case-control analyses; we examined the group with limb-reduction 
malformations separately.
We used the EUROCAT antiepileptic-study database to compare the 
odds of exposure to valproic acid monotherapy among cases (for each of 
the 14 malformations identifi ed from the literature review) with the odds 
of exposure in two groups of controls — a group with major malformations 
other than those under study and a group with malformations associated 
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with chromosomal abnormalities. Exposure to valproic acid monotherapy 
during the fi rst trimester was compared with the absence of exposure to 
antiepileptic drugs and with exposure to an antiepileptic-drug monotherapy 
other than valproic acid.
Cases were defi ned as all live births, fetal deaths after at least 20 weeks 
of gestation, and terminations of pregnancy after prenatal diagnosis with 
at least one of the following malformations: spina bifi da, microcephaly, 
ventricular septal defect, atrial septal defect, tetralogy of Fallot, pulmonary-
valve atresia, hypoplastic right heart, cleft palate (without associated cleft 
lip), diaphragmatic hernia, gastroschisis, hypospadias, clubfoot, polydactyly, 
and craniosynostosis. All cases with a diagnosed chromosomal or monogenic 
syndrome were excluded.
Control group 1 included livebirths, fetal deaths after 20 weeks or more of 
gestation, and pregnancy terminations after prenatal diagnosis that involved 
major malformations other than the 14 malformations under study. We 
excluded chromosomal disorders (the disorders in control group 2), as well as 
identifi ed syndromes (1806 registrations); cleft lip, cleft lip and palate, or the 
Pierre Robin sequence without a reported cleft palate (3382); limb-reduction 
defects (1704); and anencephaly or encephalocele (1759). We also excluded 
fi ve controls for which type of birth was unknown. Control group 2 comprised 
live births, fetal deaths after 20 weeks or more of gestation, and pregnancy 
terminations after prenatal diagnosis that involved malformations associated 
with chromosomal abnormalities. We excluded two of the entries in this 
group because type of birth was unknown.
All registrations with recorded maternal antiepileptic-drug use or maternal 
epilepsy were selected, verifi ed by the registry, and coded according to the 
name of the antiepileptic drug. After verifi cation, 99.9% of the antiepileptic 
drugs to which mothers were exposed in the fi rst trimester of pregnancy 
had been identifi ed. To minimize the risk of misclassifi cation, we excluded 
all registrations for which there had been a previous diagnosis of maternal 
epilepsy but for which there was no history of maternal antiepileptic-drug 
use in the fi rst trimester (a total of 96 cases, 122 controls in group 1, and 19 
controls in group 2).
Statistical Analysis
Logistic-regression analysis was used to calculate odds ratios with Stata 
software, version 10. Crude odds ratios were calculated for all registries, 
including those without records of valproic acid exposure. Odds ratios were 
adjusted for maternal age (categorized as less than 25 years, 25 to 29 years, 30 
to 34 years, or more than 34 years) and the child’s year of birth (categorized 
as being between 1995 and 1998, between 1999 and 2001, or between 
2002 and 2005). Odds ratios were also adjusted for the individual registry 
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(registries with no entries for valproic acid exposure were excluded) in the 
comparison of exposure to valproic acid monotherapy with no exposure to 
antiepileptic drugs; there were too few controls to make this adjustment in 
other comparisons. For anomalies for which there were fewer than six cases 
with exposure to valproic acid, no adjustments were made and the exact 
confi dence intervals are presented.
Results
A total of 37,154 cases, 39,472 controls without chromosomal abnormalities 
(control group 1), and 11,763 controls with chromosomal abnormalities 
(control group 2) were included in the study. The frequency of maternal use of 
antiepileptic drugs overall in the fi rst trimester of pregnancy was 5.7 per 1000 
registrations, and the frequency of maternal use of valproic acid specifi cally 
was 2.0 per 1000. The frequency of exposure to valproic acid was three times 
as high among cases (3.3 per 1000 registrations) as among controls in both 
groups (1.1 per 1000) (Table 2).
Table 2:  Antiepileptic drug (AED) exposure in the fi rst trimester of pregnancy among 







number Per 1,000 
registrations
number Per 1,000 
registrations
number Per 1,000 
registrations
Unexposed to AED 36,869 39,290 - 11725 -
Any AED 285 7.7 182 4.6 38 3.2
Any AED monotherapy
   Valproic acid
    Other monotherapy
223 6.0 155 3.9 32 2.7
 122  3.3  45  1.1  13  1.1
 101^  2.7  110^^  2.8  19^^^  1.6
*  All cases with spina bifi da, microcephaly, VSD, ASD, tetralogy of Fallot, pulmonary valve atresia, 
hypoplastic right heart, cle  palate, diaphragmatic hernia, gastroschisis, hypospadias, club foot, 
polydactyly, or craniosynostosis.
^  58 carbamazepine, 21 lamotrigine, 8 phenobarbital, 4 oxcarbazepine, 3 clonazepam, 2 phenytoin, 
1 methylphenobarbital, 1 topiramate and 3 unspecifi ed
^^  65 carbamazepine, 18 lamotrigine, 9 phenobarbital, 7 oxcarbazepine, 3 phenytoin, 3 primidon, 
2 clonazepam, 1 ethosuximide, 1 methylphenobarbital and 1 topiramate
^^^  10 carbamazepine, 4 phenobarbital, 2 lamotrigine, 1 clonazepam, 1 oxcarbazepine and 1 phenytoin
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Table 3:  Odds ratios (OR) for valproic acid (VPA) monotherapy exposure compared to no 
antiepileptic drug (AED) exposure and other AED monotherapy exposure, using two 
malformed control groups
VPA monotherapy










27 C1~ 12.7 [7.7-20.7]   5.7 [2.6-12.3]+
C2~ 16.3 [8.0-33.4]   3.5 [1.2-10.0]+
microcephaly*
N=696
2 C1   2.5 [0.3-9.7]^   1.6 [0.1-14.7]^














19 C1   1.6 [0.9-2.7]   2.2 [1.1-4.4]+
C2   1.8 [0.8-3.9]   1.5 [0.6-4.2]+
ASD
N=8,267
19 C1   2.5 [1.4-4.4]   3.2 [1.5-7.0]+
C2   3.3 [1.4-7.4]   2.4 [0.8-7.0]+
tetralogy of Fallot N=960 3 C1   2.8 [0.6-8.6]^   1.5 [0.2-7.9]^
C2   2.8 [0.5-10.4]^   0.9 [0.1-5.5]^
pulmonary valve atresia
N=311
1 C1   2.8 [0.1-16.7]^   2.4 [0.0-193.6]^
C2   2.9 [0.1-19.5]^   1.5 [0.0-120.7]^
hypoplastic right heart
N=85




13 C1   5.2 [2.8-9.9]   3.0 [1.2-7.4]+
C2   5.2 [2.2-12.3]   1.9 [0.6-5.9]+
diaphragmatic hernia
N=754
2 C1   2.3 [0.3-9.0]^   1.2 [0.1-8.9]^
C2   2.4 [0.3-10.7]^   0.7 [0.1-6.1]^
gastroschisis
N=798
1 C1   1.1 [0.0-6.5]^   1.2 [0.0-24.0]^
C2   1.1 [0.0-7.6]^   0.7 [0.0-15.6]^
hypospadias, boys only
N=5,395
32 C1 4.8 [2.9-8.1] 6.7 [2.9-15.2]+





6 C1   1.6 [0.7-3.7]   1.3 [0.5-3.9]+
C2   2.2 [0.8-6.7]   1.2 [0.3-4.7]+
Polydactyly
N=3,500
9 C1   2.2 [1.0-4.5]   7.1 [1.8-28.4]+
C2   2.4 [0.9-6.4]   4.4 [0.8-22.6]+
craniosynostosis
N=520
4 C1   6.8 [1.8-18.8]^   4.9 [0.7-55.2]^
C2   7.0 [1.7-22.9]^   2.9 [0.4-35.8]^
**  one case/control can be counted in more than one subgroup.
*  club foot and microcephaly without spina bifi da
#  OR are adjusted for reporting registry, birth year and maternal age
~  C1 control group 1: registrations without chromosomal abnormalities. C2 control group 2: 
registrations with chromosomal abnormalities (numbers are presented in table 2).
+  OR adjusted for birth year and maternal age
^  OR not adjusted due to small number of exposed cases
  The number of unexposed cases can be found in web appendix 3
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In analyses of cases and the controls in group 1, exposure to valproic acid 
monotherapy during the fi rst trimester as compared with no exposure 
to antiepileptic drugs during that period was associated with signifi cant 
increases in the risks of spina bifi da, atrial septal defect, cleft palate, 
hypospadias, polydactyly, and craniosynostosis but not in the risks of 
microcephaly, tetralogy of Fallot, pulmonary-valve atresia, diaphragmatic 
hernia, ventricular septal defect, hypoplastic right heart (no exposed cases), 
gastroschisis, or club foot (Table 3). Adjustment for reporting registry, birth 
year of the registration, and maternal age did not substantively aff ect the 
results (see Section 3 in the Supplementary Appendix for details).
Using the same control group, we found generally similar associations 
between valproic acid exposure and malformations when valproic acid 
monotherapy was compared with monotherapy with another antiepileptic 
drug — with two exceptions. When compared with use of another antiepileptic 
drug, valproic acid use was not associated with a signifi cantly increased risk 
of craniosynostosis but was associated with a signifi cantly increased risk of 
ventricular septal defect.
In corresponding analyses comparing cases with the controls in group 2 
(those with chromosomal abnormalities), the results were generally similar. 
Separate analyses of the suggested association between valproic acid exposure 
and limb reduction showed a signifi cantly increased risk of limb reduction 
(crude odds ratio, 3.4; 95% CI, 1.6 to 7.2) as compared with the absence of 
exposure to antiepileptic drugs.
In control group 1, we also compared the distribution of malformations 
among controls exposed to valproic acid with the distribution among controls 
without exposure to antiepileptic drugs and found no signifi cant diff erences 
(data not shown). We found no malformations other than those reported in 
the literature that had a signifi cant association with valproic acid exposure 
in this group.
Discussion
In a review of published cohort studies, we identifi ed 14 major congenital 
malformations for which the risk appeared to be signifi cantly increased 
in association with exposure to valproic acid monotherapy during the fi rst 
trimester of pregnancy as compared with no exposure to antiepileptic 
drugs during the fi rst trimester. We then tested these indications in a large 
population-based case-control study and found signifi cant associations 
between exposure to valproic acid monotherapy in the fi rst trimester (as 
compared with no exposure to antiepileptic drugs) and six of these conditions: 
spina bifi da, atrial septal defect, cleft palate, hypospadias, polydactyly, and 
craniosynostosis. Risks for fi ve of these conditions were 2 to 7 times as high 
for exposed fetuses, and the risk for the sixth condition, spina bifi da, was 12 
or 16 times as high, depending on the control group used. We also found an 
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association between limb defects and exposure to valproic acid monotherapy 
as compared with no exposure to antiepileptic drugs, as suggested in previous 
case-control studies.
Signifi cant associations with valproic acid exposure were noted for 
fi ve of the six specifi c malformations in analyses comparing exposure to 
valproic acid monotherapy with other antiepileptic-drug monotherapy; an 
association with craniosynostosis was not found. A signifi cant association 
with ventricular septal defect was detected, but only for the comparison of 
cases with controls in the group that had malformations not associated with a 
chromosomal abnormality — not for the comparison of cases with the other 
control group. Although the observational nature of this study precludes a 
conclusion about cause and eff ect, these fi ndings support a relationship of 
these malformations to valproic acid specifi cally rather than to antiepileptic 
drugs generally or to underlying epilepsy. Valproic acid is used for various 
indications in European countries, which means that its use is unlikely to 
be very strongly related to a particular type or severity of epilepsy. However, 
we do not have information on the type or severity of epilepsy and therefore 
cannot rule out the possibility of confounding by indication.
Studies evaluating the risk of general malformations after in utero 
exposure to an antiepileptic drug as compared with no such exposure have 
shown that the risk is signifi cantly higher with exposure to valproic acid than 
with exposure to other antiepileptic drugs. Furthermore, these studies have 
suggested increased risks of malformations in general in association with 
higher doses of valproic acid as compared with lower doses [13,15-17]. Since 
our data set does not include dose information, we were not able to address 
this question.
Previous studies of valproic acid monotherapy during the fi rst trimester 
and the risk of specifi c malformations, other than spina bifi da, have generally 
been limited by relatively small samples or potential selection bias, since they 
have not been population-based [11,13,15,17,27-28]. Our results are in line 
with those of another large, population-based, case-control registry study 
of congenital malformations in which the control group had malformations; 
specifi c associations were reported between valproic acid exposure and 
spina bifi da, hypospadias, malformations of the brain and heart, and limb-
reduction malformations [26].
A recent study showed that children exposed to valproic acid in utero were 
more likely to have impaired cognitive function at 3 years of age than children 
exposed in utero to other antiepileptic drugs [29]. The American Academy of 
Neurology has recommended avoiding valproic acid in pregnancy, if possible, 
on the basis of evidence that exposure to valproic acid is associated with 
an increased risk of major congenital malformations and poor cognitive 
outcomes and confers a higher risk than that associated with exposure to 
other antiepileptic drugs [9].
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For malformations seen less frequently, our study was able to rule out very 
large risks but not smaller risks. The confi dence limits were wide, showing 
that even a study of nearly 4 million pregnancies is not enough to address a 
potentially moderate association between rare malformations and relatively 
rare drug exposures.
A limitation of our study, as discussed above, is the lack of information on 
potential confounders. Furthermore, we used controls with malformations 
instead of those without malformations, since EUROCAT does not 
include detailed population-based data on pregnancy outcomes without 
malformations. An advantage of using controls with malformations is 
that it minimizes the potential for recall bias and other possible sources of 
diff erential exposure ascertainment, although such biases would be unlikely 
to infl uence the results, since most drug information was recorded before 
the outcome of pregnancy was known. Use of controls with malformations 
for comparison could lead to a conservative estimation of the risk associated 
with valproic acid exposure if some of the malformations present in the 
control group were also associated with this exposure; however, by design we 
excluded from the control groups malformations previously associated with 
valproic acid exposure. The rate of valproic acid exposure was similar in the 
two control groups (1.1 per 1000), and the point estimates for the control group 
with chromosomal abnormalities were similar but slightly higher than those 
for the control group without chromosomal abnormalities in comparisons 
of exposure to an antiepileptic drug with no such exposure. We therefore 
concluded that there was likely to be little or no contamination of our control 
groups with malformation types associated with valproic acid exposure and 
that underestimation of odds ratios because of this bias was unlikely.
Although the relative risks of several malformations were increased in 
association with exposure to valproic acid during the fi rst trimester, it should 
be recognized that the absolute rates of specifi c malformations are low, 
and the majority of children born to mothers who take valproic acid do not 
have malformations. For example, the baseline prevalence of spina bifi da 
is about 0.5 cases per 1000 (see Section 2 in the Supplementary Appendix). 
We calculated an adjusted odds ratio of 12.7 for the risk of spina bifi da when 
comparing exposure to valproic acid with no exposure to an antiepileptic drug 
(Table 3); the absolute risk of having a child with spina bifi da is approximately 
0.6% in cases of exposure to valproic acid monotherapy during the fi rst 
trimester. The estimated absolute risks for the other fi ve malformations 
after exposure are as follows: atrial septal defect, 0.5%; cleft palate, 0.3%; 
hypospadias, 0.7%; polydactyly, 0.2%; and craniosynostosis, 0.1%. In 
determining whether to prescribe antiepileptic drugs, as well as which drug 
to prescribe, several factors must be taken into account, among them the goal 
of optimizing seizure control in the individual patient. The decision should be 
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made by the patient and her clinician after consideration of the benefi ts and 
risks of various agents.
In summary, we found that exposure to valproic acid during the fi rst 
trimester was associated with increased risks of six specifi c malformations, 
as compared with no exposure to antiepileptic drugs, and the risks of fi ve of 
these six malformations remained signifi cantly increased when we compared 
valproic acid exposure with exposure to other antiepileptic drugs. Our fi ndings 
provide further support for the recommendation of the American Academy of 
Neurology to avoid the use of valproic acid, if possible, in pregnant women [9]. 
Since switching drugs during or just before pregnancy is diffi  cult, the risks 
associated with valproic acid use should be routinely considered in choosing 
therapy for women with childbearing potential.
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Members of the EUROCAT Antiepileptic Study Working Group include the 
following: C. Verellen-Dumoulin (Centre de Génétique Humaine Institut de 
Pathologie et de Génétique), V. Nelen (Provinciaal Instituut voor Hygiene), 
Belgium; I. Barisic (Children’s University Hospital Zagreb), Croatia; E. Garne 
(Lillebaelt Hospital, Kolding), Denmark; B. Khoshnood (Institut National de 
la Santé et de la Recherche Medicale), B. Doray (Registre des Malformations 
Congenitales d’Alsace), France; S. Poetzsch (Otto-von-Guericke Universität 
Megdeburg), A. Wiesel (Johannes Gutenberg Universität, Geburtenregister 
Mainzer Modell), Germany; M. O’Mahony (Health Service Executive), 
Ireland; A. Pierini (Istituto di Fisiologia Clinica del Consiglio Nazionale 
delle Ricerche), F. Rivieri (Azienda Ospedaliero Universitaria di Ferrara), 
Italy; M. Gatt (Department of Health Information and Research), Malta; M. 
Bakker (University Medical Center Groningen, University of Groningen), 
the Netherlands; K. Melve (Norwegian Institute of Public Health, Medical 
Birth Registry of Norway), Norway; A. Latos-Bielenska, J.P. Mejnartowicz 
(Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu), Poland; I. 
Portillo (Direccion Salud Publica, Departamento Sanidad, Gobierno Vasco), 
Spain; M.-C. Addor (Registre Vaudois des Malformations), Switzerland; D. 
Tucker (Swansea National Health Service Trust, Congenital Anomaly Register 
and Information Service for Wales), D. Wellesley (Southampton University 
Hospitals Trust), United Kingdom.
Web Appendix 1
Participating registries: Belgium (Antwerp and Hainaut), Croatia (Zagreb), 
Denmark (Odense), France (Paris and Strasbourg), Germany (Mainz and 
Saxony Anhalt), Ireland (Cork & Kerry), Italy (Emilia Romagna and Tuscany), 
Malta, Netherlands (northern part), Norway, Poland (Wielkopolska, Poland), 
Spain (Basque Country), Switzerland (Vaud) and UK (Wales)
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Web Appendix 2
We searched PubMed, Web of Science and Embase for studies addressing 
VPA exposure in pregnancy and found over 1500 studies using the following 
search strategy: {“valproic acid”[Mesh] OR “epilepsy/drug therapy”[Majr] OR 
“antiepileptic drugs”[ti] OR “AED”[ti]} AND {“congenital abnormalities”[Majr] 
OR “pregnancy complications/drug therapy”[Majr] OR “birth defects”[ti]}. The 
criteria for selecting studies were: non-overlapping cohort studies that reported 
a case list with detailed information about malformations, reported the size of 
the VPA exposed cohort and reported the defi nition of the study population 
and the study period. Eight cohort studies met the criteria (Table 1) [12-17, 23-
24]. Authors of two studies that did not include suffi  cient details to categorize 
some malformations were contacted to obtain additional information [13,16].
In the 8 studies, malformations reported in off spring with fi rst trimester 
VPA exposure were classifi ed according to the EUROCAT congenital anomaly 
subgroups. The EUROCAT AED database was used as the reference group; 
the prevalences of various malformations in this database were calculated 
after excluding registrations with maternal AED exposure, maternal epilepsy, 
or chromosomal anomalies. Diff erences in prevalence between the published 
studies and EUROCAT reference group were compared using a chi square test 
with Yates’ correction (Program used: S-PLUS7.0). All malformation subgroups 
for which the prevalence in studies of maternal VPA exposure was signifi cantly 
higher than in the EUROCAT referent group (at p-value less than 0.05) were 









Malformation sub group number prev./1000 number* prev./1000  p-value#
spina bifi da 22 14.1 1933 0.5  p < 0.001
microcephaly 2 1.3 745 0.2  p = 0.030
VSD 12 7.7 11896 3.1  p < 0.001
ASD 11 7.0 8428 2.2  p < 0.001
tetralogy of Fallot 3 1.9 991 0.3  p = 0.001
pulmonary valve atresia 3 1.9 339 0.1  p < 0.001
hypoplastic right heart 1 0.6 99 0.03  p = 0.023
cle  palate 13 8.3 2338 0.6  p < 0.001
diaphragmatic hernia 4 2.6 766 0.2  p < 0.001
Gastroschisis 2 1.3 807 0.2  p = 0.041
Hypospadias 22 14.1 5418 1.4  p < 0.001
club foot 8 5.1 3847 1.0  p < 0.001
Polydactyly 8 5.1 3594 0.9  p < 0.001
craniosynostosis 5 3.2 551 0.1  p < 0.001
^ All specifi c malformations found in the literature review were defi ned over 75 malformation 
sub groups; 41 sub groups were fi lled with at least one case and 14 of these sub groups showed 
a signifi cant increased prevalence compared with the EUROCAT population.
# calculated with a chi square test with Yate’s correction
* excluding chromosomal and AED exposed registrations
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Web Appendix 3
Unadjusted odds ratio’s for VPA monotherapy compared with ‘no AED’ (fi rst column) and 
‘other AED monotherapy’ (second column) using non-chromosomal controls (C1) and 
chromosomal controls (C2)
VPA monotherapy

















27 C1 11.9 [7.0-19.5]   5.1 [2.3-11.6] 1996 13
C2 12.2 [6.1-25.8]   3.0 [1.0-8.9]
microcephaly*
N=696
2 C1   2.5 [0.3-9.7]   1.6 [0.1-14.7] 690 3














19 C1   1.4 [0.8-2.5]   2.0 [09-4.3] 11659 23
C2   1.5 [0.7-3.2]   1.2 [0.4-3.4]
ASD
N=8,267
19 C1   2.0 [1.1-3.5]   3.1 [1.3-7.1] 8216 15
C2   2.1 [1.0-4.6]   1.9 [0.6-5.5]
tetralogy of Fallot 
N=960
3 C1   2.8 [0.6-8.6]   1.5 [0.2-7.9] 951 5
C2   2.8 [0.5-10.4]   0.9 [0.1-5.5]
pulmonary valve atresia
N=311
1 C1   2.8 [0.1-16.7]   2.4 [0.0-193.6] 309 1
C2   2.9 [0.1-19.5]   1.5 [0.0120.7]
hypoplastic right heart
N=85




13 C1   5.1 [2.5-9.7]   2.9 [1.1-7.7] 2215 11
C2   5.3 [2.3-12.4]   1.7 [0.5-5.8]
diaphragmatic hernia
N=754
2 C1   2.3 [0.3-9.0]   1.2 [0.1-8.9] 747 4
C2   2.4 [0.3-10.7]   0.7 [0.1-6.1]
gastroschisis
N=798
1 C1   1.1 [0.0-6.5]   1.2 [0.0-24.0] 794 2
C2   1.1 [0.0-7.6]   0.7 [0.0-15.6]
hypospadias, boys only
N=5,395
32 C1 4.5 [2.6-7.8] 6.6 [2.8-16.6] 5343 11





6 C1   1.4 [0.5-3.4]   1.2 [0.4-3.8] 3651 12
C2   1.5 [0.5-4.2]   0.7 [0.2-2.8]
Polydactyly
N=3,500
9 C1   2.3 [1.0-4.7]   5.5 [1.4-25.4] 3481 4
C2   2.3 [0.9-5.9]   3.3 [0.7-17.4]
craniosynostosis
N=520
4 C1   6.8 [1.8-18.8]   4.9 [0.7-55.2] 513 2
C2   7.0 [1.7-22.9]   2.9 [0.4-35.8]
The numbers in the table can not be summed to get the total because polytherapy is not shown (eg. 
spina bifi da 27+1996+13=2036 plus 10 polytherapy exposed=2046)
^  C1: Control group 1: all non-chromosomal, non-monogenic registrations without any of the 
malformations under study
  C2: Control group 2: all chromosomal malformations ( for exact defi nitions, see Methods)
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INTRAUTERINE EXPOSURE TO CARBAMAZEPINE 
AND SPECIFIC CONGENITAL MALFORMATIONS: 
SYSTEMATIC REVIEW AND CASE-CONTROL STUDY
J Jentink, H Dolk, MA Loane, JK Morris, D Wellesley, E Garne, LTW De Jong-van den 
Berg, the EUROCAT Antiepileptic Study Working Group
BMJ 2010;341:c6581
Objective: To identify specifi c major congenital malformations associated with 
use of carbamazepine in the fi rst trimester of pregnancy.
Design: A review of all published cohort studies to identify key indications and a 
population based case-control study to test these indications.
Setting: Review of PubMed, Web of Science, and Embase for papers about 
carbamazepine exposure in the fi rst trimester of pregnancy and specifi c 
malformations, and the EUROCAT Antiepileptic Study Database, including data 
from 19 European population-based congenital anomaly registries, 1995-2005.
Participants: The literature review covered eight cohort studies of 2680 
pregnancies with carbamazepine monotherapy exposure, and the EUROCAT 
dataset included 98 075 registrations of malformations covering over 3.8 
million births.
Main outcome measures: Overall prevalence for a major congenital 
malformation after exposure to carbamazepine monotherapy in the fi rst 
trimester. Odds ratios for malformations with exposure to carbamazepine 
among cases (fi ve types of malformation identifi ed in the literature review) 
compared with two groups of controls: other non-chromosomal registrations 
of malformations and chromosomal syndromes.
Results: The literature review yielded an overall prevalence for a major 
congenital malformation of 3.3% (95% confi dence interval 2.7 to 4.2) after 
exposure to carbamazepine monotherapy in the fi rst trimester. In 131 
registrations of malformations, the fetus had been exposed to carbamazepine 
monotherapy. Spina bifi da was the only specifi c major congenital malformation 
signifi cantly associated with exposure to carbamazepine monotherapy (odds 
ratio 2.6 (95% confi dence interval 1.2 to 5.3) compared with no antiepileptic 
5
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drug), but the risk was smaller for carbamazepine than for valproic acid (0.2, 
0.1 to 0.6). There was no evidence for an association with total anomalous 
pulmonary venous return (no cases with carbamazepine exposure), cleft lip 
(with or without palate) (0.2, 0.0 to 1.3), diaphragmatic hernia (0.9, 0.1 to 6.6), 
or hypospadias (0.7, 0.3 to 1.6) compared with no exposure to antiepileptic 
drugs. Further exploratory analysis suggested a higher risk of single ventricle 
and atrio-ventricular septal defect.
Conclusion: Carbamazepine teratogenicity is relatively specifi c to spina bifi da, 
though the risk is less than with valproic acid. Despite the large dataset, 
there was not enough power to detect moderate risks for some rare major 
congenital malformations.
Introduction
Carbamazepine is one of the most commonly used antiepileptic drugs in 
Europe among women of child-bearing age. Several cohort studies have 
evaluated the risk of major congenital malformations associated with 
carbamazepine, and it seemed to be less teratogenic than valproic acid [1-6]. 
Although around 3000 pregnancies with recorded carbamazepine exposure 
have been described in the literature, each individual study on its own is 
too small to have the statistical power to detect risks for specifi c congenital 
malformations compared with other antiepileptic drugs [4,7-8].
The EUROCAT (European Surveillance of Congenital Anomalies) 
Antiepileptic Study Database, which was set up for a study of lamotrigine, 
covered 3,881,592 births and contains 131 registrations of malformation in 
pregnancy outcomes exposed to carbamazepine monotherapy, more than 
in any other published study [9]. This enabled the examination of risks of 
specifi c major congenital malformations associated with carbamazepine 
monotherapy.
We reviewed and combined studies on carbamazepine to identify 
indications of increased risks of specifi c malformations after intrauterine 
exposure to carbamazepine monotherapy in the fi rst trimester of pregnancy. 
We tested these indications, or prior hypotheses, in a case-control study using 
two control groups of malformations.
Methods
EUROCAT
The EUROCAT Antiepileptic Study Database has been previously described 
[6,9-10]. It was drawn from 19 population based registries of congenital 
anomaly in Europe, covering 3,881,592 births in Europe in 1995-2005 and 
98,075 major congenital malformations: 86,291 non-chromosomal and 11,784 
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chromosomal. Information was available for live births, still births or late fetal 
deaths from 20 weeks’ gestation, and terminations of pregnancy after prenatal 
diagnosis. The database includes data from registries in Belgium(Antwerp and 
Hainaut), Croatia (Zagreb), Denmark (Odense), France (Paris and Strasbourg), 
Germany (Mainz and Saxony-Anhalt), Ireland (Cork and Kerry), Italy (Emilia 
Romagna and Tuscany), Malta, Netherlands (northern part), Norway, Poland 
(Wielkopolska, rest of Poland), Spain (Basque Country), Switzerland (Vaud), 
and the United Kingdom (Wales).
Literature review
We reviewed PubMed, Web of Science, and Embase for papers about 
carbamazepine exposure in the fi rst trimester of pregnancy and specifi c 
malformations using the following search strategy: ((“Carbamazepine”[Mesh] 
OR “antiepileptic drugs”[ti] OR “AED”[ti]) AND (“Congenital 
Abnormalities”[Majr] OR “Pregnancy Complications/drug therapy”[Majr] 
OR “birth defects”[ti]) NOT “Clinical Trials, Phase I as Topic”[Mesh] NOT 
(“Models, Animal”[Mesh] OR “Animal Experimentation”[Mesh])) AND “Cohort 
Studies”[Mesh] (PubMed n=44) and ‘carbamazepine and malformation and 
pregnancy’ (Web of Science n=141 and Embase n=30). We identifi ed nine 
cohort studies that contained a specifi ed case list of all pregnancy outcomes 
with malformation (table 1) [1-5,11-14]. We contacted four authors to get more 
information about the case list; three were able to supply the information 
requested and were included, the fourth was excluded [1, 3-5].
The eight cohort studies included outcomes of 2,680 pregnancies 
with carbamazepine monotherapy exposure. Of these, 101 babies had a 
malformation, 89 of which were classifi ed as major according to EUROCAT 
and were classifi ed according to 49 standard EUROCAT congenital anomaly 
subgroups10. A case could be counted only once in each subgroup but could 
be counted in more than one subgroup. The 12 cases classifi ed as only minor 
malformations according to the EUROCAT classifi cation were excluded [10]. 
Based on these eight cohorts, the overall prevalence for a major congenital 
malformation after exposure to carbamazepine monotherapy in the fi rst 
trimester was 3.3% (95% confi dence interval 2.7 to 4.2) (table 1).
The prevalence for specifi c subgroups of congenital anomaly was calculated 
by dividing the subgroup totals by the total outcomes in pregnancies with 
carbamazepine monotherapy exposure. This prevalence was compared with 
the prevalence in the population covered by the EUROCAT Antiepileptic 
Study Database (excluding pregnancies with exposure to antiepileptic drugs), 
with χ2 test with Yate’s correction in S-PLUS 7.0. In the combined literature 
cohort fi ve subgroups had a signifi cantly higher prevalence than expected 
(P<0.05) (table 2) and were considered “indications” to be tested in the case-
control study: spina bifi da, total anomalous pulmonary venous return, cleft 
lip (with or without palate), diaphragmatic hernia, and hypospadias.
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Table 1: Overview of the included cohort studies [2-5,11-14]
Carbamazepine mono exposed
Study Country Included years number malformed Rate (CI 95%)














108 6 5.6% (2.6-11.8)
Kaaja 2003 Finland, Helsinki 01/1980-09/1998 363 10 2.8% (1.5-5.0)
Sabers 2004 Denmark, 6 hospitals 09/1996-05/2000 18 0 0% (0.0-17.6)
Wide 2004 Sweden 07/1995-12/2001 703 28 4.0% (2.8-5.7)
Meador 
2006
25 epilepsy centres 
UK & US
10/1999-02/2004
110 5 4.5% (2.0-10.2)
Morrow 
2006
UK, pregnancy registry 12/1996-03/2005
900 20 2.2% (1.4-3.4)
Vajda 2007 Australia, pregnancy 
registry
07/1999-10/2002
198 10 5.1% (2.8-9.0)
All studies 1972-2005 2680 101 3.8% (3.1-4.6)
All studies, according to the EUROCAT 
MCM classifi cation* 2680 89 3.3% (2.7-4.2)
*  According to the EUROCAT major congenital malformation classifi cation (based on ICD-10) 12 
were only minor malformations and therefore excluded.
Table 2:  Result of the review of the 8 cohort studies. All specifi c malformations found in the 
literature review were classifi ed to 75 malformation subgroups; 49 subgroups had at 
least one case and 5 of these subgroups showed a signifi cant increased prevalence 









2 0.75 134 0.03 p < 0.0000
cle  lip, with or without 
palate
7 2.61 3634 0.94 p = 0.0121
diaphragmatic hernia 3 1.12 766 0.20 p = 0.0070
hypospadias 12 4.48 5418 1.40 p = 0.0001
spina bifi da 6 2.24 1933 0.50 p = 0.0003
#  Calculated with a chi square test with Yate’s correction
*  excluding chromosomal and antiepileptic drug exposed registrations
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To check if we missed any indication by concentrating on published cohort 
studies in the literature review, we searched for additional indications in 
abstracts of case-control studies. We found one additional indication for 
the risk of cleft palate [15]. We excluded cleft palate malformations from our 
study control group and examined these registrations separately. Indications 
from other case-control studies had all been identifi ed in the review of cohort 
studies.
Case-control study
We carried out a population based case-control study to test the fi ve 
indications identifi ed in the literature review. We compared the odds 
of exposure to carbamazepine monotherapy among each of these fi ve 
malformations under study (cases) with the odds of exposure among two 
control groups of malformations: a non-chromosomal and a chromosomal 
control group. As valproic acid has been shown to be more teratogenic 
than other antiepileptic drugs, we compared carbamazepine monotherapy 
exposure with “no antiepileptic drug exposure”, “valproic acid monotherapy”, 
and “other antiepileptic drug monotherapy” (excluding valproic acid) [6].
Case defi nition
Cases were defi ned as all live births, fetal deaths from 20 weeks’ gestation, 
and terminations of pregnancy after prenatal diagnosis, non-chromosomal 
and non-monogenic, with at least one of the following major congenital 
malformations: spina bifi da, total anomalous pulmonary venous return, 
cleft lip (with or without palate), diaphragmatic hernia, and hypospadias. We 
excluded all cases of diagnosed monogenic syndrome (n=180).
Control defi nition
Control group 1 included livebirths, fetal deaths from 20 weeks’ gestation, 
and terminations of pregnancy after prenatal diagnosis that involved major 
malformations other than the fi ve malformations under study. We excluded 
chromosomal syndromes as well as registrations with cleft palate or Pierre 
Robin sequence (n=2320) and all anencephaly or encephalocele (n=1860) to 
avoid possible misclassifi cation from an aetiologically similar diagnosis. Five 
controls were excluded because of unknown type of birth.
Control group 2 included live births, fetal deaths from 20 weeks’ gestation, 
and terminations of pregnancy after prenatal diagnosis with chromosomal 
syndromes. Two controls in this group were excluded because of unknown 
type of birth.
Exposure
All registrations with associated maternal use of antiepileptic drugs or 
maternal epilepsy, or both, were selected, verifi ed by the local registry, and 
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coded by ATC (Anatomical Therapeutic Chemical Classifi cation) code  [16]. 
After verifi cation over 99% of all drug names were known. In 95% of 
all registrations with carbamazepine exposure, there was a diagnosis of 
maternal epilepsy. To avoid misclassifi cation of exposure we excluded all 
registrations with an associated reported diagnosis of maternal epilepsy but 
without maternal use of antiepileptic drugs in the fi rst trimester (42 cases: 
spina bifi da (8), cleft lip (12), diaphragmatic hernia (5), and hypospadias (17); 
and 195 controls). We compared carbamazepine monotherapy in the fi rst 
trimester of pregnancy with “no antiepileptic drug exposure”, “valproic acid 
monotherapy”, and “other antiepileptic drug monotherapy excluding valproic 
acid”. In the comparison with valproic acid monotherapy we excluded from 
the control group malformations associated with valproic acid exposure: 
atrial septal defect, polydactyly, and craniosynostosis [6].
Statistical analyses
Odds ratios were calculated with logistic regression in Stata. Crude odds 
ratios were calculated without correction for any possible confounder and 
including all registries even if they had no registration with carbamazepine 
exposure (see appendix 1 on). Odds ratios were adjusted for maternal age 
(categorized into <25, 25-29, 30-34, and >34 years) and year of birth of the 
child (categorized as before 1999, 1999-2001, and 2002 onwards). If there 
were suffi  cient numbers of cases the adjusted odds ratio was also corrected 
for the reporting registry (registries with no carbamazepine exposure were 
excluded). No systematically recorded information on other potentially 
important confounders was available in our dataset.
We also conducted an exploratory analysis to check if there was evidence 
in the data of specifi c malformations related to carbamazepine monotherapy 
that were not identifi ed by the literature review. We compared the proportion 
of each subgroup of specifi c non-chromosomal congenital anomalies 
(excluding the fi ve case groups, but reincluding cleft palate, anencephaly, 
and encephalocele) for malformations with carbamazepine monotherapy 
exposure with all non-chromosomal EUROCAT registrations without 
reported epilepsy or use of antiepileptic drugs. We compared diff erences 
between proportions with a χ2 test.
Results
In the included study population 516 registered malformations were in 
pregnancy outcomes with recorded exposure to any antiepileptic drug in 
the fi rst trimester of pregnancy, 5.5 per 1000 registrations (516/93 436). The 
exposure to antiepileptic drugs was more than twice as high among the 
cases (10.9 per 1000 registrations) than among the controls (5.0 and 3.2 per 
1000 registrations) (table 3). This diff erence between cases and controls 
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was not seen in registered malformations with any recorded exposure to 
carbamazepine monotherapy. The exposure to carbamazepine monotherapy 
was comparable among cases (1.4/1000) and among non-chromosomal 
controls (1.5/1000). The exposure among chromosomal controls was lower 
(0.9/1000). The exposure to valproic acid monotherapy was higher among 
cases than among both control groups (table 3).
The fi ve case subgroups included 11,790 cases (table 4). Eighty two cases 
were included in two diff erent subgroups. The control groups consisted of 
69,883 non-chromosomal malformed registrations and 11,763 chromosomal 
registrations.
Carbamazepine monotherapy v no antiepileptic drugs
In the comparison of carbamazepine monotherapy exposure with no 
antiepileptic drugs, one of the fi ve indications found in the literature was 
confi rmed: the odds ratio for spina bifi da was 2.6 (95% confi dence interval 
1.2 to 5.3) compared with non-chromosomal controls and 4.2 (1.5 to 11.2) 
compared with chromosomal controls. The odds ratios for cleft lip (with or 
without palate), diaphragmatic hernia, and hypospadias were not appreciably 
increased; they were all around or below 1, though for diaphragmatic hernia 
the confi dence interval was wide. We could not perform meaningful analyses 
for total anomalous pulmonary venous return because we did not have any 
cases with exposure to carbamazepine (table 4).
Table 3: Antiepileptic drug (AED) exposure among registrations (cases and controls)
Non chromosomal 




Control group 2^ 
N=11,763
number Per 1,000 
registrations
number Per 1,000 
registrations
number Per 1,000 
registrations
Any AED 129 10.9 349 5.0 38 3.2
Any AED monotherapy 104 8.8 282 4.0 32 2.7
   VPA monotherapy  66 5.6  102 1.5  13 1.1
   CBZ monotherapy  16 1.4  105 1.5  10 0.9
   other monotherapy  22~ 1.9  75** 1.1  9^^ 0.8
*  All cases with anomalous pulmonary venous return, cle  lip (with or without palate), 
diaphragmatic hernia, hypospadias or spina bifi da.
#  non chromosomal malformed registration without any of the malformations under study
^  all chromosomals
~  9 phenobarbital, 5 lamotrigine, 3 clonazepam, 2 levetriacetam and 3 unspecifi ed antiepileptic 
drugs.
**  33 lamotrigine, 15 phenobarbital, 10 oxcarbazepine, 5 phenytoin, 3 clonazepam, 3 primidon, 
2 methylphenobarbital, 2 topiramate, 1 ethosuximide and 1 unspecifi ed AED.
^^ 4 phenobarbital, 2 lamotrigine, 1 clonazepam, 1 oxcarbazepine, 1 phenytoin
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Table 4:  Adjusted odds ratios (OR) for antiepileptic drug (AED) and carbamazepine (CBZ) 
exposure compared to no antiepileptic drug, valproic acid (VPA) and other 
antiepileptic drug exposure, using a non-chromosomal malformed control group (C1) 
and chromosomal control group (C2)
        Carbamazepine monotherapy












C1 2.6 [1.2-5.3] 0.2 [0.1-0.6]+ 1.1 [0.4-3.6]+
C2 4.2 [1.5-11.2] 0.3 [0.1-1.2]+ 1.4 [0.3-6.6]+
total anomalous pulm. v. return
N=132 0
C1 - - -
C2 - - -
cle  lip (with or without palate)
N=3,544 1
C1 0.2 [0.0-1.3] 0.3 [0.0-2.6]+ 0.1 [0.0-0.6]+
C2 0.2 [0.0-1.7] 0.2 [0.0-2.7]+ 0.0 [0.0-0.5]+
diaphragmatic hernia
N=755 1
C1 0.9 [0.1-6.6] 0.5 [0.0-4.5]+ 0.2 [0.0-2.2]+
C2 1.0 [0.1-8.5] 0.4 [0.0-5.8]+ 0.2 [0.0-2.5]+
hypospadias, boys only
N=5,393 6
C1 0.7 [0.3-1.6] 0.2 [0.1-0.5]+ 0.8 [0.2-2.9]+
C2 0.5 [0.2-1.8] 0.1 [0.0-0.7]+ 0.4 [0.1-4.0]+
~  valproic acid  (VPA) exposed malformed excluding malformations associated with valproic 
acid exposure. Cases exposed to VPA: 27 spina bifi da, 2 TAPVR, 3 cle  lip, 2 diaphragmatic 
hernia, 32 hypospadias.
^  other monotherapy, excluding valproic acid. Cases exposed to other AED monotherapy: 5 
spina bifi da, 0 TAPVR, 10 cle  lip, 3 diaphragmatic hernia, 5 hypospadias.
#  OR are adjusted for reporting centre, year of birth, maternal age
+  Ors adjusted for year of birth and maternal age (not centre)
Carbamazepine monotherapy v other antiepileptic drug monotherapy
In contrast with the comparison with “no antiepileptic drugs” the exposure 
to carbamazepine monotherapy resulted in a reduced risk for spina bifi da 
compared with valproic acid monotherapy, which was signifi cant in the 
comparison with control group 1 (0.2, 0.1 to 0.6).
Compared with other antiepileptic drug monotherapy excluding valproic 
acid, exposure to carbamazepine monotherapy showed no diff erence in the 
risk for spina bifi da (1.1, 0.4 to 3.6).
For hypospadias we found a signifi cantly lower risk for carbamazepine 
monotherapy than for valproic acid monotherapy (0.2, 0.1 to 0.5) and again no 
diff erence in risk in comparison with other antiepileptic drug monotherapy 
excluding valproic acid (0.8, 0.2 to 2.9).
The risk for cleft lip with or without palate was signifi cantly lower for 
carbamazepine monotherapy than for other antiepileptic drug monotherapy 
excluding valproic acid (0.1, 0.0 to 0.6) (over half of these cases had recorded 
exposure to phenobarbital). No  signifi cant diff erence was seen for carbamazepine 
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monotherapy compared with valproic acid monotherapy (0.3, 0.0 to 2.6), but the 
point estimate was decreased. The results for diaphragmatic hernia also showed 
decreased odds ratios but with wide confi dence intervals (table 4).
We tested the one additional indication identifi ed in literature, cleft palate, 
in the EUROCAT dataset, but we did not confi rm this indication compared 
with no antiepileptic drug exposure (crude odds ratio 1.3 (0.4 to 4.1) with non-
chromosomal controls) [15].
Exploratory analysis
The exploratory analysis of all malformation subgroups found that all 
proportions were similar (P>0.05) except for two subgroups: single ventricle 
(2.3% (n=3) of carbamazepine exposed 0.3% expected, χ2 P<0.001) and 
atrioventricular septal defect (3.1% (n=4) of carbamazepine exposed 0.8% 
expected, χ2 P<0.011, data available on request). When we removed registrations 
with these malformations from our non-chromosomal control group, our 
results regarding the fi ve indication case groups stayed essentially the same.
Discussion
Interpretation of the results
Of the fi ve indications for specifi c malformations associated with exposure 
to carbamazepine monotherapy that we identifi ed from published cohort 
studies, spina bifi da was the only confi rmed indication (odds ratio 2.6 (1.2 to 
5.3) for comparison with no exposure to antiepileptic drug and with the non-
chromosomal controls). All other case groups resulted in an odds ratio around 
or below 1. According to the upper confi dence limits, we could exclude 50%of 
excess risks for cleft lip and hypospadias with some degree of certainty, but 
further surveillance would be necessary to gain larger numbers to estimate 
risks for diaphragmatic hernia and total anomalous pulmonary venous return 
with more precision.
In our analyses comparing exposure to carbamazepine monotherapy with 
valproic acid monotherapy we found a signifi cantly decreased risk for spina 
bifi da (odds ratio 0.2, 0.1 to 0.6) and hypospadias (odds ratio 0.2, 0.1 to 0.5), 
indicating that the risk of spina bifi da and hypospadias with carbamazepine 
is less than with valproic acid. In our study of valproic acid we found a six fold 
risk for spina bifi da and a sevenfold risk for hypospadias with valproic acid 
monotherapy compared with exposure to another antiepileptic drug with the 
non-chromosomal control group [6].
It is noteworthy that the risk for cleft lip with or without palate was 
signifi cantly more related to other antiepileptic drug monotherapy (excluding 
valproic acid) than to carbamazepine monotherapy (odds ratio 0.1, 0.0 to 0.6). 
Over half of these cases were exposed to phenobarbital, which is known to be 
associated with cleft lip and palate [17].
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Comparison with other studies
The rate of major malformation with exposure to carbamazepine that we 
found when combining the eight cohort studies (3.3%) was lower than the 
rate reported in the only meta-analysis in the literature (44/797; 5.5%, 4.1% 
to 7.3%) [18]. Eleven of the 16 studies included in the meta-analysis contained 
information about malformations. Three of these 11 presented a case list 
with specifi c malformations and were included in our literature review. The 
diff erence in the rate of malformations could be explained by dissimilarities 
in classifi cation of minor malformations for exclusion.
In a general review of the literature, we did not fi nd any strong suggestions 
of specifi c malformations other than our fi ve case groups, except for a recently 
published abstract based on the North American AED Pregnancy Registry, 
which suggested a 24-fold (7.9 to 74.4) increase in the rate of isolated cleft 
palate with carbamazepine [15]. In the EUROCAT dataset we did not confi rm 
this strong indication, either in the proportional exploratory analysis or by 
calculation of odds ratios.
Strengths and limitations of the study
One limitation of our study is that we used controls with malformations. 
Controls with non-chromosomal malformations will result in an 
underestimation of the eff ect if there are any individuals left in the control 
group with malformations that are related to the exposure. Our exploratory 
analysis was designed to see if there were specifi c malformations of concern; 
we found single ventricle and atrioventricular septal defect to represent a 
higher proportion than expected (though this might be a chance fi nding 
associated with multiple comparisons). When we excluded these two 
malformations from the control group, our results stayed essentially the same. 
Chromosomal controls can lead to an overestimation of eff ect of drug exposure 
if exposure is not recorded completely because of the lack of relevance of drug 
exposure in early pregnancy. We have examined this in previous studies of 
lamotrigine and valproic acid and found no evidence of substantially poorer 
recording of exposure to antiepileptic drugs for chromosomal controls, 
either by examination of exposure rates or by examination of information 
gathering procedures for exposure [6,9]. Exposure information is mainly 
collected prospectively in medical records and is ascertained by the registry 
regardless of type of malformation. In a previous study evaluating exposure 
to valproic acid and specifi c congenital malformations, we found similar odds 
ratios for non-chromosomal and chromosomal controls, while in our study 
of lamotrigine exposure and orofacial clefts, as in the current carbamazepine 
study, we found greater odds ratios with chromosomal controls than with 
non-chromosomal control group. One interpretation is that there is a 
generalized risk of malformation associated with carbamazepine, which 
is not specifi c to a few malformation groups. With that interpretation, the 
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diff erence in exposure rate between the control groups would suggest an up to 
50% generalized increase risk of major malformations with carbamazepine. 
Another interpretation is that carbamazepine “protects” against chromosomal 
malformations—for example, by raising the chance of an early miscarriage 
for aff ected pregnancies. In relation to the fi nding regarding spina bifi da, we 
consider that the true odds ratio is likely to be between the estimates obtained 
from the two control groups.
The apparent specifi city of eff ect of carbamazepine for spina bifi da, 
compared with valproic acid, with a much larger range of eff ects, might be a 
useful biological clue in elucidating the underlying teratogenic mechanism. It 
is also possible that spina bifi da is in part related to the underlying epilepsy 
rather than the drug used, though our results show that the drug used at least 
aff ects the level of risk of spina bifi da. In this large population based study, we 
carried out a direct comparison between the risks for specifi c malformations 
associated with carbamazepine monotherapy compared with valproic acid 
monotherapy. A limitation in our comparison of risks between exposure to 
diff erent types of antiepileptic drug was that we did not have the information 
to adjust for type of epilepsy, frequency of seizures, used of folic acid, and 
dose of the antiepileptic drug.
Conclusions and policy implications
Although most antiepileptic drugs taken during pregnancy signifi cantly 
increase the risk for one or more specifi c fetal malformations, the occurrence 
of these malformations is nevertheless rare. Most exposed pregnancies result 
in a baby without malformation. The best option regarding antiepileptic 
drug treatment can be chosen only on an individual basis by the woman 
and neurologist before pregnancy, weighing the benefi ts of epilepsy control 
against the risk of teratogenicity. In this study we have confi rmed that 
carbamazepine is less teratogenic than valproic acid. A Cochrane review 
found no evidence to support the belief that valproic acid is superior to 
carbamazepine for generalized tonic-clonic seizures [19]. Therefore, we agree 
with the recent recommendation of the American Academy of Neurology to 
avoid valproic acid in pregnancy if possible [20]. Our literature review gives a 
3.3% risk of major malformations with carbamazepine monotherapy, and our 
case-control study shows that the major concern is a moderately increased 
risk of spina bifi da. This should to help in decision regarding whether 
carbamazepine should be the antiepileptic drug of choice in pregnancy.
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Crude odds ratios (OR) for antiepileptic drug (AED) and carbamazepine (CBZ) exposure 
compared to’ no antiepileptic drug’, valproic acid (VPA) and other antiepileptic drug 
exposure, using a non-chromosomal malformed control group (C1) and chromosomal control 
group (C2)
        Carbamazepine monotherapy












C1  2.7 [1.3-5.5] 0.2 [0.1-0.6] 1.1 [0.4-3.6]
C2  4.7 [1.9-11.9] 0.4 [0.1-1.2] 1.4 [0.3-6.1]
Total anomalous pulm. v. return
N=132 0
C1 - - -
C2 - - -
Cle  lip (with or without palate)
N=3,544 1
C1  0.2 [0.0-1.4] 0.3 [0.0-2.6] 0.1 [p0.0-0.6]
C2  0.3 [0.0-2.6] 0.4 [0.0-4.6] 0.1 [0.0-0.9]
Diaphragmatic hernia
N=755 1
C1  0.9 [0.1-6.4] 0.4 [0.0-4.5] 0.2 [0.0-2.3]
C2  1.6 [0.2-12.3] 0.6 [0.1-7.9] 0.3 [0.0-3.4]
Hypospadias, boys only
N=5,393 6
C1  0.7 [0.3-1.7] 0.2 [0.1-0.5] 0.8 [0.2-2.7]
C2  1.1 [0.4-3.3] 0.2 [0.1-0.9] 0.4 [0.1-2.9]
~  valproic acid exposed malformed excluding malformations associated with valproic acid 
exposure
^  other monotherapy excluding valproic acid
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practice
Chapter 6:  Does folic acid use decrease the risk for spina bifida after in 
utero exposure to valproic acid?
Chapter 7:  Economic evaluation of antiepileptic drug therapies in young 
women; with specifi c focus on teratogenic outcomes
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DOES FOLIC ACID USE DECREASE THE RISK FOR SPINA 
BIFIDA AFTER IN UTERO EXPOSURE TO VALPROIC ACID?
J Jentink, MK Bakker, CM Nijenhuis, B Wilff ert, LTW de Jong-van den Berg
PDS 2010;19:803-807
Purpose: Women with child wish are advised to take folic acid supplements 
to reduce the risk for spina bifida. However, there is less evidence for this 
protective eff ect in women using valproic acid. We investigated the eff ect of 
folic acid in women exposed to valproic acid in the first trimester of pregnancy.
Methods: A case-control study was performed with data from a population-
based registry of congenital malformations. Our cases were spina bifida 
registrations and all other malformed registrations (excluding folic acid 
sensitive malformations) were used as controls.
Results: The odds ratios for the eff ect of correct folic acid use were calculated 
among antiepileptic drug (antiepileptic drug) unexposed pregnancies 0.5 
[95%CI: 0.3–0.7] and among valproic acid exposed pregnancies 1.0 [95%CI: 
0.1–7.6].
Discussion: Due to power-reasons, we cannot conclude that folic acid has no 
eff ect on the risk for spina bifida among valproic acid exposed pregnancies. 
Although for antiepileptic drug unexposed pregnancies we found a decreased 
risk. Results from (animal) studies support a biologically plausible association 
between valproic acid, folic acid and spina bifida. While folic acid might not 
be able to reduce the risk for lower spina bifida lesions caused by valproic 
acid, the use of folic acid might be important to reduce the risk for higher, 
folic acid sensitive spina bifida lesions. Further research is needed to get more 
insight in the most eff ective form and dose of folic acid in women that use 
valproic acid to reduce the risk for (higher forms of) spina bifida.
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Introduction
Folic acid has been proven to reduce the risk of neural tube defects (NTDs) and 
it also seems to lower other specific malformations [1-2]. In the Netherlands, 
women wishing to become pregnant are advised to take 0.5mg folic acid from 
4 weeks before conception till 8 weeks into pregnancy [3]. Additionally, in some 
parts of the world but not in the Netherlands, flour is mandatory fortified with 
folic acid. Due to the fortification and the maternal use of supplements the 
prevalence of NTDs decreased [4-5]. Although there is evidence for the protective 
eff ect of folic acid in the general population, there is still no clear evidence for this 
eff ect in women using antiepileptic drugs. Scientific publications report diff erent 
results of the eff ect of folic acid use by women using antiepileptic drugs [6-9].
Our objective was to describe and try to understand the eff ect of folic 
acid use on the risk for spina bifida in women taking valproic acid during 
pregnancy compared to those not taking antiepileptic drugs.
Methods
Setting
We performed a case-control study using data recorded in a population-based 
registry for congenital anomalies, EUROCAT Northern Netherlands. The 
methodology for data collection is described in detail previously [10-12]. From 
this database we created a subset of registrations that were available by July 
2008 and born in the period 1981–2007. A registration is defined as a pregnancy 
outcome with a major malformation registered in EUROCAT. During this 
study period, 443,165 births took place in the registration area and 12,534 
malformed pregnancy outcomes were registered in EUROCAT (including 
livebirths, stillbirths and terminations following prenatal diagnosis). These 
figures lead to a major congenital malformation prevalence of 2.8%, which 
corresponds with the prevalence found in literature (2–3%). Data on folic acid 
and antiepileptic drug exposure were obtained from pharmacy records and a 
written and spoken interview with the mother.
Definitions
We selected and validated from the subset of the EUROCAT database all 
pregnancies in which the mother had a prescription for an antiepileptic drug 
in the 3 months before pregnancy or during pregnancy, and all pregnancies 
aff ected by maternal epilepsy. All registrations with confirmed maternal 
monotherapy or polytherapy with valproic acid in the first trimester of 
pregnancy and all pregnancies not exposed to antiepileptic drugs were 
included. All registrations exposed to antiepileptic drugs other than valproic 
acid (N=41), all registrations with maternal epilepsy without reported 
antiepileptic drug use (N=33) and all registrations with missing data on folic 
acid exposure (N=2,615) were excluded from the analyses. Cases were defined 
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as registrations with spina bifida, while all other registrations excluding folic 
acid sensitive malformations (cardiac defects, clefts, limb defects, NTDs and 
urinary anomalies (N=4,680)) were used as controls [13].
Folic acid exposure was defined in three groups: no folic acid, some folic 
acid (including women who used folic acid only for a few days) and folic 
acid (defined as women using at least 0.4mg folic acid from 4 weeks before 
conception until 8 weeks in pregnancy) (Figure 1).
Registrations exposed to some folic acid (N=1,139) were not included in the 
analyses to avoid misclassification, because we do not know the protective 
eff ect of folic acid if it is used irregularly or only in a part of the advised period.
Analysis
All included registrations were put into a flowchart, with divisions for valproic 
acid exposure, folic acid use and spina bifida (Figure 1). Using case-control 
analyses, we analyzed the eff ect of folic acid use on the risk for spina bifida 
in pregnancies exposed to valproic acid and in antiepileptic drug-unexposed 
pregnancies. In the EUROCAT dataset it is possible to control for maternal 
age and year of birth, although no significant trend was seen within these 
variables and we therefore decided not to perform adjustments due to our 






(VPA incl. 1 SB)
Effect of correct folic acid use on spina bifida:
Non AED exposed registrations: OR: (29 * 2809) / (166 * 1006) = 0.51 [CI95% 0.3-0.7]





























*  All registrations excluding: folic acid use unknown, maternal epilepsy without AED exposure, 
and AED exposure not including valproic acid. And excluding folic acid sensitive malformations 
(cardiac, cle , limb, NTD and urinary defects)
Figure 1:  decision tree# and odds ratios for the eff ect of correct folic acid use among AED 
exposed and unexposed registrations.
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Results
The prevalence of spina bifida in the EUROCAT database decreased over time 
from 5.2 (1981–1985) to 3.9 per 10 000 (2002–2007). The antiepileptic drug 
exposure in the dataset was 6.6 per 1000 registrations (83/12 534) in the first 
trimester of pregnancy and the exposure to valproic acid specifically was 
3.4 per 1000 (42/12 534; 34 monotherapy, 8 polytherapy). Over 80% of the 
antiepileptic drug exposed registrations were exposed to antiepileptic drug 
monotherapy. The use of folic acid supplements did increase over time and 
the use was higher among antiepileptic drug exposed registrations.
In total, 5,165 pregnancy outcomes, born 1981–2007, were included in the 
case-control analyses. A flowchart shows valproic acid exposure, folic acid 
use and outcome (Figure 1). Folic acid (at least 4 weeks before conception till 8 
weeks after conception) was used by 20% of the included registrations, while 
58% did not use folic acid at all.
In antiepileptic drug unexposed pregnancies, the use of folic acid reduced 
the risk for spina bifida by 51% (OR=0.5 [95%CI: 0.3–0.7]).We found no eff ect 
of folic acid use in valproic acid exposed pregnancies in relation to the risk for 
spina bifida OR=1.0 [95%CI: 0.1–7.6].
Looking at the location of the spina bifida lesions, no thoracic or higher 
located lesions were found among valproic acid exposed cases. We did find 
higher located lesions among our antiepileptic drug unexposed cases and in 
this group the location of the lesion tended to be lower in cases exposed to 
folic acid (Table 1).
Table 1:  Location of the spina bifi da lesion in valproic acid exposed and antiepileptic drug 
unexposed, specifi ed for folic acid use (frequencies).
valproic acid No antiepileptic drug
folic acid no folic acid folic acid no folic acid
sacral & sacral-lumbar 1 1 10 47
lumbar 2 2 10 41
lumbar-thoracic and higher 0 0 5 67
not otherwise specifi ed 0 0 4 11
Total spina bifi da 3 3 29 166
Folic acid: use of folic acid supplements from at least 4 weeks before conception until 8 weeks in 
pregnancy
It is noteworthy that in our total dataset, 7 of the 42 valproic acid exposed 
women using folic acid during the entire advised period consumed 5mg rather 
than 0.5mg. None of these women delivered a baby with spina bifida, although 3 
of these 7 registrations were excluded in the analyses because of a cardiac defect.
Discussion
We found a reduction in the risk for spina bifida of over 50% among pregnancies 
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not exposed to antiepileptic drugs, as expected. No eff ect on the risk for spina 
bifida in pregnancies exposed to valproic acid was detected. However, based on 
our low numbers we cannot conclude that folic acid does not reduce the risk 
for spina bifida in pregnancies with first trimester VPA exposure (OR: 1.0 [0.1–
7.6]). However, our findings are in line with the findings in a case-control study 
performed in the US and a cohort study from the UK [7,9]. Both studies did not 
find a significant reduction in the risk for NTDs in VPA exposed pregnancies.
If we stratified our valproic acid exposed registrations by consumed dose 
of folic acid by the mother, no cases of spina bifida were seen among mothers 
using 5 mg folic acid from 4 weeks before till 8 week during pregnancy or longer. 
Our numbers were too small to perform meaningful statistical analyses.
We wondered if it would be biologically plausible that folic acid reduces 
the risk for spina bifida in valproic acid exposed fetuses.
The majority of published studies show that valproic acid does not reduce the 
total serum folate levels in contrast to enzyme-inducing antiepileptic drugs like 
carbamazepine [14-16]. Despite the fact that the total serum folate levels are not 
reduced due to valproic acid exposure, several cases are described in which folic 
acid use did not protect against spina bifida in case of maternal valproic acid use 
[6,17-18]. Notable is that the spina bifida lesion in these published cases (N=9) for 
all specified ones (N=5) is diagnosed as lumbosacral, a lower form of spina bifida 
[6,18]. The four other published spina bifida cases were not otherwise specified [17]. 
Also in our study population, the spina bifda cases that were exposed to valproic 
acid and folic acid have lumbar or sacral forms of spina bifida (Table 1). Among the 
antiepileptic drug unexposed cases we additionally see higher lesions and it seems 
to be that higher lesions tend to be more frequent without folic acid use. However, 
due to our small numbers we cannot perform meaningful analyses.
The theory of the closure of the human neural tube: existing of five closure 
sites, is well-known although we know that the model is not accepted by all 
investigators [19-22]. However, according to this model valproic acid is thought 
to interact with the fusion of closure site 5 (the lowest closure site). Failure 
in the fusion of this lowest site is thought to be independent of folic acid, 
in contrast to closure sites 1 (caudal), 2 and 4 [19]. Based on these studies it 
seems that folic acid is important for women using valproic acid in pregnancy 
to reduce higher located lesions, but it will not avoid the lower ones.
Is 0.5mg enough or is it better to give 5  mg folic acid to women using 
valproic acid? In our data we saw no cases of spina bifida in which 5  mg 
folic acid was used (at least from 4 weeks before pregnancy until 8 week in 
pregnancy). Due to the low number of registrations in this 5  mg group, we 
could not perform detailed analysis on dose and thus we cannot conclude 
that 5 mg daily supplements give a better protection against the increased risk 
for having a baby with spina bifida in case of valproic acid use. Human data is 
scarce on folic acid dosing among valproic acid users [3]. Additionally, animal 
studies do not provide consistent evidence about the eff ect of folic acid 
Risk assessment of antiepileptic drug use in pregnancy
100
supplementation [24-27]. Although, in mice models it was discovered that 
valproic acid inhibited the transfer of the formyl group necessary to convert 
tetra-hydrofolate into folinic acid (5-formyl tetrahydrofolate) the most active 
form of folic acid [28-29]. This could explain why the total serum folate 
levels are not decreased, but the efficacy is. If folic acid stays in a less active 
form, more folic acid might help to increase the eff ect. On the other hand, 
folinic acid is also registered and might be much more eff ective for women 
using valproic acid with a child wish (to reduce the risk for higher lesions). 
Folinic acid or a higher dose of folic acid might be an option, but we need to 
be aware of possible interactions of folic acid and monitor the effi  cacy of the 
antiepileptic drug. However more research is needed to test these theories.
This study focused on the eff ect of folic acid in valproic acid exposed 
pregnancies, but it is impossible to see folic acid as an independent factor, 
because an alteration of one substance within the folic acid cycle influences 
the whole metabolism. Therefore, it is also important to keep in mind that the 
decrease in methionine might play an important role in the transmethylation 
or the decrease in glutathione which is important in the detoxification of 
radicals [30-34]. Additionally to the eff ect on the folate metabolism valproic 
acid interacts with many other pathways as described in a recent study [32-35].
Recently, the American Academy of Neurology published an extensive 
review concerning the care for pregnant women with epilepsy. One of the main 
conclusions was to avoid valproic acid in pregnancy if possible, because of 
the evidence that valproic acid is associated with an increased risk of multiple 
congenital malformations and developmental delay, and that valproic acid 
confers a higher risk than other antiepileptic drugs [36-37]. However, for some 
women valproic acid is the only eff ective therapy and, above all, most children 
are born healthy. For those women who are dependent of valproic acid treatment 
it is very important to perform further research in comparing diff erent doses of 
folic acid with the eff ectiveness of folinic acid to reduce the risk for spina bifida 
and other folic acid sensitive malformations. The best design to test the effi  cacy 
would ideally be in a clinical trial. In the meanwhile, women using valproic 
acid should be recommended to use folic acid, even though the evidence for a 
reductive eff ect is scarce, but there is no evidence of harm [23,38].
Despite the folic acid related forms of spina bifida, valproic acid exposed 
women probably will keep an increased risk for lower located spina bifida lesions. 
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ECONOMIC EVALUATION OF ANTIEPILEPTIC DRUG 
THERAPIES IN YOUNG WOMEN; WITH SPECIFIC 
FOCUS ON TERATOGENIC OUTCOMES
Janneke Jentink MSc, Cornelis Boersma PhD, Lolkje TW de Jong-van den Berg PhD 
ParmD, Maarten J Postma PhD.
Objectives: To perform an economic evaluation of the antiepileptic drug 
choice in young women, with a potential child wish, to estimate the impact of 
teratogenicity on the costs per quality adjusted life year (QALY).
Methods: A decision-tree model is used to calculate the costs per QALY, 
taking into account the malformation risk in off spring due to the exposure 
to carbamazepine, lamotrigine or valproic acid, based on the European birth 
cohort of 2007. Probabilistic sensitivity analyses were performed using Monte 
Carlo simulation.
Results: Valproic acid is dominated by carbamazepine after rank ordering 
on costs. The cost–eff ectiveness of lamotrigine versus carbamazepine was 
estimated at €175,534 per QALY. Though valproic acid was dominated by 
carbamazepine in terms of costs and related eff ects, it is clinically relevant 
to compare lamotrigine with valproic acid. In particular, treatment options 
are dependent on several individual and clinical characteristics and these 
agents are therefore not always considered as interchangeable for all specifi ed 
populations. The cost-eff ectiveness for lamotrigine versus valproic acid was 
estimated at €13,370 per QALY. With assuming a willingness to pay threshold 
of €50,000 per QALY, results from the probabilistic analysis resulted in an 
acceptance level for lamotrigine versus carbamazepine and lamotrigine 
versus valproic acid of 4% and 99%, respectively.
Conclusion: Based on epidemiological data it is advised to whenever possible 
avoid valproic acid during pregnancy. Both carbamazepine and lamotrigine 
are estimated to be cost-eff ective treatment options versus valproic acid if 
focused on teratogenicity.
7
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Introduction
Epilepsy is a chronic disease with age-dependent increase in prevalence. 
About a half percent of all teenage girls are using antiepileptic drugs [1-
2]. A considerable part of these girls are still using the same antiepileptic 
drug when they have a child wish as switching is not considered to be easy. 
Therefore, it is important for the prescribers to keep in mind while making the 
therapy choice that younger girls develop a future child wish with potential 
implications for the choice of treatment. In pregnancy, around 3.3 per 1000 
women are using antiepileptic drugs in the fi rst trimester, the period in which 
congenital malformations occur [3-4].
Carbamazepine, valproic acid and lamotrigine are the most used antiepileptic 
drugs, both among pregnant and non-pregnant women [5-6]. All three agents 
are fi rst choice options for partial epilepsy. However, in case of generalized 
epilepsy only valproic acid is the drug of fi rst choice and both carbamazepine 
and lamotrigine are second choice therapies [7-8]. Although a recent Cochrane 
review could not fi nd evidence to support the belief that valproic acid is superior 
to carbamazepine in generalized tonic-clonic seizures [9].
Valproic acid is a relatively cheap and very eff ective antiepileptic drug 
which is already a successful treatment option in epilepsy for over 40 
years. However, it is associated with an increased risk for major congenital 
malformations compared to other antiepileptic drugs [10]. Maternal use 
increases the risk for spina bifi da, cleft palate, hypospadias, atrial septal 
defect, polydactyly and craniosynostosis. In contrast, carbamazepine has 
been shown to be only associated with an increased risk for spina bifi da, 
with a risk even signifi cantly lower than for valproic acid [11]. Lamotrigine on 
the other hand is more expensive, but up to now not associated to specifi c 
malformations [5, 12-13].
It is not ethical to perform randomized clinical trials with pregnant women 
to estimate human teratogenicity and therefore, all available evidence is 
derived from post-marketing observational data. In particular, these studies 
provide less strong evidence and are more sensitive to bias and confounding. 
Also, it is uncommon to express prevented malformations due to the choice 
of a specifi c drug in terms of money. However, in society the willingness 
to pay for a healthy child is often high and therefore hard to compare to 
the willingness to pay for an intervention which will add an extra year to 
individuals’ life expectancies. ‘Interventions’ with a higher willingness to pay 
are certainly not uncommon for economic analyses considering safety risks 
(e.g. blood products) [14]. Also, the general willingness to pay to avoid health 
losses is greater than the willingness to pay for health gains [15].
The aim of this study is to perform an economic evaluation for antiepileptic 
drugs initiated in young women, with a potential child wish, applying the 






















NOS, not otherwise specifi ed
Figure 1:  Decision tree, prevalence per specifi c malformation associated with valproic acid (VPA), 
carbamazepine (CBZ) and lamotrigine (LTG) [5, 10-11].
Methods
Data and Assumptions
Based on the EUROCAT Antiepileptic Study Database the prevalence for 
major congenital malformations in the general population is around 2.8% 
[12]. This prevalence increases in case of maternal carbamazepine (3.3%) [11], 
lamotrigine (3.2%) [5] or valproic acid (7.5%) [10] exposure. The decision tree 
for specifi c malformations associated with antiepileptic drug use is presented 
in fi gure 1. Some specifi c malformations are increased by these antiepileptic 
drugs however it does not explain the total prevalence. The unexplained part 
is defi ned as ‘not otherwise specifi ed’ (NOS).
Health Gains
Teratogenicity of valproic acid is higher than for other treatment options in 
epilepsy. However, for each patient the best therapy can only be chosen by 
the neurologist and the patient, but in case there are more possible treatment 
options valproic acid might not be the drug of fi rst choice in women with child 
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bearing potential as teratogenic risks for other antiepileptic drugs seem to be 
lower [10-11]. Prevention of teratogenesis with considering potential risks at 
therapy initiation will therefore result in lifetime health gains.
For all associated malformation subgroups we estimated the quality of life 
and the life expectancy based on the published literature (table 1) [16-31]. For 
our ‘rest group’ of not otherwise specifi ed malformations it was not possible to 
fi nd any reference. Therefore we took the quality of life of pregnancy outcomes 
with an extreme low birthweight as a proxy (0.97) in the base case analysis [23]. 
This assumption was varied in both univariate (to see how sensitive the analysis 
is for this parameter) and probabilistic sensitivity analysis.
Costs
We assumed lifetime use of antiepileptic drugs starting at age 15. Based on 
European life tables, we estimated the lifetime costs for the three antiepileptic 
drugs in 2010 Euros,: carbamazepine (dose 1000mg/day) €2,707, lamotrigine 
(dose 300mg/day) €11,329 and valproic acid (dose 1500mg/day) €3,694 [8, 32]. 
These values were based on Dutch prices and costs were discounted at 4%.
Lifetime costs for each of the specifi c malformations were estimated based 
on published literature. All costs are presented for 2010 euro’s. If costs were 
originally calculated in another currency or from another year we used the 
historical exchange rate and infl ation correction [33-34]. Table 1 gives an 
overview of all lifetime costs per malformation subgroup.
Cost-eff ectiveness and Cost-utility analysis
In the cost-eff ectiveness analysis the net costs per quality adjusted life year 
(QALY) were calculated comparing the three antiepileptic drugs, by dividing 
the diff erence in the ‘total net life-time costs’ by the sum of the diff erence 
in respectively the ‘total life years lost’ and the ‘total quality of life lost’ 
(presented in table 2). All costs and health gains were discounted following 
the Dutch guidelines for conducting pharmacoeconomic studies with 4% and 
1.5%, respectively [35].
The analysis is performed based on the European Union (27 countries) 
birth cohort of 2007 which consist of 5,285,057 live births (49% male) and the 
average life expectancy at birth of this cohort: 79.2 year [32]. As the prevalence 
of fi rst trimester exposure to antiepileptic drugs is around 3.3 per 1000 about 
17,441 pregnancies of the EU 2007 birth cohort were expected to be fi rst 
trimester exposed [3-4]. We calculated the total costs and eff ects based on 
assuming that all 17,441 women used carbamazepine, lamotrigine or valproic 
acid. For our model, we assumed equal eff ectiveness of the three drugs in 
all women. We know that in practice this is not the case due to diff erence in 
severity, type of epilepsy and interpersonal diff erences. However, it is diffi  cult 
to account for such hetereogeneity and all three drugs have proven to be 
eff ective in the most common types of epilepsy [7, 9].
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Probabilistic analysis was conducted to estimate uncertainty around the life-
time costs of the malformations, the prevalence of the specifi c malformations 
and the QALYs and LYL per treatment option were taken into account. 
Incremental cost-eff ectiveness planes were constructed based on Monte 
Carlo simulation (10000 replicates) to test the robustness of the health 
economic outcome. Additionally, cost-eff ectiveness acceptability curves were 
derived to estimate the probability of acceptance with varying willingness to 
pay thresholds.
Table 1:  Quality of life (QALY) and life years lost and the lifetime costs per case for the 





life years lost (1.5% 
disc)
Lifetime costs per 
case (4% disc)
Spina bifi da 20.3 15.1 € 138,964
ASD 0.4 0 €     6,591
Cle  palate 1.3 0 €   13,345
Hypospadias 0.8 0 €     5,890
Polydactyly 0 0 €        893
Craniosynostosis 5.0 0 €   14,990
NOS malformation 1.2 4.9 €   94,052
Results
Table 1 presents the estimated loss in quality of life and life expectancy 
together with the expected lifetime costs per malformation. These estimates 
are derived from various published studies [16-31]. It is estimated that 3.3% 
or 17,441 pregnancies of the European birth cohort 2007 are exposed to 
antiepileptic drugs. The total number of malformed pregnancy outcomes, 
life-expectancy and quality of life estimated for these 17,441 pregnancies 
are shown in table 2. The general risk for malformations is 2.8% which 
would result in 493 malformed pregnancy outcomes. This background risk 
is presented in the fi rst column. The expected number of malformations, 
life time costs for the three antiepileptic drugs, calculated for the whole 
birth cohort, and the total life years and quality of life lost are presented the 
second to fi fth column. Medical costs are estimated based on the estimated 
costs per case as presented in table 1 weighted with the prevalence of each 
malformation (fi gure 1). The analyses are performed based on the incremental 
estimates compared to the background risk.
If the three drugs are rank ordered on costs, one can directly see that 
valproic acid is dominated (higher costs and more quality of life losses than 
carbamazepine). From an economic point of view, due to the dominance, valproic 
acid would not be considered as a fi rst choice treatment option. However, as the 
indications for the three drugs are not exactly the same and therefore not 100% 
interchangeable, the cost-eff ectiveness is calculated for both lamotrigine versus 
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carbamazepine and lamotrigine versus valproic acid. The cost-eff ectiveness of 
lamotrigine versus carbamazepine and lamotrigine versus valproic acid were 
estimated at €175,534 and €13,370 per QALY, respectively.
Table 2:  Total net costs (4% discounted) and eff ects (1.5% discounted) for carbamazepine, 
lamotrigine and valproic acid for the European birth cohort of 2007 (17,441 exposed 
births) the background risk is presented in the fi rst column.
Background 
risk
carbamazepine lamotrigine valproic acid
N malformed 493 579 566 1247
Total costs malformation
Life time costs drug
Total net life-time costs
€ 46,393,507
€                 0
€ 46,393,507
€   55,642,951
€   47,206,615
€ 102,849,566




€   64,418,409
€ 165,120,598
Total life years lost 2417 3104 2774 6110
total quality of life lost 591 1192 679 3752



















willingness to pay (per QALY)
lamotrigine vs. carbamazepine








willingness to pay (per QALY)
lamotrigine vs. valproic acid
Figure 2:  Incremental cost-eff ectiveness planes for lamotrgine versus carbamazepine and 
versus valproic acid.
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Figure 3:  Cost-eff ectiveness acceptability curves for lamotrigine versus carbamazepine and 
lamotrigine versus valproic acid.
Chapter 7
109
Table 2 shows that the antiepileptic drug price is the main driver of the cost-
eff ectiveness. In particular, this is caused by lifetime use of these agents. The 
price of carbamazepine and valproic acid are quite stable over recent years. 
In contrast, the price of lamotrigine still decreases. If the prize of lamotrigine 
would decrease with 50%, it could be considered as  cost-saving if compared 
to valproic acid. Also, the cost-eff ectiveness ratio for lamotrigine versus 
carbamazepine would decrease to around €60,000 per QALY in such a scenario.
Although there were limited sources for quality of life data for specifi ed 
and not otherwise specifi ed malformations (NOS) the outcomes were quite 
robust. In particular, results remained essentially unchanged with increasing 
or decreasing the estimated QALY loss and life years lost with 50% (€170,168-
184,074 per QALY for lamotrigine versus carbamazepine and €11,685-14,793 
per QALY for lamotrigine versus valproic acid).
In fi gure 2 the incremental cost-eff ectiveness planes are presented for 
both lamotrigine versus carbamazepine and lamotrigine versus valproic acid. 
All estimates for the comparison of lamotrigine versus carbamazepine are 
located in the northern quadrants, with the highest density in northeast. For 
the comparison of lamotrigine versus valproic acid all estimates are located in 
the northeast quadrant, indicating a better quality of life for additional costs.
As there is no formal willingness to pay threshold in the Netherlands, cost-
eff ectiveness acceptability curves are calculated to estimate the probability 
of acceptance for diff erent willingness to pay thresholds in fi gure 3 [36]. 
With considering a willingness to pay threshold of €50,000 per QALY, the 
probability of the acceptance for lamotrigine versus carbamazepine and 
lamotrigine versus valproic acid were estimated at 4% and 99%, respectively. 
The median cost-eff ectiveness is estimated at €173,353 per QALY for 
lamotrigine versus carbamazepine and at €13,548 per QALY for lamotrigine 
versus valproic acid.
Discussion
Carbamazepine, lamotrigine and valproic acid are all fi rst-choice therapy 
options in the treatment of partial epilepsy. In general, valproic acid is widely 
used, but from a health economic point of view it would not be a fi rst-choice 
therapy option for women with a potential child wish with partial epilepsy as 
it is dominated by carbamazepine. Lamotrigine results in better quality of life 
outcomes in the off spring at higher costs of €175,534 per QALY. This could be 
interpreted as unfavorable. However, we should keep in mind that economic 
evaluations based on solely safety outcomes of drugs for the next generation 
could might be comparable to other economic evaluations in which safety is 
important, for example, blood transfusions. In this fi eld, interventions are 
still implemented with a net cost of several millions per QALY [14]. These 
estimates are very conservative mainly as they do not take into account 
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that these drug costs cover all costs for mother independent of the number 
of children. If a woman delivers two children, the drug costs can be divided 
by two. Additionally, we took into account the lifetime drug costs starting at 
age 15. The cost-eff ectiveness ratio would change in favor of lamotrigine if 
we would only count the fertile years. This method could also be advocated 
as this is the period in which the ‘event’ takes place. However, as switching 
increases the risk to get a relapse we choose to take lifetime drug costs for one 
drug being used consistently.
In the analyses, we assumed that the three drugs are equally eff ective in 
all women who require these antiepileptic drugs. This does not necessarily 
correspond with the daily practice situation as, for example, not all women 
will receive the standard dose. Therefore, in daily practice the therapy choice 
should be made on an individual level based on eff ectiveness which is 
dependent on several factors and an uncontrolled woman is probably more 
expensive. Therefore, despite the dominance, valproic acid will not be ruled 
out as an alternative treatment option in clinical practice as valproic acid is 
a very eff ective drug with a lot of treatment experience. It is also true that 
there is a subgroup of women that only successfully respond to valproic acid 
and for some specifi c types of epilepsy, valproic acid might be considered 
as the best, or even the only, treatment option. Looking at the indications, 
lamotrigine is for some types of epilepsy more comparable to valproic acid 
than carbamazepine. Therefore, we also calculated the cost-eff ectiveness 
ratio for lamotrigine versus valproic acid, resulting in €13,370 per QALY, 
which can be conceived as a favorable cost-eff ective ratio.
We did not include eff ects on the cognitive development of the children. 
Valproic acid exposure during pregnancy has been associated with a lower 
IQ in the child [37]. No evidence exists for a comparable cognitive eff ect for 
carbamazepine or lamotrigine. Notably, as lamotrigine is a newer drug there 
is no data yet available on the school performance of children exposed to 
lamotrigine. Additionally, lower IQ could possibly result in less contribution 
to society over lifetime (e.g. production losses). The same holds true for some 
of the malformations (e.g. spina bifi da). Potential production losses and 
related losses in tax contribution in the next generation are nicely described in 
the fi eld of assisted reproduction [38]. For this case it would be the additional 
costs for a more expensive drug instead of the costs for IVF and it would be the 
additional expected tax due to a higher IQ or no physical disability potentially 
resulting in favorable outcomes on the long run.
Notably, only limited evidence exists on the parameter assumptions for the 
economic evaluation. The available studies presenting quality of life and life 
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expectancy data were based on various methods. Also, cost data were derived 
from several studies performed all over the world. Apart from acknowledging 
this limitation and justify these assumptions as the best there is, we feel that 
this analysis also nicely illustrates one of the major problems in performing 
economic evaluations in the fi eld of teratology research. For example the 
estimates for the lifetime costs for any malformation are based on a study 
which took into account only 16 diff erent malformations (accounting for 33% 
of the prevalence of all major malformations)[12].
Pharmacoeconomic analyses are not common in the fi eld of teratology, but 
could help to make initial therapy choices taking into account potential safety 
risks for the off spring. From the current analysis, it becomes clear that there 
are still a lot of important methodological issues left that need to be discussed 
further. In this paper the analysis is performed for a specifi c birth cohort. 
Analyses taking into account the risk for malformations need to be based 
on large numbers as the prevalence of major malformations is only around 
3% of all births, which correspondingly could require economic analysis 
based on multiple cohorts. Furthermore, an imminent question relates to 
the willingness to pay threshold for avoiding teratogenic risks in off spring; in 
particular, is this comparable to that for drugs improving the quality of life of 
the actual consumer? Finally, one might ask what the optimal data sources are 
for this type of research.
Ideally most assumptions are derived from clinical trial data, however these 
study designs are unethical to use for estimating teratogenicity of drugs. 
Information has to be derived from observational studies. For economic 
evaluations information is required on the association between a specifi c 
drug and a specifi c malformation. Cohort studies often do not have enough 
power to provide a precise estimate, but results of case-control studies are 
often more diffi  cult to use in economic analyses.
In short, based on epidemiological data it is recommended to avoid 
valproic acid exposure during pregnancy due to a higher risk of teratogenicity 
[39]. Also from a health economic point of view the use of the less teratogenic 
antiepileptic drugs, carbamazepine and lamotrigine, is estimated to be cost-
saving and cost-eff ective, respectively. This defi nitely holds true if analyses 
investigating teratogenicity are interpreted as interventions to enhance 
safety [14]. The cost-eff ectiveness of such interventions directed at safety 
and averting losses in quality of life are generally interpreted diff erently with 
much higher willingness to pay. Therefore policy makers and those controlling 
the budgets should look further than drug costs and adverse eff ects in the 
actual consumer if it concerns women with child bearing potential. In 
clinical practice, this information seems in line with the epidemiological data 
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showing that for women with childbearing potential, valproic acid might not 
be the best fi rst treatment option. However, the best treatment option can 
only be made on an individual tailor-made base and does not only rely on 
health economic outcomes.
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GENERAL DISCUSSION
Utilization of antiepileptic drugs around pregnancy
Teratogenicity of drugs is a highly relevant issue for the majority of women 
with a child wish. As presented in chapter 1 almost 80% of all pregnant 
women received at least one prescription for a drug during pregnancy. More 
than half of these prescriptions are for pregnancy related symptoms and most 
of these drugs are considered to be safe (= drugs that have been taken by a 
large number of pregnant women and women of childbearing age, without 
any proven increase in the frequency of malformations or other direct or 
indirect harmful eff ects on the fetus having been observed). The remaining 
half can be categorized into drugs used for chronic conditions and drugs for 
occasional and short-time use. The risks of both of these groups of drugs 
are more frequently undetermined or (potentially) harmful. Therefore, it 
is important that women try to plan their pregnancy and discus with their 
health care provider if they need (to continue) the drug for their condition 
and if so, what would be the best treatment option in their situation before 
they get pregnant.
In case of antiepileptic drugs, most women do need to continue their drug use 
during pregnancy. However, as described in the introduction this depends on 
the indication for which the antiepileptic drug is used. As described in chapter 
2, the prevalence of the use of antiepileptic drugs varies between (European) 
countries. The prevalence of at least one prescription for antiepileptic drugs 
during pregnancy varied between 4.0 and 5.2 per 1000 pregnancies for the 
included countries as presented in chapter 2. Also, it was found that use of 
specifi c antiepileptic drugs varied between the country-specifi c pregnant 
populations.
The reason for performing this study was that the proportions of specifi c 
antiepileptic drugs varied between the local EUROCAT congenital malformation 
registries. The total number of antiepileptic drug exposed registrations per 
registry is low which raised the question whether the diff erence between the 
registries was due to these low numbers or due to a diff erence in treatment 
practice between European countries. Table 1 shows the proportions with 95% 
confi dence intervals of the most frequently prescribed antiepileptic drugs 
among the general pregnant population (based on data of chapter 2) and for the 
EUROCAT registries located in the same country.
Risk assessment of antiepileptic drug use in pregnancy
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Table 1:  Proportion and 95% confi dence interval of the most frequently prescribed 
antiepileptic drugs in the general pregnant population and among pregnancies 
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*  comparing the region of Midi-Pyrenees (data ’03-’08) with the region of Paris (data ’02-’08) 
plus the region of Strasbourg (data ‘02-’04)
^  both data comes from the same region in the northern part of the Netherlands (data general 
’95-’09, EUROCAT ’95-’07)
#  comparing the region of Emilia Romagna (data ’04-‘07) with the regions Emilia Romagna 
(data ’03-’08) plus the region of Tuscany (data ’03-’08)
In particular, the proportion of valproic acid exposure is higher among 
malformed pregnancy outcomes, for the countries included in this study. 
This was in line with the expectations as valproic acid has been reported to 
be the strongest teratogenic agent out of commonly used antiepileptic drugs 
(based on experience up until now) [1-5]. Though these are descriptive results, 
it is hard to identify other trends within this table. The proportions vary both 
between and within countries, which can be partly due to the low numbers, 
but fi gures in published literature show similar variations. The top three of 
most used antiepileptic drugs around pregnancy in a hospital based cohort 
study in Denmark (data ’96-’00) were lamotrigine (35%), oxcarbazepine 
(25%) and valproic acid (20%) [6]. The most reported antiepileptic drugs in 
the Australian Pregnancy Registry of Antiepileptic drugs (data ’99-09) were 
carbamazepine (29%) lamotrigine (23%) and valproic acid (21%) [7]. Over half 
of the women exposed to antiepileptic drugs during pregnancy in a population-
based cohort study in Sweden (data ’95-’01) used carbamazepine (56%), 
valproic acid and phenytoin were reported for 25% and 10%, respectively 
[4]. In the UK Pregnancy Registry carbamazepine (38%), valproic acid (31%) 
and lamotrigine (28%) were the most reported (data ’96-’05) [1]. It has to be 
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emphasized that the methods used within the cited studies and the years of 
data collection were not the same and that the inclusion in the Danish study 
was based on a diagnosis of epilepsy (instead of use of antiepileptic drugs) The 
more recent studies show that the second generation antiepileptic drugs are 
more commonly used in the recent years [8-9]. As guidelines include available 
evidence from all over the world, one would ideally expect these proportions of 
specifi c antiepileptic drug use to be comparable between countries. However, 
the variation between countries clearly shows how diffi  cult it is to change 
daily practice in concordance with constantly updating scientifi c evidence 
[10]. Non-adherence to clinical guidelines is widely identifi ed across health 
services [11]. It therefore, seems that doctors rely on their own experience and 
interpret new evidence slightly diff erent. Several interventions are developed 
and evaluated to improve the adherence to prescribing guidelines. Computer-
based interventions providing reminders during a consultation are likely to be 
eff ective in the improvement of clinical performance and change a health care 
professionals’ behavior [12-13]. Prescribing of drugs during pregnancy can be 
seen as a preventive health care service and these guideline reminder systems 
have been found eff ective in this fi eld of care [14]. In case of antiepileptic 
drug use and the risk for teratogenicity, the reminder could be given based on 
characteristics such as gender and age.
Teratogenicity of antiepileptic drugs
Antiepileptic drugs can be split into fi rst and second generation drugs. First 
generation antiepileptic drugs are all antiepileptic drugs that were introduced 
on the market before the nineties and second generation agents are those 
approved since the nineties. In general, more experience exists with fi rst 
generation drugs as these agents are available for a longer period of time. 
Lamotrigine is the most often used second generation antiepileptic drug and 
is the drug with most information available about the use around pregnancy 
of the second generation drugs.
Lamotrigine is marketed as treatment for young women with epilepsy 
and a (future) child wish. Previous results of Antiepileptic drug & Epilepsy 
registries in Australia, UK and the US, displayed no evidence that the general 
teratogenicity of lamotrigine was not comparable with the risk in the general 
population [1,7,15]. Combining the 2,675 lamotrigine monotherapy exposed 
pregnancy outcomes described within all published prospective cohort 
studies gives a general malformation rate of 3.0% [2.3-3.6%] (including 
possible overlap between some cohorts) [1,4,6-7,15-19].However in 2006 an 
FDA warning was issued based on a conference abstract presenting a 24-times 
increased risk for isolated orofacial clefts and 32-times for cleft palate in 
specifi c [20-21]. The EUROCAT network tested the indication for an elevated 
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risk for isolated orofacial clefts using a study population covering about four 
million births including almost hundred thousand pregnancy outcomes with 
a major congenital malformation (chapter 3). Despite the large dataset only 
two lamotrigine monotherapy exposed cases with an isolated orofacial cleft, 
of which one cleft palate, were included in the analyses. This nicely illustrates 
the major problem within the research fi eld of teratology: power!
With the data included no evidence was found for an increased risk for 
isolated orofacial clefts (0.80 [0.11-2.85]) or isolated cleft palate in specifi c 
(1.01 [0.03-5.57]) for lamotrigine monotherapy exposure in the fi rst trimester 
of pregnancy, relative to other malformations. Although the point-estimates 
were close to 1 the upper limits of the confi dence intervals still included a 
possible moderate risk [22]. To estimate the risk of orofacial clefts relative 
to other malformations more precisely and to further explore whether 
lamotrigine exposure may be associated with other malformations, a follow-
up study was initiated with yearly updates for fi ve years.
The explorative analyses of chapter 3 showed an indication for club foot. 
This indication requires further investigation, especially as club foot is a 
complex malformation which can be related to other malformations (like 
spina bifi da) and which is associated with specifi c risk factors (e.g. smoking 
and family history). However, the signal has to be interpreted with caution as 
one should expect to fi nd something in case of multiple testing.
Although lamotrigine monotherapy may increase the risk of club foot, 
the drug seems to be relatively safe in pregnancy. Both valproic acid and 
carbamazepine are associated with spina bifi da and valproic acid is also 
associated with several other malformations (chapter 4 and 5). Spina bifi da is 
generally considered to be a more severe malformation than a cleft (or a club 
foot). The risks for specifi c malformations associated with other antiepileptic 
drugs are mostly unknown.
As there are no save antiepileptic drug alternatives it is very important in 
which way study results and conclusions based on generally small studies are 
presented and communicated [2,23-24]. It is important to publish all available 
information, although unconfi rmed indications should be placed in context 
and tested/confi rmed as soon as possible. This could help in preventing 
unnecessary doubts and fears of patients and health care professionals (here, 
neurologists). Ideally, indications are tested as quickly as possible and the 
results should be available in the public domain (e.g. publications). The study 
design used in the studies presented in the chapters 4 and 5 are examples of 
this. Moreover, in these chapters both, the in published literature identifi ed 
indications and the results of the ‘confi rming’ studies, are presented in 
one paper. In chapter 4, 14 indications for specifi c malformations that are 
associated with valproic acid monotherapy, were identifi ed from literature. 
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Using a case-control design only 6 of these signals were confi rmed. In a 
similar study on carbamazepine only 1 out of the 5 indications for specifi c 
malformations identifi ed from published literature were confi rmed.
Another way to investigate the eff ects and impact of teratology is to express 
prevented malformations associated with the choice of a specifi c drug in 
terms of money. In chapter 8 a cost utility analysis is performed to estimate 
the diff erences in costs and health gains if all pregnant women that require 
antiepileptic drugs would take carbamazepine, lamotrigine or valproic acid. 
Carbamazepine is not a fi rst choice option for all types of epilepsy; however, 
if suitable this drug could be considered as a good treatment option as there is 
a lot of experience with this drug. Furthermore, it seems that carbamazepine 
is relatively safe in terms of teratogenicity and the drug is cheap. From a 
health economic point of view valproic acid would not be considered as a fi rst 
choice treatment option if carbamazepine is indicated too, due to dominance. 
Lamotrigine seems to give a higher quality of life to the off spring, but this 
drug is more expensive. Estimated costs per QALY were €175,534 compared 
to carbamazepine and €13,370 compared to valproic acid, assuming equal 
eff ectiveness of these three drugs. These estimates are very conservative 
mainly as they do not take into account that these drug costs cover all costs 
for mother independent of the number of children. If a woman delivers two 
children, the drug costs can be divided by two. Additionally, these rates are 
expected to change in favor of lamotrigine as the prices of lamotrigine are 
decreasing every year (at least in the Netherlands). The extra money spent to 
prescribe life-long lamotrigine instead of valproic acid will avoid almost 700 
babies to be born with a major congenital malformation in Europe, annually 
(assuming equal eff ectiveness of both drugs).
Regardless the methods used for exploration and investigation of the risks 
and consequences of malformations associated with antiepileptic drugs, in 
the end the choice for the best treatment for a woman can only be made on 
an individual basis. However, it is generally wise to follow the advice of the 
American Academy of Neurology which recommends avoiding valproic acid 
during pregnancy if possible [25]. Switching between antiepileptic drugs is not 
easy, and it would therefore also be recommendable not to start with valproic 
acid in newly diagnosed girls/women with a (possible future) child wish. 
In this thesis, only major congenital malformations are taken into account. 
In daily practice also risks for minor malformations and behavioral eff ects, 
which are possibly more common than major malformations, will infl uence 
the therapy choice [26-27]. Furthermore, if women using antiepileptic drugs 
have a preconception discussion with their neurologist, it is important to 
recommend folic acid use from at least 4 weeks before conception till 8 weeks 
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in pregnancy. In the general population, it is estimated that the risk for a baby 
with a neural tube defect is reduced with approximately 65% if a women used 
0.4-0.5mg folic acid supplements daily in the recommended period [28-29]. 
Only women who previously delivered a child with a neural tube defect are 
advised to take 5 mg around subsequent pregnancies in the Netherlands. 
The Dutch advice for women using antiepileptic drugs is to take the normal 
dose, whereas in some countries these women are advised to take 5 mg of 
folic acid [30-33]. Also the summary of product characteristics of valproic 
acid recommends women using valproic acid to use 5 mg folic acid [34]. While 
no conclusive evidence exists for the eff ectiveness of this higher folic acid 
dose, this policy is often explained by the fact that some of the antiepileptic 
drugs have folic acid antagonistic eff ects [34-35]. In chapter 6, the preventive 
eff ect of folic acid on spina bifi da was estimated for valproic acid exposed 
pregnancies. No evidence was found for a protective eff ect: OR 1.0 [0.1-7.6], but 
the confi dence interval is wide. Although, not accepted by all investigators, 
there is a theory explaining the absence of the protective eff ect. According 
to this theory the neural tube exists of fi ve closure sites of which folic acid is 
involved with the closure of sites 1 (caudal), 2 and 4. Valproic acid is thought 
to interfere with site 5 (the lowest closure site) which closes independently of 
folic acid [36]. If this theory holds true it explains the more prevalent lower 
lesions among women who delivered a child with spina bifi da while using 
valproic acid [37-38]. As the prevalence of spina bifi da is 13-times increased 
among valproic acid exposed pregnancies (chapter 4), it is very important for 
women requiring valproic acid to collect more evidence on the eff ect of folic 
acid. In particular, it is important to investigate further the mechanisms of 
action on the spine of both folic acid and valproic acid.
As stated in the introduction section of this thesis, health care professionals 
are more likely to prescribe drugs with more experience in pregnancy rather 
than newer drugs in women with a child wish. This also holds true for 
antiepileptic drugs. On the one hand this seems logical, as we do not know 
the size of the teratogenic risk for the second generation antiepileptic drugs. 
On the other hand this does not seems logical, as we do know that the fi rst 
generation antiepileptic drugs do increase the risk for major congenital 
malformations. Among data available for the second generation antiepileptic 
drugs it is mainly topiramate being associated with a specifi c malformation. 
Data available up till now show more cleft cases than expected, which 
resulted in an FDA label change in March 2011 [9,39-40]. This association will 
be tested in case-control studies in Europe using the EUROCAT Antiepileptic 
Study database and the US using data of National Center of Birth Defects and 
Developmental Disabilities and Slone Epidemiology Center.
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Within EUROCAT, the proportion of malformed pregnancy outcomes exposed 
to second generation antiepileptic drugs increases in the most recent years, 
but the absolute numbers per individual antiepileptic drug are still small. 
Therefore it is hard to perform analytical studies on specifi c malformations 
with suffi  cient power. The reason for these small numbers could be preference 
for older antiepileptic drugs with more experience in pregnancy or these 
second generation antiepileptic drugs are less teratogenic. For a potential 
safe (future) antiepileptic drug it will be very hard to perform a study within 
EUROCAT as it will take many years to include enough pregnancy outcomes 
for suffi  cient power.
For example, the risk for a major congenital malformation in the general 
population is around 3 per 100, the use of any antiepileptic drug in pregnancy 
is around 4 per 1000 which means that you will need about 8333 pregnancies 
to expect to fi nd 1 major malformed outcome exposed to antiepileptic drugs 
in case of no increased risk. This is not even taking into account the specifi c 
antiepileptic drugs. For most second generation antiepileptic drugs, the 
prevalence of monotherapy is around 0.5 per 1000 (or even less) which means 
that it approximately requires 66,666 pregnancies to identify one major 
malformed pregnancy outcome exposed to the antiepileptic drug of interest 
for an antiepileptic drug that does not increase the risk of malformations. 
In other words you would in this case expect only 3 malformed pregnancy 
outcomes exposed to the drug of interest per year in the total Dutch birth 
cohort (≈180,000). This is not even taking into account the prevalence of a 
specifi c malformation.
To have a good impression of the maternal drug use in the general pregnant 
population (and not only among those with a malformed outcome), it is very 
valuable to include non-malformed pregnancy outcomes in EUROCAT. As 
long as non-malformed outcomes are not registered, it is valuable to perform 
population-based drug utilization studies in the EUROCAT region. These 
non-malformed controls or these utilization studies can provide an estimate 
of the prevalence of exposure to specifi c antiepileptic drugs in the general 
pregnant population and will help to estimate the frequencies you can expect 
within EUROCAT.
Control groups, bias and confounding
Within the EUROCAT network information is available for live born, still 
born and terminated (after prenatal diagnosis) pregnancy outcomes with 
major malformations. In case-control studies, we use malformed controls not 
associated with the exposure under study. The odds ratios calculated in chapter 
3, 4 and 5 are presented compared to other malformed pregnancy outcomes, 
rather than compared to the general population. In other words these analyses 
relate more to specifi city of eff ect rather than the eff ect size as a whole.
General discussion
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Non-malformed control groups can be very valuable, as these groups off er 
the opportunity to calculate the risks relative to the risk in the general non-
malformed population. This eff ect-size is easier to interpret. However, not all 
non-malformed control groups are appropriate. The control group needs to 
be representative for the general population (or the sub population). This is 
not always the case as it is hard to deal with selection and information bias.
Due to the criticism in literature it was decided to collect a non-malformed 
control group that could be used in case-control studies with the Dutch 
EUROCAT [41-43]. Since 2004, non-malformed pregnancy outcomes were 
collected in the northern Netherlands with the aim to gather drug exposure 
information of a non-malformed control group. However, the control group 
turned out to be not representative [44]. Especially the low prevalence of drug 
use can be considered as a problem in pharmacoepidemiological case-control 
studies. If we would have used this non-malformed control group it would lead 
to an overestimation of the risk (in case of OR>1) and we would therefore detect 
false associations. The results of this evaluation strengthened our feeling that a 
control group is not just good because it is a non-malformed group.
For the choice of ‘our’ control group it is more important that exposure to 
drugs is representative than the fact that the control group consists of non-
malformed pregnancy outcomes. Especially, because using malformed 
controls can help to reduce recall bias, which is a problem with retrospective 
studies like case-control studies. Although the evidence supporting the eff ect 
of recall bias is inconsistent, some studies found diff erences in their recall 
of exposures in pregnancies resulting in non-malformed outcomes compared 
to mothers delivering a malformed child [45-46]. The risk for recall bias 
depends on the way the exposure data is collected. Exposure data based on 
questionnaires is most sensitive, although the design of the questions can 
help to reduce the bias [47]. However, since most drug exposure information 
was recorded in medical records before the pregnancy outcome was known, 
recall bias seems unlikely for the case-control studies included in this thesis.
Ideally, one would use a non-malformed, a genetic and a non-chromosomal 
malformed control group which are all collected in the same population-
based system. The non-malformed group is sensitive for recall bias and 
selection bias if only a sample of the non-malformed pregnancy outcomes 
is included. Underreporting of drug use will lead to an overestimation and 
an unrepresentative sample can both lead to an over- or an underestimation 
of the investigated relative risk. The two malformed control groups (gathered 
using the same methods in the same registry) are less sensitive to recall bias 
as both groups of mothers will feel responsible (guilty). However as genetic 
malformations are assumed to be unrelated to drug exposure this group is 
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more sensible for information bias as the exposure information might be less 
complete (as the collection of these data might seems less important). The non-
chromosomal control group on the other hand might give an underestimation 
of the relative risk if malformations that are associated with the exposure of 
interest are included in the control group. This last point could also be true 
for the chromosomal controls: valproic acid exposure is associated with ASD 
(chapter 4) and pregnancy outcomes with chromosomal malformations have 
an increased risk for ASD. However, in case of valproic acid exposure and a 
chromosomal pregnancy outcome the ASD could be related to both; the drug 
or the genetic malformation.
Chapters 4 and 5 raise another point that needs to be mentioned here: some 
of the malformation subgroups that were cases in the valproic acid study were 
controls in the carbamazepine study. This was no problem in the comparison 
of carbamazepine with ‘no antiepileptic drug use’. However, in the direct 
comparison between carbamazepine and valproic acid this resulted in a 
relation between ‘unexposure’ (=valproic acid exposure) and some subgroups 
included in the control group. It is important to not only exclude malformation 
subgroups associated with the exposure under study (=carbamazepine) from 
the control group, but also those associated with ‘unexposure’ (=valproic 
acid). If we would have included these related malformations, this could have 
led to an underestimation of the risk (in the analysis of spina bifi da, odds 
ratios below 1).
Confounding factors are important to take into account. Although within the 
case-control studies presented in this thesis we were not able to adjust for 
all factors one would like to adjust for, for two reasons: low numbers or no 
information about the specifi c characteristic. In our analyses we adjusted (if 
possible) for maternal age, year of birth of the child and reporting local registry.
If we would have had (complete) data on folic acid use, family history, 
type and severity of epilepsy and dose information of the antiepileptic drug it 
would be important to investigate the infl uence of these characteristics and 
to take them into account (if possible with regard to the numbers). Especially 
information about the dosage used would be very important as more and more 
evidence is available showing higher risks for higher dosages of antiepileptic 
drugs [1,3,5,48-49].
In case-control studies the odds ratio is a good approximation of the relative 
risk if the outcome is infrequent. This is the case for (specifi c) malformations 
and therefore the outcome can be interpreted as a relative risk: it presents the 
risk for an event in the exposed group compared to the risk for this event in an 
unexposed group. It is not possible to use a case-control study to calculate an 
absolute risk: the risk to get an event for the population under study.
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Although absolute risks cannot be calculated in a case-control study, an 
estimate can be given by multiplying the prevalence of the outcome in the 
general population with the odds ratio found in the case-control study, like 
presented in the discussion of chapter 4. The prevalence of spina bifi da is 
about 0.5 per 1000 births, the odds ratio of spina bifi da among valproic acid 
exposed pregnancies is 12.7; the estimated absolute risk for spina bifi da in 
case of maternal valproic acid exposure is 0.6%.
This example clarifi es that a moderate relative risk for a specifi c 
malformation, does not necessary coincides a high absolute risk. In particular, 
for specifi c malformations these absolute risks are generally small.
Conclusion & future implications
In this thesis the utilization of antiepileptic drugs in pregnancy is estimated for 
three European countries showing major diff erences between these regions. 
This refl ects the importance of performing this type of utilization studies as 
the treatment practice varies between regions. If the use of antiepileptic drugs 
in the general pregnant population is known, it might be easier to estimate 
risks for congenital malformations of (the second generation) antiepileptic 
drugs. The prevalence found among the general pregnant population can give 
an estimate of what prevalence to expect within EUROCAT. This may help 
to fi nally improve the management of epilepsy around pregnancy. Although 
changing daily practice is known to be hard [11,13].
The studies presented in this thesis are the fi rst pharmacoepidemiological 
studies performed with the international EUROCAT congenital malformation 
registries network. The EUROCAT network demonstrated to be a capable source 
to perform risk assessment studies for drugs that are chronically used. Due to 
the large population-based regions covered, studies looking at associations 
between specifi c drugs and specifi c malformations can be performed. In 
particular, the dataset is suitable to test indications identifi ed in other sources 
(e.g. literature) and to perform direct comparisons between individual drugs. 
As non-malformed controls are not (yet) available, all analyses are performed 
relative to other malformations. This is a point that could be improved in future 
as well as the drug exposure information. Improvement could be achieved by 
linkage with sources that contain maternal prescription histories and with 
sources providing information on non-malformed pregnancy outcomes. 
These two important topics will be explored in EUROmediCAT within an EU 
Framework 7 funding that started March 2011.
The three case-control studies as presented in part II of this thesis increase 
the available evidence on safety of the three most often used antiepileptic 
drugs during pregnancy (in most countries). This information can be used 
to update or create treatment guidelines for women requiring antiepileptic 
drugs with childbearing potential.
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This thesis also describes results from a health-economic analysis. Such 
analyses are not common in the fi eld of teratology although it might get 
more attention in the near future. Due to the ageing of most populations in 
the western world and the health costs related to this ageing process in the 
society, it will become even more important that the off spring is healthy. 
Therefore this type of analyses might help to investigate the best treatment 
options; not only for the mother but also for the unborn child.
It is easy to conclude from this thesis that women requiring antiepileptic 
drugs having a child wish are in an awkward position. They need to use a 
class of drugs, for which drugs are proven not to be safe in pregnancy or for 
which no suffi  cient evidence is available to assume that these agents are safe 
during pregnancy. The second generation antiepileptic drugs are assumed 
to be potentially safer, but there are hardly any powered published studies 
available to confi rm this. Altogether, it seems even more complicated due 
to the fact that there is not a very clear population-based picture of the use 
of specifi c new antiepileptic drugs in the general pregnant population. In 
particular, both the prevalence and the use of the specifi c types of drugs vary 
between countries.
However, we should keep in mind that despite the increased relative 
risk for malformations and the advice to try to avoid valproic acid exposure 
during pregnancy, still the majority of all babies with intra-uterine exposure 
to valproic acid monotherapy are born without major malformations. The 
best treatment option can only be made on an individual tailor-made basis. 
Hopefully, in the near future there will be a very eff ective ‘broad spectrum’ 
antiepileptic drug that turns out to be safe for the unborn child.
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SUMMARY
Teratogenicity of drugs is a highly relevant issue for the majority of women 
with a child wish. In the Netherlands, almost 80% of all pregnant women 
received at least one prescription for a drug during pregnancy (chapter 1). 
Therefore, it is important that women try to plan their pregnancy and discus 
with their health care provider if they need (to continue) the drug for their 
condition and if so, what would be the best treatment option considering 
their situation before pregnancy.
In case of antiepileptic drugs, depending on therapy indication, most 
women do need to continue their drug use during pregnancy. Four to fi ve 
per 1000 women receive at least one prescription for antiepileptic drugs 
during pregnancy (chapter 2). The prescribed type of antiepileptic drugs 
to women in the general pregnant population varies between countries. 
The most frequently prescribed antiepileptic drugs in France, Italy and 
Netherlands were carbamazepine, lamotrigine, phenobarbital and valproic 
acid (alphabetical order).
Antiepileptic drugs can be split into fi rst and second generation drugs. 
First generation antiepileptic drugs are all antiepileptic drugs that were 
introduced on the market before the nineties and second generation agents 
are those approved since the nineties. Lamotrigine is the most often used 
second generation antiepileptic drug and is the drug with most information 
available about the use around pregnancy. Combining the 2,675 lamotrigine 
monotherapy exposed pregnancy outcomes described within all published 
prospective cohort studies, gives a general malformation rate of 3.0% [2.3-
3.6%] (including possible overlap between some cohorts).
However in 2006 an FDA warning was issued based on a conference 
abstract presenting a 24-times increased risk for isolated orofacial clefts 
and 32-times for cleft palate in specifi c with fi rst trimester lamotrigine use. 
The EUROCAT network tested the indication for an elevated risk for isolated 
orofacial clefts using a study population covering about four million births 
including almost hundred thousand pregnancy outcomes with a major 
congenital malformation. With the data included no evidence was found for 
an increased risk for isolated orofacial clefts (0.80 [0.11-2.85]) or isolated cleft 
palate in specifi c (1.01 [0.03-5.57]) for lamotrigine monotherapy exposure in 
the fi rst trimester of pregnancy, relative to other malformations (chapter 3).
Explorative analyses for lamotrigine showed an indication for club 
foot, which needs further investigation although the drug seems to be 
relatively safe in pregnancy. In particular, both alternatives valproic acid 
and carbamazepine are associated with spina bifi da and valproic acid is also 
associated with several other specifi c malformations (chapter 4 en 5). Spina 
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bifi da is generally considered to be a more severe malformation than a cleft 
(or a club foot). The risks for specifi c malformations associated with other 
antiepileptic drugs are generally unknown.
As there are no save antiepileptic drug alternatives for use during pregnancy, 
it is very important in which way study results and conclusions based on 
generally small studies are presented, interpreted and communicated. This 
could help in preventing unnecessary doubts and fears of patients and health 
care professionals. It is important to publish all available relevant information, 
although unconfi rmed indications should be placed in context and tested/
confi rmed as soon as possible. 
Another way to investigate the eff ects and impact of teratology is to 
express prevented malformations associated with the choice of a specifi c 
drug in terms of money. A cost utility analysis was performed to estimate 
the diff erences in costs and health gains if all pregnant women that require 
antiepileptic drugs would take carbamazepine, lamotrigine or valproic acid 
(chapter 7). Carbamazepine is not a fi rst choice option for all types of epilepsy; 
however, if suitable this drug could be considered as a good treatment option 
as there is a lot of experience with this drug. Furthermore, it seems that 
carbamazepine is relatively safe in terms of teratogenicity level and the drug 
is cheap. From a health economic point of view valproic acid would not be 
considered as a fi rst choice treatment option if carbamazepine is indicated 
as possible treatment too, due to dominance. Lamotrigine seems to result in 
a higher quality of life among the off spring, but this drug is more expensive.
Regardless the methods used for exploration and investigation of the risks and 
consequences of malformations associated with antiepileptic drugs, the choice 
for the best treatment for a woman can only be made on an individual basis.
In this thesis, only major congenital malformations are taken into account. 
In daily practice also risks for minor malformations and behavioral eff ects, 
which are possibly more common than major malformations, infl uence the 
therapy choice.
For women using antiepileptic drugs, it is recommendable to have a 
preconception discussion with the neurologist. Next to the antiepileptic drug 
treatment, it is important to recommend folic acid use from at least 4 weeks 
before conception till 8 weeks in pregnancy, although no conclusive evidence 
exists for the most eff ective dose of folic acid among women using valproic 
acid. In this thesis, no evidence was found for a protective eff ect of folic acid 
for valproic acid exposed pregnancies (OR 1.0 [0.1-7.6]) (chapter 6). As the 
prevalence of spina bifi da is 13-times increased among valproic acid exposed 
pregnancies it is important to investigate further the mechanisms of action 
on the spine of both folic acid and valproic acid.
Within the EUROCAT network, information is available for live born, still 
born and terminated (after prenatal diagnosis) pregnancy outcomes with 
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major malformations. In case-control studies, we use malformed controls not 
associated with the exposure under study. Non-malformed control groups 
can be very valuable, as these groups off er the opportunity to calculate the 
risks relative to the risk in the general population. This eff ect-size is easier to 
interpret. However, not all non-malformed control groups are appropriate. As 
long as non-malformed outcomes are not registered, it is valuable to perform 
population-based drug utilization studies in the EUROCAT region. These 
non-malformed controls or these utilization studies can provide an estimate 
of the prevalence of exposure to specifi c antiepileptic drugs in the general 
pregnant population and will help to estimate the frequencies you can expect 
within EUROCAT.
For the choice of ‘our’ control group it is more important that exposure 
to drugs is representative than the fact that the control group consists of 
non-malformed pregnancy outcomes. Especially, because using malformed 
controls can help to reduce recall bias. Ideally, one would separately use a 
non-malformed, a chromosomal and a non-chromosomal malformed control 
group which are all collected in the same population-based system.
Conclusion & future implications
The studies presented in this thesis are the fi rst pharmacoepidemiological 
studies performed using the international EUROCAT congenital 
malformation registries network. The EUROCAT network demonstrated to 
be a capable source to perform risk assessment studies for drugs that are 
chronically used. Due to the large population-based regions covered, studies 
looking at associations between specifi c (antiepileptic) drugs and specifi c 
malformations can be performed.
The three case-control studies as presented in part II of this thesis increase 
the available evidence on safety of the three most often used antiepileptic 
drugs during pregnancy (in most countries). This information can be used to 
update or create treatment guidelines for women requiring antiepileptic drugs 
with childbearing potential. This thesis also describes results from a health-
economic analysis. Such analyses are not common in the fi eld of teratology but 
may possibly receive more attention in the near future for investigation of the 
best treatment options; not only for the mother but also for the unborn child.
It is easy to conclude from this thesis that women requiring antiepileptic 
drugs who are having a child wish are in an awkward position. They need to 
use a class of drugs, for which drugs are proven not to be safe in pregnancy 
or for which no suffi  cient evidence is available to assume that these agents 
are safe during pregnancy. In particular, both the prevalence and the use of 
the specifi c types of drugs vary between countries, although the available 
teratogenic information is comparable between countries.
However, we should keep in mind that despite the increased relative 
risk for malformations and the advice to try to avoid valproic acid exposure 
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during pregnancy, still the majority of all babies with intra-uterine exposure 
to valproic acid monotherapy are born without major malformations. The 
best treatment option can only be made on an individual tailor-made basis. 
Hopefully, in the near future there will be a very eff ective ‘broad spectrum’ 
antiepileptic drug that turns out to be safe for the unborn child.
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SAMENVATTING
De teratogeniteit van geneesmiddelen is zeer relevant voor het merendeel 
van de vrouwen met een kinderwens. In Nederland ontvangt bijna 80% van 
de vrouwen minimaal een receptgeneesmiddel via de apotheek tijdens de 
zwangerschap. Het is daarom belangrijk dat vrouwen hun zwangerschap 
plannen en overleggen met hun zorgverleners of zij in hun specifi eke situatie 
een middel moeten (door)gebruiken en zo ja, welk middel dan de beste optie is.
De meeste vrouwen die anti-epileptica gebruiken, moeten (afhankelijk 
van de indicatie) deze middelen blijven gebruiken tijdens een eventuele 
zwangerschap. Tijdens de zwangerschap halen vier a vijf op de duizend 
vrouwen ten minste een anti-epilepticum bij de apotheek. De voorgeschreven 
typen anti-epileptica verschillen tussen landen, maar de meest voorgeschreven 
middelen in Frankrijk, Italie en Nederland zijn carbamazepine, fenobarbital, 
lamotrigine en valproinezuur (alfabetische volgorde).
Anti-epileptica kunnen worden opgesplitst in eerste en tweede generatie 
middelen. De eerste generatie middelen zijn geregistreerd voor 1990 en de 
tweede generatie anti-epileptica zijn geregistreerd sinds 1990. Lamotrigine 
is het meest gebruikte tweede generatie middel en hiervan is dan ook de 
meeste informatie beschikbaar over het gebruik rondom de zwangerschap. 
Als de 2675 eerste trimester lamotrigine monotherapie blootgestelde 
zwangerschapsuitkomsten die zijn beschreven in gepubliceerde prospectieve 
cohort studies worden gecombineerd, levert dit een risico op aangeboren 
afwijkingen van 3.0% [2.3-3.6%] (overlap mogelijk tussen sommige cohorten).
Ondanks dat het algemene risico niet is verhoogd, heeft de FDA in 2006 
een waarschuwing afgegeven van een 24 keer verhoogd risico op orofacial 
clefts. Meer specifi ek betekent dit een 32 keer verhoogd risico voor cleft 
palate bij maternaal lamotrigine gebruik tijdens het eerste trimester van 
de zwangerschap. Dit signaal is getest met het EUROCAT netwerk in een 
‘population-based’ case-controle onderzoek. De studiepopulatie omvatte bijna 
vier miljoen geboortes en bijna honderdduizend zwangerschapsuitkomsten 
met aangeboren afwijkingen. Op basis van de geïncludeerde data is geen 
bewijs gevonden voor een verhoogd risico op orofacial clefts (OR 0.80 
[0.11-2.85]) of meer specifi ek geïsoleerde cleft palate (OR 1.01 [0.03-5.57]) 
bij lamotrigine monotherapie gebruik tijdens het eerste trimester van de 
zwangerschap, vergeleken met andere aangeboren afwijkingen.
Signaalgenererende analyses gaven een indicatie voor een verhoogd risico 
op een klompvoet. Dit signaal moet verder uitgezocht worden. Al met al, lijkt 
lamotrigine relatief veilig gebruikt te kunnen worden tijdens de zwangerschap 
als men kijkt naar het risico op aangeboren afwijkingen. Zeker gezien de twee 
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meest gebruikte alternatieven: carbamazepine en valproïnezuur, beide zijn 
geassocieerd met een verhoogd risico op spina bifi da bij het nageslacht en 
valpoïnezuur daarnaast ook met andere specifi eke aangeboren afwijkingen 
is geassocieerd.
Aangezien er geen anti-epileptica zijn waarvan vast staat dat ze veilig 
gebruikt kunnen worden tijdens de zwangerschap is het erg belangrijk hoe 
studieresultaten en conclusies, meestal gebaseerd op kleine studies, worden 
gepresenteerd, geïnterpreteerd en gecommuniceerd. Bovenal is het van belang 
dat alle beschikbare informatie wordt gepubliceerd, in specifi eke context 
wordt geïnterpreteerd en dat nieuwe signalen zo snel mogelijk worden getest 
in andere studiepopulaties. Accurate informatie is belangrijk voor patiënten 
en behandelaren om (onnodige) twijfel en bezorgdheid te verminderen.
Een andere methode om het eff ect en de impact van teratogeniteit te 
onderzoeken is het in geld uitdrukken van aangeboren afwijkingen die 
worden voorkomen als er een ander middel wordt gekozen. De verschillen in 
kosten en gezondheidswinst zijn geschat voor de situaties dat alle zwangere 
vrouwen die anti-epileptica nodig hebben carbamazepine, lamotrigine of 
valproïnezuur zouden slikken. In situaties waar carbamazepine geïndiceerd 
is lijkt dit een middel om in overweging te nemen gezien de ruime ervaring 
met dit middel, de relatieve veiligheid als het gaat om teratogeniteit en de 
lage prijs. Anderzijds zou valproïnezuur vanuit een gezondheidseconomisch 
uitgangspunt niet als een eerste keus behandeling worden gezien als 
carbamazepine ook geïndiceerd is in verband met dominantie: carbamazepine 
is minder teratogeen en kost minder dan valproïnezuur. Lamotrigine ten 
slotte, lijkt te resulteren in een hogere kwaliteit van leven in het nageslacht, 
maar het middel is ook duurder.
Ongeacht de methode die wordt gebruikt om de risico’s en consequenties 
in kaart te brengen voor aangeboren afwijkingen geassocieerd met anti-
epileptica, kan het beste middel tijdens de zwangerschap alleen per individu 
worden bepaald. Resultaten zijn gebaseerd op populatieniveau, niet op het 
niveau van het individu.
De focus in dit proefschrift is gericht op ernstige aangeboren afwijkingen. 
In de dagelijkse praktijk zijn ook de risico’s op minder ernstige aangeboren 
afwijkingen en ontwikkelingseff ecten, die wellicht frequenter voorkomen, 
van belang voor de uiteindelijke therapiekeuze.
Voor vrouwen die anti-epileptica nodig hebben is het sterk aan te bevelen om 
ruim voor conceptie een consult te hebben met de neuroloog om daarin hun 
kinderwens kenbaar te maken en afspraken te maken over het handhaven of 
veranderen van de huidige therapie. Naast de behandeling met anti-epileptica 
is het belangrijk dat het gebruik van foliumzuur van minimaal 4 weken voor 
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conceptie tot en met 8 weken erna wordt geadviseerd. Er is discussie over de 
meest eff ectieve dosering van foliumzuur voor vrouwen die anti-epileptica 
gebruiken. Echter, in een case controle studie in dit proefschrift is geen 
beschermend eff ect gevonden van foliumzuur gebruik in valproïnezuur 
blootgestelde zwangerschappen (OR 1.0 [0.1-7.6]). Aangezien de prevalentie van 
spina bifi da dertien keer verhoogd is onder zwangerschappen blootgesteld aan 
valproïnezuur is het zeer belangrijk dat de werkingsmechanismen van zowel 
foliumzuur als valproïnezuur op de neuraalbuis verder worden onderzocht.
In het EUROCAT netwerk neemt in de recentere jaren het aandeel 
zwangerschapsuitkomsten met aangeboren afwijkingen toe die zijn 
blootgesteld aan tweede generatie anti-epileptica. Wel blijven de absolute 
aantallen per tweede generatie middel klein. Mogelijke redenen hiervoor 
zijn voorkeur voor anti-epileptica waarmee meer ervaring is of lagere 
teratogeniteit van de tweede generatie anti-epileptica. Om een goed overzicht 
te hebben van maternaal anti-epileptica gebruik in de algemene zwangere 
populatie (en niet alleen van zwangerschapsuitkomsten met aangeboren 
afwijkingen) is het belangrijk om zwangerschappen zonder aangeboren 
afwijkingen te includeren in EUROCAT. Zolang alleen zwangerschappen 
met aangeboren afwijkingen zijn geregistreerd op een systematische 
‘population-based’ manier in EUROCAT is het zeer waardevol om 
‘population-based’ geneesmiddel gebruikersstudies naar anti-epileptica te 
doen in de EUROCAT regio. Deze controles zonder aangeboren afwijkingen 
of deze gebruikersstudies geven een beeld van de prevalentie van specifi eke 
anti-epileptica blootstelling in de algemene zwangere populatie en helpen 
te schatten welke frequenties verwacht kunnen worden in EUROCAT 
als het middel niet geassocieerd zou zijn met aangeboren afwijkingen.
Binnen het EUROCAT netwerk is informatie beschikbaar over levend 
geborenen, dood geborenen en afgebroken zwangerschappen (na een 
prenatale diagnose) met aangeboren afwijkingen. In case controle studies met 
EUROCAT worden controles met aangeboren afwijkingen gebruikt die niet 
zijn geassocieerd met de blootstelling die wordt onderzocht. Controle groepen 
zonder aangeboren afwijkingen kunnen erg waardevol zijn, omdat hiermee 
het risico kan worden berekend ten opzichte van de algemene populatie 
zonder aangeboren afwijkingen. Deze uitkomstmaat is makkelijker te 
interpreteren dan een berekening ten opzichte van zwangerschapsuitkomsten 
met andere aangeboren afwijkingen. Toch zijn niet alle controle groepen 
zonder aangeboren afwijkingen geschikt.
Het is voor de keuze van de controle groep belangrijker dat de blootstelling 
aan geneesmiddelen representatief is dan dat de controle groep bestaat uit 
zwangerschapsuitkomsten zonder aangeboren afwijkingen (binnen farmaco-
epidemiologie). Vooral omdat het gebruik van controles met aangeboren 
afwijkingen voordelen kan hebben: ze zijn vaak op dezelfde manier verzameld 
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en ze kunnen helpen om ‘recall bias’ te verminderen. In het ideale geval worden 
er drie controle groepen gebruikt: een zonder aangeboren afwijkingen, een 
met chromosomale afwijkingen en een met non-chromosomale aangeboren 
afwijkingen, die alle drie zijn verzameld in hetzelfde ‘population-based’ 
systeem.
Conlusie & toekomstperspectieven
De studies in dit proefschrift zijn de eerste farmaco-epidemiologische studies 
uitgevoerd met het internationale EUROCAT netwerk voor registraties van 
aangeboren afwijkingen. Het EUROCAT netwerk heeft bewezen geschikt 
te zijn om ‘risk-assessment’ studies uit te voeren voor geneesmiddelen die 
chronisch worden gebruikt. Door de grote ‘population-based’ dataset is het 
mogelijk om associaties te onderzoeken tussen specifi eke anti-epileptica en 
specifi eke aangeboren afwijkingen.
De drie case controle studies in deel twee van dit proefschrift vergroten 
de beschikbare informatie over de veiligheid van de drie meest gebruikte 
anti-epileptica tijdens de zwangerschap (in de meeste landen). Deze nieuwe 
informatie kan worden gebruikt om behandelrichtlijnen voor vrouwen in de 
vruchtbare leeftijd die anti-epileptica nodig hebben op te stellen of te vernieuwen.
Dit proefschrift beschrijft verder de resultaten van een gezondheids-economische 
analyse. Dergelijke analyses zijn niet gebruikelijk binnen het onderzoeksgebied 
van de teratologie, maar wellicht komt hiervoor meer aandacht in de toekomst 
door de vergrijzing en het daaruit voortkomende groeiende belang van een 
optimale verdeling van het gezondheidszorgbudget. Economische analyses 
kunnen wellicht bijdragen aan de inventarisatie van de beste behandeloptie, niet 
alleen voor de vrouw zelf, maar ook voor het ongeboren kind.
Het is gemakkelijk om op basis van dit proefschrift te concluderen dat 
vrouwen met een kinderwens die anti-epileptica nodig hebben in een 
lastige situatie zitten. Ze hebben een groep van geneesmiddelen nodig 
waarvan bewezen is dat ze niet veilig zijn of waarvan de veiligheid tijdens de 
zwangerschap onbekend is. Bovendien variëren zowel de prevalentie als de 
gebruikte specifi eke middelen in verschillende Europese landen. Dit terwijl 
er geen reden is om te veronderstellen dat het teratogene risico anders is in 
Frankrijk dan in Nederland en terwijl de richtlijnen worden gebaseerd op 
dezelfde wereldwijd beschikbare informatie.
Uiteindelijk is het belangrijk om in het achterhoofd te houden dat ondanks 
het verhoogde relatieve risico op aangeboren afwijkingen en het advies om 
valproïnezuur gebruik te vermijden tijdens de zwangerschap, het merendeel 
van de kinderen die zijn blootgesteld aan valproïnezuur monotherapie, wordt 
geboren zonder ernstige aangeboren afwijkingen. De beste behandeling 
kan alleen per situatie worden bepaald; hopelijk komt er in de toekomst een 




Met de afronding van mijn proefschrift is er een eind gekomen aan mijn tijd 
op de Rijksuniversiteit Groningen. Een zeer leerzame en leuke periode! Zowel 
tijdens mijn studietijd als tijdens mijn promotietraject heb ik veel mensen 
ontmoet waarvan ik veel heb geleerd, op allerlei gebied. Graag wil ik dan ook 
op deze plek van de gelegenheid gebruik maken om de mensen die ik door 
mijn werk op de Rijksuniversiteit Groningen heb ontmoet te bedanken voor 
hetgeen ze voor mij hebben betekend of nog steeds betekenen.
Toen ik voor het schrijven van dit dankwoord een lijstje maakte met namen 
van mensen die ik graag persoonlijk wil bedanken, ontdekte ik dat het niet 
zwart-wit is wie er wel en niet op komt. Ook realiseerde ik mij direct dat het 
onvermijdelijk is dat ik na het drukken ontdek dat ik leuke anekdotes of zelfs 
personen die mij hebben geholpen vergeten ben in dit dankwoord. Als je na 
het lezen van de rest van het dankwoord te vergeefs naar jouw naam hebt 
gezocht behoor je misschien tot deze categorie; in dat geval mijn excuses en 
alsnog bedankt!
Boven aan mijn lijstje staan met stip mijn twee promotoren: Lolkje en Helen.
Lolkje, in 2004 klopte ik voor het eerst aan jouw deur voor mijn 
bachelorproject en vanaf dat moment was ik veel op de afdeling te vinden 
voor onderzoek en vakken. Vooral het uitwerken van een onderzoeksvraag 
tot een werkzame design vond ik erg leuk. Dit heeft in al die jaren samen met 
jou frisse kijk en enthousiasme geleid tot leuke studies. Dankjewel voor je 
begeleiding. Tijdens mijn masterproject met EUROCAT en in het begin van 
mijn promotie traject zijn we samen vaak naar Belfast gevlogen. Ik heb deze 
reisjes altijd erg bijzonder gevonden: zeer leerzaam, effi  cient en interessant, 
maar ook erg vermoeiend. Tijdens deze reisjes bezochten we mijn tweede 
promotor Helen Dolk aan de University of Uster. Helen I learnt a lot from 
you, especially your cautious way of working and your last minute inspiration 
improved my research. Thank you! I will never forget the last days of July 
2007, just before the deadline of the original lamotrigine study. Our working 
days were inspiring and very long, but we made it! I very much enjoyed our 
sightseeing trip on the fi rst of August.
Graag wil ik ook de leden van de leescommissie bedanken. Dear professor 
Irene van Langen, associate professor Sonia Hernandez-Diaz and professor 
Dick Lindhout, I would like to thank you for your time spent to read and judge 
my thesis.
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I would like to thank all my co-authors. Without you it would not have been 
possible to perform the studies. Especially, I would like to thank all people 
from the local EUROCAT registries for their collaboration, inspiration and 
trust. Dear Vera and Guy from Antwerp; Isabel and Larraitz from Basque 
Country; Mary and Maria from Cork & Kerry; Ingeborg and Ljubica from 
Croatia; Elisa, Amanda and Francesca from Emilia Romagna; Yves, Christine 
and Myriam from Hainaut, Annette and Awi from Mainz, Miriam from Malta; 
Marian, Hermien and Linda from Netherlands, Lorentz, Stein Emil, Jon 
Gunnar and Kari from Norway; Ester from Odense; Catherine, Babak and 
Nathalie from Paris; Anna and Jan from Wielkopolska and Poland; Simone 
and Anke from Saxony Anhalt; Bérénice from Strasbourg; Fabrizio and Anna 
from Tuscany; Marie-Claude from Vaud and David from Wales…Thank you! 
Although I missed the last two, I really enjoyed the interesting and ‘gezellige’ 
EUROCAT meetings. Those meetings were like family days!
I also would like to thank Maria, Barbara and Ruth from the Central 
Registry. Thank you for your support and help. Maria, thank you for all the 
time you put in the creation of the datasets. I enjoyed working with you. Ester, 
Ingeborg, Elisa and Diana, I learnt so much from you about malformations, 
ICD-classifi cation and syndromes. Thank you, your experience was extremely 
valuable! Joan, thank you for your help and support in the statistics on small 
and large numbers!
Beste Marian, graag wil ik je bedanken dat ik in 2008 1 dag per week in 
de Nederlandse EUROCAT registratie kon werken. Dit was zeer leerzaam. 
Daarnaast hebben we een aantal leuke projecten samen gedaan (chapter 1 en 6).
Graag wil ik de door mij begeleidde studenten bedanken. Ik vind het 
werken met studenten altijd erg inspirerend en het houd je scherp. Bedankt.
Graag wil ik alle medewerkers van de afdeling FE2 en FTFPZ bedanken. Een 
paar mensen wil ik graag nog even apart benoemen. Maarten, je hebt me bij 
een aantal farmacoeconomische projecten begeleid. Ook al had ik in eerste 
instantie een puur epidemiologisch project, jouw vakgebied interesseert me 
sterk. Ook qua persoonlijkheid viel er veel te leren; in sommige opzichten 
zijn we denk ik echt tegenpolen en vullen we elkaar aan. Bedankt voor je 
begeleiding en warme interesse.
Natuurlijk wil ik ook graag mijn kamergenoten bedanken voor de 
gezelligheid en goede discussies. Tijdens het begin van mijn promotie aan de 
Bloemsingel 1 mocht ik een zeer ruime kamer delen met Silvia. We begonnen 
onze communicatie in het Engels maar als 1 van ons niet op een woord kon 
komen kwam je altijd feilloos met het Nederlandse woord. Naar verloop van 
tijd zijn we dan ook geheel overgegaan op het Nederlands. Helaas ben je door 
de scheiding van de afdelingen naar een andere kamer verhuisd en hebben 
alleen nog even samengewerkt aan jouw case-controle studie. Ik wens je veel 
succes bij afronding van je proefschrift.
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Na de kamer herindeling mocht ik mijn kamer delen met Hao. Every time I 
here you talking Chinese I start smiling. I cannot understand a single word, 
but it always sounds so happy and funny. I will never forget the day that 
Lolkje entered our room with an article, which she co-authored, translated 
into Chinese. Lolkje thought that it was a summary as it was much shorter 
than the original paper. She looked so surprised when you had a look at the 
symbols and started translating the paper. You will take over the lamotrigine 
follow-up project next to your EUROmediCAT work. Since I started to show 
you the ropes within the EUROCAT dataset, I  more and more realized how 
interesting and special the EUROCAT network is. I wish you all the best.
Ineke als externe aio was je vaak tijdens mijn vrije dag op de universiteit. 
Wel hebben wij samen een reis naar Boston gemaakt voor de ‘Human 
Teratogens course’ aan de Harvard Medical School. Een mooie ervaring. Ik 
wens je veel succes met de afronding van je proefschrift.
Priscilla, samen waren wij de twee parttime werkende moeders bezig 
met hun promotietraject. Naast inhoudelijke discussies konden we gezellig 
kletsen over het wel en wee van onze gezinnetjes. Er zit heel wat werk van 
jou in het ‘Gezond Zwanger’ project. Helaas bleek na evaluatie (general 
discussion) dat de geïncludeerde zwangerschappen niet representatief waren 
voor de algemene zwangere populatie in Noord Nederland. Gelukkig, zijn er 
volop nieuwe plannen! Veel succes en plezier met je promotie traject 
Graag wil ik ook de heren van de IADB.nl bedanken voor het feit dat ze 
elke |keer over hun hart streken en de door mij uitgedachte platte tabel 
produceerden. Ook zullen jullie af en toe wel hard hebben moeten lachen 
als ik weer eens bij jullie binnen liep voor advies bij rare computer dingen. 
Dankjewel dat jullie altijd voor mij klaar stonden!
Een promotietraject blijft voor familie en vrienden soms maar een lastig iets. Is 
het nou werk of opleiding en hoe noem je die scriptie ook al weer waar je alles 
in bundelt aan het einde. Whatever, … Bedankt voor jullie eeuwige interesse en 
jullie luisterend oor als het niet allemaal liep zoals ik graag zou willen!
Lieve Marlies, ik vind het fi jn dat jij mijn paranimf bent. Soms zien we 
elkaar regelmatig, soms een hele tijd niet. Maar als we bijkletsen is het altijd 
gezellig en net alsof we elkaar pas nog hebben gezien. Tijdens de studie deden 
we samen commissiewerk en in onze aio-tijd waren we samen zwanger. Het 
lijkt mij erg gezellig als jij met je mannen op termijn ook afzakt naar het 
midden van het land!
Lieve papa & mama, Hermy, William, Anouk & Marloes, Wilma, Mark, 
Arjen, Anne & Heike, Robert, Ellen & Tom, heit & mem en Johannes, Annie 
& Anton het onderzoek aan de universiteit moet voor jullie vaak behoorlijk 
abstract zijn geweest, toch hebben jullie mij altijd gesteund en gestimuleerd. 
Dankwoord
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Dankjewel! Paps en mams, jullie kleine meisje was al ‘lang’ (thuis), maar 
ondertussen wordt ze ook een beetje groot! Door jullie positieve, inspirerende en 
bezige voorbeeld heb ik naast mijn studie en promotietraject vele leuke ervaringen 
opgedaan. Ik hoop dat ik straks voor Coen ook zo’n inspiratiebron kan zijn!
Lieve Cornelis, ruim twee jaar geleden ging jij mij voor en mocht ik aan 
je zijde staan als paranimf. Nu draaien we de rollen om! De afgelopen jaren 
hebben we samen heel wat mogen meemaken, gelukkig vooral mooie dingen. 
Ik wil je graag bedanken, omdat je er altijd voor me bent, je dingen weet te 
relativeren als mijn relativeringsvermogen me even in de steek laat en me 
helpt om dingen voor elkaar te krijgen. Vooral in de periode dat jij al bij GSK 
werkte en we nog in Haren woonden realiseerde ik mij hoe gelukkig ik ben 
met jouw aanwezigheid en jouw liefde in mijn leven. Het gaf de weekenden 
een extra dimensie, straks ook door de week! Zeker het afgelopen jaar, samen 
met onze trots!
Lieve Coen, ook al snap je er nog helemaal niets van en heb je het liefst 
dat mama niet werkt en gewoon de hele dag bij jou is. Door het afronden van 
dit boekje word je mama doctor, maar je mag nooit vergeten dat mama haar 
mooiste titel heeft gekregen door jouw geboorte!
Lieve mannen, ik heb zin in de toekomst samen met jullie!
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